

JC690 U.S. PTO  
04/06/0004-7-00  
KAPlease type a plus sign (+) inside this box → PTO/SB/05 (4/98)  
Approved for use through 09/30/2000. OMB 0651-0032Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. OMRF 178

First Inventor or Application Identifier Brian Lee Sauer

Title METHOD FOR SELECTING RECOMBINASE VARIANTS  
WITH ALTERED SPECIFICITY

Express Mail Label No. EL 381 208 196 US

P  
541045U  
S  
P  
T  
O  
04/06/00**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1.  \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2.  Specification [Total Pages 116]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3.  Drawing(s) (35 U.S.C. 113) [Total Sheets 18]
4. Oath or Declaration [Total Pages ]
- a.  Unexecuted
- b.  Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)
  - i.  DELETION OF INVENTOR(S)  
Signed statement attached deleting  
inventor(s) named in the prior application,  
see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

**\* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).**

Assistant Commissioner for Patents  
ADDRESS TO: Box Patent Application  
Washington, DC 20231

5.  Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a.  Computer Readable Copy
  - b.  Paper Copy (identical to computer copy)
  - c.  Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

7.  Assignment Papers (cover sheet & document(s))
8.  37 C.F.R. § 3.73(b) Statement  Power of  
(when there is an assignee)  Attorney
9.  English Translation Document (if applicable)
10.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS  
Statement
11.  Preliminary Amendment
12.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
- \* Small Entity Statement(s)  Statement filed in prior application,  
(PTO/SB/09-12)  Status still proper and desired
13.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
14.  Other: Check for \$732.00  
.....  
.....  
.....

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

 Continuation  Divisional  Continuation-in-part (CIP)

of prior application No: \_\_\_\_\_ / \_\_\_\_\_


Prior application information: Examiner \_\_\_\_\_

Group / Art Unit: \_\_\_\_\_

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**17. CORRESPONDENCE ADDRESS**

<input checked="" type="checkbox"/> Customer Number or Bar Code Label		 (Insert Customer Number or Bar Code Label here)		or <input type="checkbox"/> Correspondence address below	
Name	Patrea L. Pabst Arnall Golden & Gregory, LLP PATENT TRADEMARK OFFICE				
Address	2800 One Atlantic Center 1201 West Peachtree Street				
City	Atlanta	State	GA	Zip Code	30309-3450
Country	United States	Telephone	(404) 873-8794	Fax	(404) 873-8795

Name (Print/Type)	Robert A. Hodges	Registration No. (Attorney/Agent)	41,074
Signature			Date 04/06/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Brian Lee Sauer and Andreas Walter Rüfer

Serial No.: Express Mail Label No.: EL 381 208 196 US

Filed: April 6, 2000 Date of Deposit: April 6, 2000

For: *METHOD FOR SELECTING RECOMBINASE VARIANTS WITH  
ALTERED SPECIFICITY*

BOX PATENT APPLICATION  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**EXPRESS MAIL TRANSMITTAL LETTER  
FOR PATENT APPLICATION AND CERTIFICATE OF MAILING**

Sir:

Pursuant to 35 U.S.C. § 21(a) as amended by Public Law 97-247 and 37 C.F.R. § 1.10, Brian Lee Sauer and Andreas Walter Rüfer encloses for filing the attached patent application entitled "Method for Selecting Recombinase Variants with Altered Specificity", which claims priority to U.S.S.N. 60/127,977 filed April 6, 1999. The application includes 1 page of Abstract, 116 pages of specification, 8 pages of claims, 18 sheets of informal drawings, and an unexecuted Declaration. An executed Declaration and A Verified Statement Claiming Small Entity Status will be submitted shortly. A check in the amount of \$732.00 to cover one half of the filing fee is enclosed.

The Commissioner is hereby authorized to charge our deposit order account no. 01-2507 in the amount of \$732.00, which represents the difference between the filing fee for a large entity and small entity.

OMRF 178  
20487/247

Filed: April 6, 2000  
Express Mail Transmittal Letter for  
Patent Application and Certificate of Mailing  
Express Mail Label No. EL 381 208 196 US


This application is being filed on April 6, 2000 by mailing the application to the Assistant Commissioner for Patents, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10. The Express Mail label number appears in the heading of this paper which is attached to the application papers pursuant to 37 C.F.R. § 1.10(b).

The Commissioner is hereby authorized to charge any fees that may be required, or credit any overpayment to Deposit Order Account No. 01-2507. To facilitate this process, applicants have enclosed a duplicate of this letter.

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq.  
ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3450

Respectfully submitted,



\_\_\_\_\_  
Robert A. Hodges  
Reg. No. 41,074

Date: April 6, 2000  
ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8796  
(404) 873-8797 Telefax

OMRF 178  
20487/247

Filed: April 6, 2000  
Express Mail Transmittal Letter for  
Patent Application and Certificate of Mailing  
Express Mail Label No. EL 381 208 196 US

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10**

I hereby certify that this Express Mail Transmittal Letter for Patent Application and any documents referred to as attached therein are being deposited with the United States Postal Service on this date, April 6, 2000, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, mailing label number EL 381 208 196 US, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

  
\_\_\_\_\_  
Teresa R. Spratt

Date: April 6, 2000

**APPLICATION  
FOR  
UNITED STATES LETTERS PATENT**

**BY**  
**BRIAN LEE SAUER**

**AND**  
**ANDREAS WALTER RÜFER**

**FOR**  
**METHOD FOR SELECTING RECOMBINASE VARIANTS  
WITH ALTERED SPECIFICITY**

## METHOD FOR SELECTING RECOMBINASE VARIANTS

### WITH ALTERED SPECIFICITY

#### CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Application No.

- 5 60/127,977, filed April 6, 1999. Application Serial No. 60/127,977, filed April  
6, 1999, is hereby incorporated herein by reference.

#### BACKGROUND OF THE INVENTION

Recombinases, integrases and resolvases (collectively referred to herein as recombinases) mediate the site-specific recombination of DNA. These 10 recombinases were first identified in phage that integrate into host chromosomes. Such integration allows the phage to remain latent in the cell as a prophage.

Site-specific recombinases catalyze conservative DNA rearrangements at specific target sequences. The 38 kDa Cre recombinase (cyclization 15 recombination), derived from the bacteriophage P1, is a well characterized and widely used enzyme of the Integrase family (reviewed by Sauer, *Methods*, 14:381-392 (1998)). Cre plays two essential roles in the life cycle of P1: First, it provides a host-independent mechanism for P1's genome cyclization after infection, which can be important when the recombination system of the host is 20 compromised. Second, Cre resolves dimerized P1 prophage plasmids to guarantee proper segregation during cell division.

Cre acts on a 34 bp sequence located on both ends of the linear P1 genome, that is called *loxP* (locus of crossover of P1; Sternberg and Hamilton, *J. Mol. Biol.*, 150:467-486 (1981)), *loxP* consists of two 13 bp inverted repeats 25 flanking a non-palindromic 8 bp core that defines the assigned direction of the sequence (as shown on the upper part of Figure 1). Depending on this direction, recombination catalyzed by Cre leads to excision or insertion of DNA flanked by *loxP* sites orientated in the same direction (indicated by *loxP<sup>2</sup>*), but leads to inversion when oriented in the opposite direction (Figure 2).

In general, Cre-recombination involves the following four events: (i) DNA binding, (ii) synapsis (as defined below), (iii) cleavage, and (iv) strand exchange. To study this process in greater detail, mutants defective for each step have been isolated using several screening procedures (Wierzbicki et al., *J. Mol. Biol.*, 195:785-794 (1987)). In addition, the crystal structure of Cre complexed with an artificial suicide substrate has been recently resolved, providing additional insights into site-specific recombination (Guo et al., *Nature*, 389:40-46 (1997)). From these studies, the following has been proposed: Four interacting Cre molecules are necessary for recombination between two *lox* sites, with each enzyme binding one inverted repeat plus the two outermost bp of the non-symmetric core region (DNA binding). This leads to the formation of a clamp, allowing DNA contacts in the major, as well as in the minor groove. In the step referred to as synapsis, the two *lox* sites with the bound Cre molecules, are aligned in parallel leading to an approximate 100° bending of the DNA. In the following step of strand cleavage, one of the two Cre molecules on each *lox* site causes a staggered cut in the core region, as indicated by the vertical arrows in Figure 1. This leads to a 6 bp 5' overhang and a covalent 3' phosphotyrosine linkage between the catalytic residue tyrosine 324 of Cre and the guanine (position 4) at the cleaving site of *loxP*. The created phosphotyrosine intermediate is thought to provide the energy for the reaction, thereby explaining why Cre does not require an external energy source. In the next step, the first strand is exchanged between the two nicked *lox* sites, creating an intermediate, named Holliday structure (Sigal and Alberts, *J. Mol. Biol.*, 71:789-793 (1972)). Of note, this first strand exchange is asymmetric, since the bottom strand (Figure 1) is always exchanged first (Hoess et al., *Proc. Natl. Acad. Sci. USA*, 84:6840-6844 (1987)). During the final step, the second strand is exchanged and Cre released from its substrate.

Because of the simplicity and the ability of Cre to function in yeast and mammalian cells (Sauer, B., *Mol. Cell. Biol.*, 7:2087-2096 (1987); Sauer and Henderson, *Proc. Natl. Acad. Sci. USA*, 85:5166-5170 (1988), Sauer and

Henderson, *Nucl. Acids Res.*, 17:147-161 (1989), and Sauer and Henderson, *The New Biologist*, 2:441-449 (1990), Cre assisted site-specific recombination has become an important tool for efficient, specific, and conditional manipulations of eukaryotic genomes (Lakso et al., *Proc. Natl. Acad. Sci. USA*, 89:6232-6236 (1992)); Kilby et al., *Genet.*, 9:413-421 (1993); Sauer, B., *Meth. enzymol.*, 225:890-900 (1993); Kühn et al., *Science*, 269:1427-1429 (1995); Metzger et al., *Proc. Natl. Acad. Sci. USA*, 92:6991-6995 (1995).

However, there are some inconveniences for the successful use of Cre-related technologies, that include the following: (i) *lox* sites need to be introduced by homologous recombination at the desired region into the genome before Cre can be used, (ii) the frequency of correct site-specific recombination due to Cre expression is not 100%, and consequently, (iii) selectable markers are necessary in most strategies involving Cre for genome manipulation in higher eukaryotes. These markers, e.g. *neo* or TK, may introduce problems in subsequent studies, particular in those related to animal development. The number of available selectable markers that can be used is limited also. Additional site-specific recombinases that also function efficiently in eukaryotic systems, but recognize different sites from *lox* would be helpful. Similar inconveniences limit the usefulness of other recombinases.

Therefore, it is an object of the present invention to provide a method of identifying variant recombinases that can mediate recombination between variant recombination sites.

It is another object of the present invention to provide variant recombinases that can mediate recombination between variant recombination sites.

It is another object of the present invention to provide a method of recombining nucleic acid molecules *in vitro* and *in vivo*.

It is another object of the present invention to provide Cre variants that recognize variant recombination sites.

BRIEF SUMMARY OF THE INVENTION

Disclosed is a method for identifying variant forms of recombinases that can mediate recombination between variant recombination sites. The method involves producing mutant recombinases and testing the mutant recombinases with specially designed constructs. The constructs contain variant recombination sites that are not recognized by non-mutant recombinase but will undergo recombination in the presence of a mutant recombinase with altered specificity. Recombination at the variant recombination sites can be monitored or detected by any suitable means. It is preferred that recombination is detected by screening or selection based on the expression or lack of expression of a reporter gene. This can be accomplished by using constructs containing a reporter gene associated with the variant recombination sites such that the reporter gene is rearranged or deleted, or a spacer sequence interrupting the reporter gene is rearranged or deleted, as a result of recombination at the recombination sites. Recombination of such constructs will result in a loss of expression of the reporter gene, where the construct contained a functional reporter gene, or in a gain in expression of the reporter gene, where the construct contained a non-functional reporter gene.

The disclosed method also involves determining whether a variant recombinase retains the ability to mediate recombination at recombination sites recognized by non-variant recombinase. This can be accomplished by using constructs containing recombination sites recognized by non-variant recombinase. Recombination at these recombination sites can be monitored or detected by any suitable means. It is preferred that recombination is detected by screening or selection based on the expression or lack of expression of a reporter gene. This can be accomplished by using constructs containing a reporter gene associated with the recombination sites recognized by non-variant recombinase such that the reporter gene is rearranged or deleted, or a spacer sequence interrupting the reporter gene is rearranged or deleted, as a result of recombination at the recombination sites. Recombination of such constructs

will result in a loss of expression of the reporter gene, where the construct contained a functional reporter gene, or in a gain in expression of the reporter gene, where the construct contained a non-functional reporter gene.

When variant recombinases are tested for activity on both variant recombination sites and recombination sites recognized by non-variant recombinase in the same system or at the same time, it is preferred that two different reporter genes, which can be separately detected or monitored, be used. In this case, the first reporter gene can be associated with the variant recombination sites and the second reporter gene can be associated with 10 recombination sites recognized by non-variant recombinase.

Recombination between two recombination sites requires (1) that the recombinase recognize the sites as recombination sites, and (2) that the sequences of the two sites is sufficiently similar. It has been discovered that recombination between two recombination sites (both of which are recognized 15 by a recombinase) can be substantially reduced or prevented by using different compatibility sequences for the recombination sites (the recognition sequences can also differ if the recombinase can recognize different sequences). Thus, it is also preferred that the variant recombination sites be made incompatible with the recombination sites recognized by non-variant recombinase by using 20 different compatibility sequences for the two sets of recombination sites.

Compatibility sequences in a recombination site are those sequences in the recombination site, other than the sequences required for recognition of the site by the recombinase, that must be similar in a pair of recombination sites for recombination to occur between them. Many recombination sites contain 25 repeats of a characteristic sequence separated by spacer sequences. In such recombination sites, the spacer sequences are generally compatibility sequences and the repeats (or parts of the repeats) are recognition sequences. Recombinases require specific recognition sequences but allow wide variation in compatibility sequences. Thus, recombination sites that are recognized by a

given recombinase but are incompatible with each other can be readily designed using the disclosed principles.

Also disclosed are variant recombinases made or identified by the disclosed method that have broadened specificity for the site of recombination.

5 Specifically, the disclosed variants mediate recombination between sequences other than recombination sites on which the wild type recombinase is active. In general, the disclosed recombinase variants can mediate efficient recombination between recombination sites that wild type recombinase can act on (referred to as wild type recombination sites), between variant recombination sites not efficiently utilized by wild type recombinase (referred to as variant recombination sites), and between a wild type recombination site and a variant recombination site.

10

Also disclosed are methods of recombining nucleic acids using the disclosed variant recombinases. For example, the disclosed variant recombinases can be used in any method or technique where wild type recombinases can be used. In addition, the disclosed variant recombinases allow different alternative recombinations to be performed since the variant recombinases can allow much more efficient recombination between wild type recombination sites and variant recombination sites. Control of such alternative 15 recombinations can be used to accomplish more sophisticated sequential recombinations to achieve results not possible with wild type recombinases. The disclosed variant recombinases also allow recombination at specific genomic sites without the need to first introduce a recombination site.

20

Also disclosed are variants of Cre recombinase that have broadened specificity for the site of recombination. Specifically, the disclosed variants mediate recombination between sequences other than the loxP sequence and other lox site sequences on which wild type Cre recombinase is active. In general, the disclosed Cre variants mediate efficient recombination between lox sites that wild type Cre can act on (referred to as wild type lox sites), between 25 variant lox sites not efficiently utilized by wild type Cre (referred to as variant

30

lox sites), and between a wild type lox site and a variant lox site. Also disclosed are methods of recombining nucleic acids using the disclosed Cre variants. For example, the disclosed Cre variants can be used in any method or technique where Cre recombinase (or other, similar recombinases such as FLP) can be used. In addition, the disclosed Cre variants allow different alternative recombinations to be performed since the Cre variants allow much more efficient recombination between wild type lox sites and variant lox sites. Control of such alternative recombination can be used to accomplish more sophisticated sequential recombinations to achieve results not possible with wild type Cre recombinase.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a comparison of three different lox sites. loxP is the original recombination site for Cre recombinase. loxK1 and loxK2 are variant lox sites.

Figure 2 is a diagram of two different forms of construct and the resulting recombination products.

Figure 3 is a diagram of an example of a random mutagenesis using DNA shuffling.

Figure 4 is a diagram of the selection plasmid for *loxK2* recombination, pBS584. Recombination of two *loxK2* sites by a potent Cre mutant will result in the excision of *EGFP* and the transcriptional terminator *rrnBT<sub>1</sub>T<sub>2</sub>*. Subsequently, *neo* transcription can take place, rendering *E. coli* resistant to kanamycin. Note that the promoter (pRSV) even though of eukaryotic origin was shown to be functional in *E. coli* (Antonucci et al., *J. Biol. Chem.*, 264:17656-17659 (1989)).

Figure 5 depicts gels of nucleic acid fragments and PCR products generated during the DNA shuffling process.

Figure 6 is a diagram of plasmid pBAD33 used for expression of mutant *cre* pools.

Figure 7 is a diagram of the construction of selection plasmids pBS568 and pBS569.

Figure 8 is a diagram of the construction of selection plasmids pBS583 and pBS584.

Figure 9 is a diagram of control plasmid pBS613.

Figure 10 is a diagram of the construction of screening plasmids pBS601  
5 and pBS602.

Figure 11 is a diagram of examples of basic types of constructs useful in  
the disclosed method. These types of constructs are: (1) interrupted constructs  
where the gene is interrupted by a nucleic acid segment (which is flanked by  
recombination sites) that is deleted during recombination, (2) flanked constructs  
10 where the gene as a unit is flanked by recombination sites and the gene is  
deleted by recombination, and (3) inverted constructs where a portion of the  
gene is on an inverted nucleic acid segment and recombination causes the  
segment to invert and reconstitute the intact gene. The type of recombination is  
indicated in parentheses.

15 Figures 12A, 12B, and 12C are diagrams of examples of constructs and  
their expected recombination when used in the disclosed method. Figure 12A  
shows examples of deletion constructs (flanked and interrupted). Figure 12B  
shows examples of inverted constructs. Figure 12C shows examples of  
constructs that combine through recombination to reconstitute an intact gene.

20 Figure 13 is a diagram showing the identified amino-acid changes in the  
six selected Cre mutants are listed according to their position in the protein's  
secondary structure (silent mutations in parenthesis). Only one amino acid  
change, E262G, is common to all mutants with remarkably increased *loxK2*  
activity (R3M1, 2, 3, 5, and 6), suggesting that this mutation is essential for the  
25 observed phenotype.

Figure 14A is a table comparing recombination frequencies *in vivo*  
obtained with a variety of *lox* sites altered at positions 11 and 12. Figure 14B is  
a table comparing recombination frequencies *in vivo* obtained with identical and  
mixed *lox* sites. Wild type Cre and five different mutant enzymes were tested  
30 for their performance on different *lox*<sup>2</sup> substrates, as indicated. Given are the

obtained percentages of recombination *in vivo* based on the described negative selection.

Figure 15 is a table comparing recombination frequencies in vitro obtained with a variety of *lox* sites altered at positions 11 and 12.

5 Figure 16 is a graph of percent of various Cre recombinases (wt, G, GA, GN, GS, R3M3) bound to various *lox* sites (*loxP*, *loxK2*, *loxK1*).

Figure 17 shows wildtype and target FRT sites.

Figure 18 shows the strategy for selection of altered specificity FLP mutants.

10 Figure 19 shows an alternate target mutant FRT site. The design and rationale for design of the target mutant FRT site is as described in Figure 17, but the mutant FRT-M2 site differs from FRT-M by carrying a different mutational alteration in the repeat elements.

#### DETAILED DESCRIPTION OF THE INVENTION

15 Disclosed is a method for identifying variant forms of recombinases that can mediate recombination between variant recombination sites. The method involves producing mutant recombinases and testing the mutant recombinases with specially designed constructs. The constructs contain variant recombination sites that are not recognized by non-mutant recombinase but will undergo recombination in the presence of a mutant recombinase with altered 20 specificity. The disclosed method also involves determining whether a variant recombinase retains the ability to mediate recombination at recombination sites recognized by non-variant recombinase.

When variant recombinases are tested for activity on both variant 25 recombination sites and recombination sites recognized by non-variant recombinase in the same system or at the same time, it is preferred that two different reporter genes which can be separately detected or monitored be used. In this case, a first reporter gene can be associated with the variant recombination sites and a second reporter gene can be associated with 30 recombination sites recognized by non-variant recombinase. It is also preferred

that the variant recombination sites be made incompatible with the recombination sites recognized by non-variant recombinase by using different compatibility sequences for the two sets of recombination sites. This allows separate assessment of the ability of a variant recombinase to mediate

- 5 recombination between variant recombination sites and recombination sites recognized by non-variant recombinase.

Also disclosed are variant recombinases made or identified by the disclosed method that have broadened specificity for the site of recombination.

Also disclosed are methods of recombining nucleic acids using the disclosed

- 10 variant recombinases. For example, the disclosed variant recombinases can be used in any method or technique where wild type recombinases can be used. In addition, the disclosed variant recombinases allow different alternative recombinations to be performed since the variant recombinases can allow much more efficient recombination between wild type recombination sites and variant  
15 recombination sites. Control of such alternative recombination can be used to accomplish more sophisticated sequential recombinations to achieve results not possible with wild type recombinases.

Also disclosed are variants of Cre recombinase that have broadened specificity for the site of recombination. Specifically, the disclosed variants

- 20 mediate recombination between sequences other than the loxP sequence and other lox site sequences on which wild type Cre recombinase is active.

Preferred forms of the disclosed Cre variants have the amino acid sequence SEQ ID NO:1 (top sequence, Table 11) altered by one or more amino acid substitutions, deletions, or insertions, where the glutamic acid at amino acid 262

- 25 has been substituted with an amino acid other than glutamic acid, and where the Cre variant recognizes (that is, mediates recombination at) a variant lox recombination site. Useful Cre variants include proteins that recognize a variant lox recombination site and have the amino acid sequence SEQ ID NO:1 altered by substitution of the glutamic acid at amino acid 262 with an amino acid other

- 30 than glutamic acid and one or more of the following amino acid substitutions:

isoleucine at amino acid 16, alanine at amino acid 29, glutamine at amino acid 101, glycine at amino acid 138, asparagine at amino acid 189, serine at amino acid 198, glutamine at amino acid 220, glutamine at amino acid 223, isoleucine at amino acid 227, glycine at amino acid 254, arginine at amino acid 255,  
5 glutamine at amino acid 284, leucine at amino acid 307, and serine at amino acid 316. Preferred amino acid substitutions at amino acid position 262 include alanine, tryptophan, or glycine.

Examples of preferred Cre variants include proteins having the amino acid sequence SEQ ID NO:1 altered by substitutions E262G and D189N;  
10 proteins having the amino acid sequence SEQ ID NO:1 altered by substitutions E262G and T316S; proteins having the amino acid sequence SEQ ID NO:1 altered by substitutions E262G and D29A; proteins having the amino acid sequence SEQ ID NO:1 altered by substitutions E262G, V16I, D189N, G198S, R223Q, Q255R, and P307L; proteins having the amino acid sequence SEQ ID  
15 NO:1 altered by substitution E262G; proteins having the amino acid sequence SEQ ID NO:1 altered by substitution E262A; and proteins having the amino acid sequence SEQ ID NO:1 altered by substitution E262W. The substitutions above are listed using the convention where the first letter is the original amino acid (in single letter amino acid code), the number is the amino acid position in  
20 the protein (in this case, using the positions of wild type Cre (SEQ ID NO:1)), and the last letter is the new amino acid (in single letter amino acid code). All of these Cre variants recognize both wild type lox sites and variant lox sites with an inverted repeat sequence NNNACNNCGTATA (SEQ ID NO:2).

The disclosed Cre variants recognize variant lox recombination sites.  
25 Preferred variant lox sites are variant lox sites recognized by the Cre variant but not recognized by wild type Cre. Examples of useful variant lox sites include sites having two 13 base pair inverted repeats flanking 8 base pairs, where one of the inverted repeats has the sequence NNNACNNCGTATA (SEQ ID NO:2); sites having the sequence N<sub>1</sub>N<sub>2</sub>N<sub>3</sub>ACN<sub>4</sub>N<sub>5</sub>CGTATANNNNNNNTATA  
sites having the sequence CGN<sub>5</sub>'N<sub>4</sub>'GTN<sub>3</sub>'N<sub>2</sub>'N<sub>1</sub>' (SEQ ID NO:3), where N<sub>1</sub>', N<sub>2</sub>', N<sub>3</sub>', N<sub>4</sub>', and N<sub>5</sub>' are

complementary to N<sub>1</sub>, N<sub>2</sub>, N<sub>3</sub>, N<sub>4</sub>, and N<sub>5</sub>, respectively; sites having the sequence N<sub>1</sub>N<sub>2</sub>N<sub>3</sub>ACN<sub>4</sub>N<sub>5</sub>CGTATANNNNNNNTACGN<sub>5</sub>'N<sub>4</sub>'GN<sub>3</sub>'N<sub>2</sub>'N<sub>1</sub>' (SEQ ID NO:3), where N<sub>4</sub>N<sub>5</sub> are AA, TC, GT, TG, GG, or CC; and sites having the sequence GATACAACGTATATACCTTCTATACTGTTGTAT (SEQ ID NO:4).

5 NO:4).

Also disclosed is a method for producing site-specific recombination of DNA in cells using the disclosed Cre variants. DNA sequences comprising first and second lox sites are introduced into cells and contacted with a Cre variant, thereby producing recombination at the lox sites. As with wild type Cre, the 10 location and orientation of the lox sites determines the nature of the recombination.

As used herein, the expression "site-specific recombination" refers to three different types of recombination events:

- 15 1. deletion of a pre-selected DNA segment flanked by recombination sites,
2. inversion of the nucleotide sequence of a pre-selected DNA segment flanked by recombination sites, and
3. reciprocal exchange of DNA segments proximate to recombination sites located on different DNA molecules.

20 It is to be understood that this reciprocal exchange of DNA segments can result in an integration event if one or both of the DNA molecules are circular. "Nucleic acid segment" refers to a linear segment of single- or double-stranded nucleic acid, which can be derived from any source. The segment may be a fragment consisting of the segment or a segment within a larger nucleic acid 25 fragment or molecule. The expression "nucleic acid in eukaryotic cells" includes all nucleic acid present in eukaryotic cells. The expression "nucleic acid in yeast" includes all nucleic acid present in yeast cells. "DNA segment" refers to a linear segment of single- or double-stranded deoxyribonucleic acid (DNA), which can be derived from any source. The expression "DNA in 30 eukaryotic cells" includes all DNA present in eukaryotic cells. The expression

"DNA in yeast" includes all DNA present in yeast cells. As used herein, a "gene" is intended to mean a DNA segment which is normally regarded as a gene by those skilled in the art. The expression "regulatory molecule" refers to a polymer of ribonucleic acid (RNA) or a polypeptide which is capable of enhancing or inhibiting expression of a gene.

"Regulatory nucleotide sequence," as used herein, refers to a nucleotide sequence located proximate to a gene whose transcription is controlled by the regulatory nucleotide sequence in conjunction with the gene expression apparatus of the cell. Generally, the regulatory nucleotide sequence is located 5' to the gene. The expression "nucleotide sequence" refers to a polymer of DNA or RNA, which can be single- or double-stranded, optionally containing synthetic, non-natural, or altered nucleotides capable of incorporation into DNA or RNA polymers. As used herein, a "regulatory nucleotide sequence" can include a promoter region, as that term is conventionally employed by those skilled in the art. A promoter region can include an association region recognized by an RNA polymerase, one or more regions which control the effectiveness of transcription initiation in response to physiological conditions, and a transcription initiation sequence. "Gene product" refers to a polypeptide resulting from transcription, translation, and, optionally, post-translational processing of a selected DNA segment.

## Materials

### A. Recombinases

Recombinases suitable for use in the disclosed method include any enzyme that mediates recombination at specific sites. This includes enzymes identified as recombinases as well as other enzymes that function to produce recombination such as integrases and resolvases. As used herein, recombination at specific sites does not refer only to recombination at completely defined sequences. Rather, a recombinase is considered to mediate recombination at specific sites when the sites of recombination are limited in some way by sequence. For example, wild type Cre recombinase mediates recombination

between sites having the sequence N<sub>1</sub>N<sub>2</sub>N<sub>3</sub>ACTTCGTATANNNNNNNT  
ATACGAAGTN<sub>3</sub>'N<sub>2</sub>'N<sub>1</sub>', which includes both specific and non-specific  
sequences. The sequences ACTTCGTATA and TATACGAAGT (an inverted  
repeat of the first sequence) are recognized by the Cre recombinase. The non-  
specific sequences (positions with "N" in the recognition sequence), although  
not limited in sequence, must be compatible with the non-specific sequences of  
the partner recombination site in order for recombination to be efficient. The  
recombination sites need not have any particular number of specific nucleotides.  
All that is required is some constraint on the sequence of the site such that the  
recombinase is limited to recombination at some set of sites.

Examples of recombinases that can be used in the disclosed method  
include Cre recombinase, FLP recombinase, Beta recombinase of pSM19035  
(Diaz et al., *J Biol Chem* 274: 6634-6640 (1999)), Int recombinases (Nunes-  
Döby et al., *Nucleic Acids Res.* 26:391-406 (1998)), and resolvases (Hallet et al.,  
15 FEMS *Microbiol Rev.* 21: 157-178 (1997); Oram et al., *Curr Biol.* 5: 1106-1109  
(1995); Mondragon, *Structure* 3: 755-758 (1995)).

## B. Recombination Sites

Recombination sites are locations within a nucleic acid where  
recombination mediated by a recombinase takes place. Recombination sites  
20 generally include specific sequences, referred to as recognition sequences,  
through which the recombinase recognizes a given nucleotide sequence as a  
recombination site. Different recombinases generally recognize different  
recognition sequences. Recombination between two recombination sites  
requires (1) that the recombinase recognize the sites as recombination sites, and  
25 (2) that the sequences of the two sites are sufficiently similar. It has been  
discovered that recombination between two recombination sites (both of which  
are recognized by a recombinase) can be substantially reduced or prevented by  
using different compatibility sequences for the recombination sites (the  
recognition sequences can also differ if the recombinase can recognize different  
30 sequences). Thus, it is also preferred that the variant recombination sites be

RECOMBINASES

made incompatible with the recombination sites recognized by non-variant recombinase by using different compatibility sequences for the two sets of recombination sites. Compatibility sequences in a recombination site are those sequences in the recombination site, other than the sequences required for 5 recognition of the site by the recombinase, that must be similar in a pair of recombination sites for recombination to occur between them. Generally, recombinases require specific recognition sequences but allow wide variation in compatibility sequences. Thus, recombination sites that are recognized by a given recombinase but are incompatible with each other can be readily designed 10 using the disclosed principles.

It should be understood that, for a given recombinase site or for a given recombinase, whether a given base position in the recombination site is a 15 recognition sequence base or a compatibility sequence base may depend on other sequences in the recombination site. For example, a particular base may function as a compatibility sequence base in a recombination site having one sequence while the same base may function as a recognition sequence base in a recombination site having a different sequence. It should also be understood that recognition sequences and compatibility sequences do not necessarily occur in blocks within a recombination site. That is, recognition sequence base and 20 compatibility sequence bases may be interspersed in a given recombination site. As discussed below, what is and is not a recognition sequence or a compatibility sequence in a given recombination site is determined functionally.

The disclosed variant recombination sites and the variant recombinases 25 that can act on them allow more freedom in the selection of sites of recombination. In particular, the disclosed variant recombinases can allow amino acid changes in a protein of interest while retaining the ability to recombine at a given site.

### **1. Recognition Sequences**

Recognition sequences are regions within a recombination site that must 30 have a specific sequence, or defined range of sequences, for the cognate

recombinase to recognize the recombination site. Recognition sequences in a recombination site need not be contiguous. Thus, required nucleotides dispersed in a recombination site are collectively considered recognition sequences.

Nucleic acid segments can be said to have a defined range of sequences when  
5 every nucleotide position in the nucleic acid segment(s) is limited to one, two, or three nucleotide bases. That is, so long as a nucleotide position cannot have one of the possible nucleotide bases, that position has a defined range of sequence. For example, a nucleotide sequence ATRVBYGC has a defined range of sequences since each nucleotide position has at least one limitation. Standard  
10 nomenclature for nucleic acid sequences is used herein. Thus, in this example, R represents A or G; V represents A, C, or G; B represents C, G, or T; and Y represents C or T.

Recognition sequences for recombinases are known or can be determined through routine analysis. In general, recognition sequences can be  
15 determined by varying the sequence of recombination sites and determining if recombination between the sites can still occur. For this purpose, the pair of sites to be recombined should be identical. That is, the same sequence changes should be made to both sites. This eliminates any incompatibility effect between the recombination sites. If recombination is eliminated or significantly  
20 reduced when a specific nucleotide is changed, then that nucleotide is required for recognition of the recombination site by the recombinase.

Examples of dissection of the critical sequences in recombination sites of recombinases are described by Hoess et al., *Nucleic Acids Res.* 14:2287-2300  
25 (1986) (involving P1 recombinase); Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996) (involving Cre recombinase); Lee and Saito, *Gene* 216(1):55-65 (1998) (involving Cre recombinase); and Umlauf and Cox, *EMBO J* 7(6):1845-52 (1988) (involving FLP recombinase). Similar techniques can be used to determine the recognition sequences of other recombinases.

## 2. Compatibility Sequences

Compatibility sequences are regions in a recombination site that must be similar in a pair of recombination sites for recombination to occur between them. In general, the sequence of recombination sites must be similar for recombination to occur between them. Examples of compatibility sequences are spacer sequences between repeats in recombination sequences. All or some of the nucleotides in the recognition sequences for a recombination site may be involved in compatibility. For example, where some degeneracy of the recognition sequences is allowed, similar recognition sequences may be required in a pair of recombination sites for recombination to occur between them. Thus, compatibility between recombination sites can be affected by using different sequences in the compatibility sequences other than the sequences required for recognition of the site by the recombinase (that is, recognition sequences), compatibility sequences that are part of the recognition sequences, or both. It is preferred that compatibility between recombination sites be altered by using different sequences in the compatibility sequences other than the sequences required for recognition of the site by the recombinase.

Compatibility sequences for many recombinases are known or can be determined through routine analysis. In general, compatibility sequences can be easily determined by varying the sequence of recombination sites and determining if recombination between the sites can still occur. For this purpose, only one of the sites in the pair of sites to be recombined should be altered. That is, the same sequence changes should not be made to both sites. This isolates incompatibility effect between the recombination sites. Further, only those nucleotide positions that are not a part of the recognition sequence of the site should be altered to avoid recognition problems. If recombination is eliminated or significantly reduced when a specific nucleotide is changed, then that nucleotide is required for compatibility of the recombination site.

Examples of dissection of the critical sequences in recombination sites of recombinases are described by Hoess et al., *Nucleic Acids Res.* 14:2287-2300

(1986) (involving P1 recombinase); Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996) (involving Cre recombinase); Lee and Saito, *Gene* 216(1):55-65 (1998) (involving Cre recombinase); and Umlauf and Cox, *EMBO J* 7(6):1845-52 (1988) (involving FLP recombinase). Similar techniques can be used to  
5 determine the compatibility sequences of other recombinases.

Recognition and compatibility sequences can be further understood using Cre recombination sites as an example. Wild type Cre recombinase mediates recombination between sites having the sequence  $N_1N_2N_3ACTTCGTATANN$   $NNNNNTATACGAAGTN_3'N_2'N_1'$ , which includes both specific and non-specific sequences (that is, recognition sequences and compatibility sequences, respectively). The sequences ACTTCGTATA and TATACGAAGT (an inverted repeat of the first sequence) are recognized by the Cre recombinase and are the recognition sequences in Cre recombinase sites. Variant Cre recombinases recognize sites having different recognition sequences. The non-specific sequences (positions with "N" in the recognition sequence), although not limited in sequence, must be compatible with the non-specific sequences of the partner recombination site in order for recombination to be efficient. Thus, the non-specific sequences are the compatibility sequences of a recombinase site.  
10  
15

20 **C. Recombination Constructs**

Recombination constructs are designed to provide an observable change when recombination between recombination sites occurs. Preferred recombination constructs include two pairs of recombination sites, one pair having a variant sequence and another pair having a sequence recognized by non-mutant recombinase (for example, wild type recombinase). Sites in the first pair are referred to as variant recombination sites. Generally, recombination constructs include a first nucleic acid sequence that includes a first reporter gene and first and second recombination sites, where the first and second recombination sites are variant recombination sites, and a second nucleic acid sequence that includes a second reporter gene and third and fourth  
25  
30

recombination sites, where the third and fourth recombination sites can be recombinated by a non-mutant recombinase. The first and second nucleic acid sequences need not be present on the same vector or on the same nucleic acid molecule (for example, the chromosome), although this is preferred. It is  
5 preferred that recombination constructs be embodied in vectors, such as plasmids.

In one embodiment of the disclosed recombination constructs, the sequence of the recombination sites in the constructs are chosen such that the recognition sequences of the first and second recombination sites differ from the  
10 recognition sequences of the third and fourth recombination sites. The sequence of the recombination sites can also be chosen such that the compatibility sequences of the first and second recombination sites differ from the compatibility sequences of the third and fourth recombination sites such that the first and second recombination sites cannot recombine with the third and fourth  
15 recombination sites. The sequence of the recombination sites can also be chosen such that the compatibility sequences of the first and second recombination sites are sufficiently similar to allow recombination between the first and second recombination sites, and such that the compatibility sequences of the third and fourth recombination sites are sufficiently similar to allow recombination  
20 between the third and fourth recombination sites. The above sequence relationships result in constructs where the first and second recombination sites can recombine (in the presence of a recombinase that recognizes the sites), the third and fourth recombination sites can recombine, but where neither the first nor second recombination site can recombine with either the third or fourth  
25 recombination site (since differences in the compatibility sequences prevent recombination).

Arriving at recombination sites having relationships as described above is preferably accomplished in the following way. Starting with a given recombination site sequence (which can be recombinated by a non-mutant  
30 recombinase), parallel changes are made in the compatibility sequences of the

first and second recombination sites. These altered recombination sites should then be tested to make sure that the non-mutant recombinase can still mediate their recombination. This helps insure that compatibility sequence changes have not inadvertently affected the function of the recombination sites. Once this is  
5 confirmed, changes can be made to the recognition sequences of the first and second recombination sites. These changes result in variant recombination sites for which variant recombinases can be identified using the method disclosed herein. The resulting recombination sites have the desired properties:  
incompatibility with the third and fourth recombination sites and variant  
10 recognition sequences that extend the range of recombination-competent sites.

The recombination sites can have a variety of properties and relationships that make them useful for particular purposes. For example, the recombination sites can be designed such that the first and second recombination sites cannot be recombined by non-mutant recombinase to a significant extent.  
15 The allows separate assessment of cleavage by mutant and non-mutant recombinase. It is also useful if the first and second recombination sites have identical sequences, and the third and fourth recombination sites have identical sequences.

Recombination between the recombination sites can have a variety of effects that allows detection of recombination. For example, the constructs can be designed such that recombination between the first and second recombination sites alters the expression of the first reporter gene, where recombination between the first and second recombination sites is determined by determining if expression of the first reporter gene is altered; recombination between the third and fourth recombination sites alters the expression of the second reporter gene,  
25 where recombination between the third and fourth recombination sites is determined by determining if expression of the second reporter gene is altered; recombination between the first and second recombination sites allows the first reporter gene to be expressed; the first nucleic acid sequence includes a spacer sequence flanked by the first and second recombination sites, where the spacer  
30

sequence interrupts the first reporter gene such that the first reporter gene is not expressed, and where recombination of the first and second recombination sites excises the spacer sequence which allows the first reporter gene to be expressed; and/or a portion of the first reporter gene is inverted, wherein the inverted

5 portion of the first reporter gene is flanked by the first and second recombination sites, wherein recombination of the first and second recombination sites inverts the inverted portion of the first reporter gene which allows the first reporter gene to be expressed.

The constructs can also be designed such that recombination between the  
10 first and second recombination sites prevents expression of the first reporter gene; the first reporter gene is flanked by the first and second recombination sites, where recombination of the first and second recombination sites excises the first reporter gene which prevents expression of the first reporter gene; a portion of the first reporter gene is flanked by the first and second recombination sites, where recombination of the first and second recombination sites inverts the flanked portion of the first reporter gene which prevents expression of the first reporter gene; recombination between the third and fourth recombination sites allows the second reporter gene to be expressed; and/or the second nucleic acid sequence includes a spacer sequence flanked by the third and fourth  
15 recombination sites, where the spacer sequence inverts the second reporter gene such that the second reporter gene is not expressed, and where recombination of the third and fourth recombination sites excises the spacer sequence which allows the second reporter gene to be expressed.  
20

The constructs can also be designed such that a portion of the second  
25 reporter gene is inverted, where the inverted portion of the second reporter gene is flanked by the third and fourth recombination sites; and where recombination of the third and fourth recombination sites inverts the inverted portion of the second reporter gene which allows the second reporter gene to be expressed; recombination between the third and fourth recombination sites prevents  
30 expression of the second reporter gene to be expressed; the second reporter gene

is flanked by the third and fourth recombination sites, where recombination of the third and fourth recombination sites excises the second reporter gene which prevents expression of the second reporter gene; and/or a portion of the second reporter gene is flanked by the third and fourth recombination sites, where  
5 recombination of the third and fourth recombination sites inverts the flanked portion of the second reporter gene which prevents expression of the second reporter gene.

Expression of a reporter gene can include transcription of the gene, translation of the transcript (if the gene encodes a protein), and/or production of  
10 an active protein. As used herein, whether a reporter gene is expressed depends on the context. In general, a gene is considered to be expressed if it produces the expression product to be detected. Such expression products include full or partial transcripts of the gene, full or partial proteins, including active or inactive forms of the proteins, translated from the transcript. Since the goal in using  
15 reporter genes in the disclosed method is the detection of expression, any of these forms of expression product can be the object of detection. For example, if the gene's transcript is to be detected, the gene will be considered to be expressed if it produces the transcript, regardless of whether the transcript is translated or whether the resulting protein is active. If the an active protein  
20 encoded by the gene is to be detected, the gene is not expressed unless active protein is produced--mere transcription of the gene, or even translation to produce an inactive protein, will not be enough in this context. As a consequence, the expression product to be detected will influence the manner in which reporter genes should be interrupted or inverted in the disclosed  
25 constructs. For example, nearly any interruption of a reporter gene would prevent expression of an active protein encoded by the gene. On the other hand, an interruption of the coding region will usually not prevent production of a transcript. The structure of the disclosed constructs should be designed with these principles in mind. As used herein, an inactive expression product refers  
30 to an expression product that does not have an activity exhibited by the active

form of the expression product where that activity is required for detection of expression in the assay scheme being used.

The constructs can be designed such that the first nucleic acid sequence is a first nucleic acid construct and the second nucleic acid sequence is on a  
5 second nucleic acid construct; the first nucleic acid construct is an extrachromosomal vector and the second nucleic acid construct is in the genome of a host cell; and/or the first and second nucleic acid constructs are on the same nucleic acid construct.

#### D. Reporter Genes

10 Reporter genes are used to monitor whether recombination occurs in the disclosed constructs. Reporter genes can be any gene the expression of which can be detected either directly or indirectly. These include genes encoding enzymes, such as  $\beta$ -galactosidase, luciferase, and alkaline phosphatase, that can produce specific detectable products, and genes encoding proteins that can be  
15 directly detected. Virtually any protein can be directly detected by using, for example, specific antibodies to the protein. A preferred reporter protein that can be directly detected is the green fluorescent protein (GFP). GFP, from the jellyfish *Aequorea victoria*, produces fluorescence upon exposure to ultraviolet light without the addition of a substrate (Chalfie *et al.*, *Science* 263:802-5 (1994)). A number of modified GFPs have been created that generate as much  
20 as 50-fold greater fluorescence than does wild type GFP under standard conditions (Cormack *et al.*, *Gene* 173:33-8 (1996); Zolotukhin *et al.*, *J. Virol* 70:4646-54 (1996)). This level of fluorescence allows the detection of low levels of expression in cells.

25 Reporter genes encoding proteins producing a fluorescent signal are useful since such a signal allows cells to be sorted using FACS. Another way of sorting cells based on expression of the reporter gene involves using the reporter protein as a hook to bind cells. For example, a cell surface protein such as a receptor protein can be bound by a specific antibody. Cells expressing such a  
30 protein can be captured by, for example, using antibodies bound to a solid

substrate, using antibodies bound to magnetic beads, or capturing antibodies bound to the reporter protein. Many techniques for the use of antibodies as capture agents are known and can be used with the disclosed method.

The reporter gene can also encode an expression product that regulates  
5 the expression of another gene. This allows detection of expression of the reporter gene by detecting expression of the regulated gene. For example, a repressor protein can be encoded by the reporter gene. Loss of expression of the reporter gene (via recombination) would then result in derepression of the regulated gene. This type of indirect detection allows positive detection of loss  
10 of the expression of the reporter gene by the effector RNA molecule. One preferred form of this type of regulation is the use of an antibiotic resistance gene regulated by a repressor protein encoded by the reporter gene. By exposing the host cells to the antibiotic, only those cells in which expression of the reporter gene has been inhibited will grow since expression of the antibiotic resistance gene will be derepressed.  
15

#### E. Expression Sequences

The reporter genes can be expressed using any suitable expression sequences. Numerous expression sequences are known and can be used for expression of the reporter genes. Expression sequences can generally be classified as promoters, terminators, and, for use in eukaryotic cells, enhancers.  
20 Expression in prokaryotic cells also requires a Shine-Dalgarno sequence just upstream of the coding region for proper translation initiation. Inducible promoters are preferred for use with the first reporter gene since it is preferred that expression of the first reporter gene be adjustable.

Promoters suitable for use with prokaryotic hosts illustratively include  
25 the β-lactamase and lactose promoter systems, tetracycline (tet) promoter, alkaline phosphatase promoter, the tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. However, many other functional bacterial promoters are suitable. Their nucleotide sequences are generally known.

Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase, enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosphosphate isomerase, phosphoglucose isomerase, and glucokinase.

Examples of inducible yeast promoters suitable for use in the disclosed vectors include the promoter regions for alcohol dehydrogenase 2, isocytchrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Yeast enhancers also are advantageously used with yeast promoters.

Preferred promoters for use in mammalian host cells include promoters from polyoma virus, Simian Virus 40 (SV40), adenovirus, retroviruses, hepatitis B virus, herpes simplex virus (HSV), Rous sarcoma virus (RSV), mouse mammary tumor virus (MMTV), and most preferably cytomegalovirus (CMV), or from heterologous mammalian promoters such as the  $\beta$  actin promoter. Particularly preferred are the early and late promoters of the SV40 virus and the immediate early promoter of the human cytomegalovirus, MMTV LTR, RSV-LTR, and the HSV thymidine kinase promoter.

Transcription of the reporter gene by higher eukaryotes can be increased by inserting an enhancer sequence into the vector. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

The disclosed vectors preferably also contain sequences necessary for accurate 3' end formation of both reporter and effector RNAs. In eukaryotic cells, this would be a polyadenylation signal. In prokaryotic cells, this would be a transcription terminator.

## Method

### A. Identification of Variant Recombinases

The disclosed method involves producing mutant recombinases and testing the mutant recombinases with specially designed constructs. The constructs contain variant recombination sites that are not recognized by non-mutant recombinase but will undergo recombination in the presence of a mutant recombinase with altered specificity. The disclosed method also involves determining whether a variant recombinase retains the ability to mediate recombination at recombination sites recognized by non-variant recombinase.

This can be accomplished by using constructs containing recombination sites recognized by non-variant recombinase. Recombination at these recombination sites can be monitored or detected by any suitable means. It is preferred that recombination is detected by screening or selection based on the expression or lack of expression of a reporter gene. This can be accomplished by using constructs containing a reporter gene associated with the recombination sites such that the reporter gene is rearranged or deleted, or a spacer sequence interrupting the reporter gene is rearranged or deleted, as a result of recombination at the recombination sites. Recombination of such constructs will result in a loss of expression of the reporter gene, where the construct contained a functional reporter gene, or in a gain in expression of the reporter gene, where the construct contained a non-functional reporter gene.

#### 1. Production of Mutant Recombinases

Mutant recombinases can be produced by any suitable technique. In general, all that is required is a method of generating a variety of recombinase proteins having a variety of amino acid sequences. the most preferred way of doing this is to mutagenize or alter nucleic acid encoding the recombinase and then expressing the mutant recombinases. Numerous techniques for introducing alterations into nucleic acid sequences are known and can be used in the disclosed method. For example, alterations can be made by chemical mutagenesis, introduction of degenerate nucleic acid fragments into the base

nucleic acid molecule, and low fidelity PCR. The goal of this mutagenesis or alteration will be the generation of a population or set of mutant recombinases having a variety of sequences. The broader the range of variants, the more raw material for the identification process.

5       **2. Identification of Variant Recombinases That Recognize Variant Recombination Sites**

Variant recombinases that can mediate recombination at variant recombination sites are identified in the disclosed method by selecting for, screening for, or otherwise detecting recombination of specially designed 10 constructs having variant recombination sites. Recombination at variant recombination sites can be monitored or detected by any suitable means. It is preferred that recombination is detected by screening or selection based on the expression or lack of expression of a reporter gene. This can be accomplished by using constructs containing a reporter gene associated with the variant 15 recombination sites such that the reporter gene is rearranged or deleted, or a spacer sequence interrupting the reporter gene is rearranged or deleted, as a result of recombination at the recombination sites. Recombination of such constructs will result in a loss of expression of the reporter gene, where the construct contained a functional reporter gene, or in a gain in expression of the 20 reporter gene, where the construct contained a non-functional reporter gene.

**3. Identification of Variant Recombinases That Recognize Non-Variant Recombination Sites**

Variant recombinases that can mediate recombination at recombination sites recognized by non-variant recombinase (non-variant recombination sites) 25 are identified in the disclosed method by selecting for, screening for, or otherwise detecting recombination of specially designed constructs having recombination sites recognized by non-variant recombinase. Recombination at these recombination sites can be monitored or detected by any suitable means. It is preferred that recombination is detected by screening or selection based on 30 the expression or lack of expression of a reporter gene. This can be

accomplished by using constructs containing a reporter gene associated with the recombination sites recognized by non-variant recombinase such that the reporter gene is rearranged or deleted, or a spacer sequence interrupting the reporter gene is rearranged or deleted, as a result of recombination at the  
5 recombination sites. Recombination of such constructs will result in a loss of expression of the reporter gene, where the construct contained a functional reporter gene, or in a gain in expression of the reporter gene, where the construct contained a non-functional reporter gene.

It is preferred that the ability of a variant recombinase to mediate  
10 recombination at both variant recombination sites and recombination sites recognized by non-variant recombinase be assessed in the same system (such as a cell strain) either sequentially or simultaneously. When variant recombinases are tested for activity on both variant recombination sites and recombination sites recognized by non-variant recombinase in the same system or at the same  
15 time, it is preferred that two different reporter genes which can be separately detected or monitored be used. In this case, a first reporter gene can be associated with the variant recombination sites and a second reporter gene can be associated with recombination sites recognized by non-variant recombinase.

#### **B. Use of Variant Recombinases**

20 Variant recombinases produced in the disclosed method can be used for any purpose that unmodified recombinases can be used. The advantage is that the variant recombinases have a different or broader site specificity. In general, the disclosed variant recombinases can be used to mediate recombination of any nucleic acid in any setting, including *in vitro*, in cell culture, and *in vivo*.  
25 Recombination can be obtained in single celled organisms, such as bacterial cells, fungal cells, yeast cells, prokaryotic cells, and archae bacterial cells, the cells of multicellular organisms, including plants and animals, both in the organism and in culture. The disclosed variant recombinases can also be used in combination with other recombinases (including other variant recombinases)  
30 having a different site specificity. Such combinations allow more complex

recombination schemes to be used. Examples of such schemes are discussed below.

For some uses of the disclosed recombinases, first, second, and fourth DNA sequences comprising a first recombination site, a second recombination site, and a third recombination site, respectively, are introduced into cells. As used herein the expression "recombination site" means a nucleotide sequence at which a recombinase or variant recombinase can catalyze a site-specific recombination.

Methods for introducing a DNA sequence into cells are known in the art. 10 These methods typically include the use of a DNA vector to introduce the sequence into the DNA of a single or limited number of eukaryotic cells and then growing such cell or cells to generate a suitable population of cells. As used herein, the term "vector" includes plasmids, viruses, and viral vectors. Preferably, the DNA sequences are introduced by a plasmid capable of 15 transforming a selected cell while carrying a DNA sequence. The particular vector which is employed to introduce the DNA sequence into a selected cell is not critical.

In the present method, the recombination sites are contacted with a variant recombinase, thereby producing the site specific recombination. A 20 preferred means of contacting the DNA to be recombined with a variant recombinase is to place the DNA to be recombined into a cell expressing nucleic acid encoding the variant recombinase. Preferably, expression of the variant recombinase is under the control of a regulatory nucleotide sequence. Suitable regulatory nucleotide sequences are known in the art. The regulatory nucleotide 25 sequence which is employed with a selected eukaryotic cell is not critical to the method. A partial list of suitable regulatory nucleotide sequences includes the long terminal repeat of Moloney sarcoma virus described by Blochlinger and Diggelmann, *Mol. Cell Bio.*, 4:2929-2931 (1984); the mouse metallothionein-I promoter described by Pavlakis and Hamer, *Proc. Natl. Acad. Sci USA*, 80:397- 30 401 (1983); the long terminal repeat of Rous sarcoma virus described by

Gorman et al., *Proc. Natl. Acad. Sci USA*, 79:6777-6781 (1982); and the early region promoter of SV40 described by Southern and Berg, *J. Mol. Appl. Genet.*, 1:327-341 (1982).

In an embodiment where the cells are yeast, suitable regulatory  
5 nucleotide sequences include GAL1, GAL10, ADH1, CYC1, and TRP5  
promoters. GAL1 and GAL10 promoters are present on plasmid pBM150 which  
is described by Johnston and Davis, *Molec. Cell. Biol.*, 4:1440 (1984). The  
ADH1 promoter, also called ADC1, is present on plasmid pAAH5 which is  
described by Ammer, *Methods Enzymol.*, 101:192 (1983). The CYC1 promoter  
10 is described by Stiles et al., *Cell*, 25:277 (1981). The TRP5 promoter is  
described by Zalkin and Yanofsky, *J. Biol. Chem.*, 257:1491 (1982). Preferably,  
the regulatory nucleotide sequence is a GAL1 promoter.

In one embodiment where the cell is yeast, the first, second, and  
optionally, third and fourth DNA sequences are introduced into one strain of  
15 yeast. Alternatively, the DNA sequences are introduced into two different  
strains of yeast of opposite mating types which are subsequently mated to form a  
single strain having all three or four DNA sequences. Preferably, the plasmid  
contains either (1) a nucleotide sequence of DNA homologous to a resident  
yeast sequence to permit integration into the yeast DNA by the yeast's  
20 recombination system or (2) a nucleotide sequence of DNA which permits  
autonomous replication in yeast. One nucleotide sequence which permits  
autonomous replication in yeast is an ARS sequence described by Stinchcomb et  
al., *Nature*, 282:39 (1979). A partial list of plasmids capable of transforming  
yeast includes YIP5, YRP17 and YEP24. These plasmids are disclosed and  
25 described by Botstein and Davis, *The Molecular Biology of the Yeast  
Saccharomyces, Metabolism and Gene Expression* (ed. Strathern et al.), (Cold  
Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982), at page 607.

Since most recombination sites are asymmetrical nucleotide sequences,  
two recombination sites on the same DNA molecule can have the same or  
30 opposite orientations with respect to each other. Recombinations between

recombination sites in the same orientation result in a deletion of the DNA segment located between the two recombination sites and a connection between the resulting ends of the original DNA molecule. The deleted DNA segment forms a circular molecule of DNA. The original DNA molecule and the 5 resulting circular molecule each contain a single recombination site (see Figure 2). Recombination between recombination sites in opposite orientations on the same DNA molecule result in an inversion of the nucleotide sequence of the DNA segment located between the two recombination sites (see Figure 2). In addition, reciprocal exchange of DNA segments proximate to recombination sites located on two different DNA molecules can occur. All of these 10 recombination events are catalyzed by recombinases, including the disclosed variants and wild type recombinases.

Recombination using the disclosed variant recombinases can be used *in vitro* to produce site-specific recombination of nucleic acid molecules. This is 15 useful for a wide variety of manipulations that currently employ wild type recombinases or involve traditional restriction enzyme cleavage followed by ligation. Examples include recombination of libraries of DNA fragments into vectors or in desired structures, and labeling of DNA via recombination. Recombined DNA formed by *in vitro* recombination can then be introduced into 20 cells. For example, constructs formed *in vitro* can be introduced into cells to resolve the structures formed *in vitro* or to select active structures. In particular, large concatemers of subject DNA and spacer/vector fragments can be made, introduced into cells, and circularized into vector units in the cells. Such recombination could also be performed *in vitro* if desired.

The disclosed variant recombinases can be used to label DNA by 25 recombining a DNA molecule of interest with a labeled DNA molecule. Use of a recombinase for labeling is advantageous since it involves fewer steps than traditional labeling via DNA synthesis or ligation. These considerations are particularly important when large DNA molecules (over 20 kb) are to be labeled 30 since such large molecules will fragment more the more they are manipulated.

Recombination mediated by the disclosed variant recombinases and variant recombination sites can be used to manipulate a host cell genome as desired and simultaneously introduce a marker gene flanked by the recognition sites of a second recombinase. After selection, leading to an accumulation of 5 cells carrying the desired genomic alteration, one could simply remove the marker gene by expression of the second site-specific recombinase. A large number of recombinases suitable for this purpose exists in nature, including  $\lambda$  Integrase (Int), yeast Flp, etc. (Nunes-Döby et al., *Nucl. Acids Res.*, 26:391-406 (1998)). Variant recombinases having different site specificity can also be used.

10 Since the disclosed variant recombinases recognize both wild type recombination sites and variant recombination sites that are not recognized by wild type recombinase, wild type recombinase and variant recombinases can be used to mediate sequential recombination between nucleic acids containing a combination of wild type recombination sites and variant recombination sites.

15 For example, generation of knockout animals and plants can be made more efficient by using a structure wild type recombination site-selectable marker-wild type recombination site-endogenous gene-variant recombination site (rather than the conventional wild type recombination site-selectable marker-wild type recombination site-endogenous gene-wild type recombination site). Such a 20 structure allows the selectable marker to be removed by the action of wild type recombinase without disturbing the gene since wild type recombinase will not recognize the variant recombination site to any significant degree. The endogenous gene can then be removed later by the action of a variant recombinase since the disclosed variant recombinases recognize both wild type 25 and variant recombination sites.

In a preferred embodiment of the disclosed method, the first and second DNA sequences are introduced into cells connected by a pre-selected DNA segment. The segment can be a gene or any other sequence of deoxyribonucleotides of homologous, heterologous or synthetic origin.

30 Preferably, the pre-selected DNA segment is a gene for a structural protein, an

enzyme, or a regulatory molecule. If the first and second recombination sites have the same orientation, activation of the regulatory nucleotide sequence produces a deletion of the pre-selected DNA segment. If the first and second recombination sites have opposite orientation, activation of the regulatory  
5 nucleotide sequence produces an inversion of the nucleotide sequence of the pre-selected DNA segment.

If a fourth DNA sequence (containing the third recombination site) is also introduced into cells, it is preferred that the second and fourth DNA sequences be introduced into cells connected by a second pre-selected DNA  
10 segment. The second segment can be a gene or any other sequence of deoxyribonucleotides of homologous, heterologous or synthetic origin. Preferably, the second pre-selected DNA segment is a gene for a structural protein, an enzyme, or a regulatory molecule. If the second and third recombination sites have the same orientation, activation of the regulatory  
15 nucleotide sequence produces a deletion of the second pre-selected DNA segment. If the second and third recombination sites have opposite orientation, activation of the regulatory nucleotide sequence produces an inversion of the nucleotide sequence of the second pre-selected DNA segment.

Combinations of wild type and variant recombination sites, and  
20 combinations of different orientations of the recombination sites, in DNA introduced into cells can multiply recombination options. For example, if the first and second recombination sites are wild type recombination sites and the third recombination site is a variant recombination site (all in the same orientation) then wild type recombinase can produce a deletion of the first pre-selected DNA segment (but not the second) and a variant recombinase can  
25 produce a deletion of the first, second, or both pre-selected DNA segments. This arrangement allows sequential deletion of the first and second pre-selected DNA segments.

If the first and second recombination sites are wild type recombination  
30 sites and the third recombination site is a variant recombination site, and the first

recombination site has the opposite orientation from the second and third recombination sites (which, of course, have the same orientation) then wild type recombinase can produce an inversion of the first pre-selected DNA segment and a variant recombinase can produce a deletion of the second pre-selected

- 5 DNA segment (and/or produce an inversion of the first pre-selected DNA segment or the entire section spanning the first, second, and third recombination sites).

If the first and third recombination sites are wild type recombination sites and the second recombination site is a variant recombination site, and the  
10 second recombination site has the opposite orientation from the first and third recombination sites (which, of course, have the same orientation) then wild type recombinase can produce a deletion of the entire section spanning the first, second, and third recombination sites, and a Cre variant can produce an inversion of the first, second, or both pre-selected DNA segments.

- 15 If the first and third recombination sites are wild type recombination sites and the second recombination site is a variant recombination site, and the first recombination site has the opposite orientation from the second and third recombination sites (which, of course, have the same orientation) then wild type recombinase can produce an inversion of the entire section spanning the first,  
20 second, and third recombination sites, and a variant recombinase can produce a deletion of the second pre-selected DNA segments and an inversion of the first pre-selected DNA segment.

Many more combinations of wild type and variant recombination sites and or recombination site orientations are possible. For example, the variant  
25 recombinase can also be used with a different variant recombinase having a different site specificity rather than wild type recombinase. The above examples illustrate the general principles involved in designing specific recombinations that may be desired. It should be understood that the above combinations of recombination sites can be extended to the use of more recombination sites (that  
30 is more than three) and more intervening, pre-selected DNA segments.

For some uses of the disclosed recombinases, first, second, and fourth DNA sequences comprising a first lox site, a second lox site, and a third lox site, respectively, are introduced into cells. As used herein the expression "lox site" means a nucleotide sequence at which the gene product of the cre gene, referred to herein as Cre, and/or the disclosed Cre variants, can catalyze a site-specific recombination. LoxP site is a 34 base pair nucleotide sequence (Figure 1) which can be directly synthesized or isolated from bacteriophage P1 by methods known in the art. The Lox P site is an example of a wild type lox site. One method for isolating a LoxP site from bacteriophage P1 is disclosed by Hoess et al., *Proc. Natl. Acad. Sci. USA*, 79:3398-3402 (1982). The LoxP site consists of two 13 base pair inverted repeats separated by an 8 base pair spacer region. The nucleotide sequences of the insert repeats and the spacer region are as follows.

ATAACTTCGTATAATGTATGCTATACGAAGTTAT

Other wild type lox sites include LoxB, LoxL and LoxR sites which are nucleotide sequences isolated from E. coli. These sequences are disclosed and described by Hoess et al., *Proc. Natl. Acad. Sci. USA*, 79:3398-3402 (1982). Preferred wild type lox sites are LoxP or LoxC2. Lox sites can also be produced by a variety of synthetic techniques which are known in the art. For example, synthetic techniques for producing lox sites are disclosed by Ito et al., *Nuc. Acid Res.*, 10:1755 (1982) and Ogilvie et al., *Science*, 214:270 (1981).

The gene product of the cre gene is a recombinase herein designated "Cre" which effects site-specific recombination of DNA at lox sites. As used herein, the expression "cre gene" means a nucleotide sequence which codes for a gene product which effects site-specific recombination of DNA in cells at lox sites. One cre gene (the wild type cre gene) can be isolated from bacteriophage P1 by methods known in the art. One method for isolating a cre gene from bacteriophage P1 is disclosed by Abremski et al., *Cell*, 32:1301-1311 (1983), the disclosure of which is incorporated herein by reference.

Genes engineered into cells for producing a foreign protein are often placed under the control of a highly active promoter. The activity of the

promoter can result in an overproduction of the protein which interferes with the growth of the engineered cell. This overproduction of the protein can make it difficult to grow the engineered cell in sufficient quantity to make protein production economically feasible. The present invention provides a method

5 whereby engineered cells can be grown to a desired density prior to expressing the engineered gene. The engineered gene is expressed, as desired, by activating a regulatory nucleotide sequence responsible for controlling expression of DNA encoding a variant recombinase. Methods of controlling the expression of an engineered gene include the following:

10 (1) A DNA segment flanked by recombination sites in the same orientation is introduced into DNA in a cell between a promoter and an engineered gene to render the promoter incapable of expressing the gene. A second DNA sequence comprising a regulatory nucleotide sequence and DNA encoding a variant recombinase is also introduced in the DNA. After the 15 engineered cells are grown to a desired density, the regulatory nucleotide sequence is activated thereby effecting expression of the variant recombinase and producing a deletion of the DNA segment. The engineered gene would then be expressed.

20 (2) A gene for a regulatory molecule flanked by recombination sites in the same orientation is introduced into DNA in a cell. The regulatory molecule inhibits expression of an engineered gene. A second DNA sequence comprising a regulatory nucleotide sequence and DNA encoding a variant recombinase is also introduced into the DNA. After the engineered cells are grown to a desired density, the regulatory nucleotide sequence is activated thereby effecting 25 expression of the variant recombinase and producing a deletion of the gene for the regulatory molecule. The engineered gene would then be expressed.

30 (3) An engineered gene lacking a promoter and flanked by two recombination sites in opposite orientations is introduced into DNA in a cell such that the 3' end of the gene lies adjacent to the transcription start site of a regulatory nucleotide sequence. A second DNA sequence comprising a

regulatory nucleotide sequence and DNA encoding a variant recombinase is also introduced into the DNA. Since the engineered gene would be transcribed in the antisense direction, no engineered protein would be produced. After the engineered cell is grown to a desired density, the regulatory nucleotide sequence  
5 is activated thereby effecting expression of the variant recombinase and producing an inversion of the desired gene. The engineered gene could then be transcribed in the proper direction and expressed.

Numerous methods and techniques have been developed for the use of Cre recombinase and other, similar recombinases such as FLP. The disclosed  
10 variant recombinases can also be used in any of these methods. Adaptation of these methods to the use of the disclosed variant recombinases is straightforward. Generally, all that is required is substitution of a variant recombinase (or a gene expressing a variant recombinase) for the original recombinase (or recombinase gene) and, if appropriate, substitution of variant  
15 (or wild type) recombination sites for the original recombination sites used in the method.

Examples of methods involving wild type recombinases and wild type recombination sites that can be adapted for use with the disclosed variant recombinases and recombination sites include recombination of DNA in phage  
20 packaging systems, recombination of DNA to form phage display libraries (for example, Fisch *et al.*, *Proc Natl Acad Sci USA* 93(15):7761-6 (1996), and Waterhouse *et al.*, *Nucleic Acids Res* 21(9):2265-6 (1993), and other uses (for example, (Sauer *et al.*, *Proc. Natl. Acad. Sci. USA* 84: 9108-9112 (1987), Mullins *et al.*, *Nucleic Acids Res* 25(12):2539-40 (1997), Aoki *et al.*, *Mol Med*  
25 5(4):224-31 (1999)).

Other examples of specific methods in which the disclosed variant recombinases can be used or substituted include methods disclosed in U.S. Patent No. 5,888,981, U.S. Patent No. 5,888,732, U.S. Patent No. 5,885,836, U.S. Patent No. 5,885,793, U.S. Patent No. 5,885,779, U.S. Patent No.  
30 5,885,776, U.S. Patent No. 5,882,893, U.S. Patent No. 5,882,888, U.S. Patent

No. 5,877,400, U.S. Patent No. 5,871,907, U.S. Patent No. 5,866,755, U.S.  
Patent No. 5,866,361, U.S. Patent No. 5,859,310, U.S. Patent No. 5,858,657,  
U.S. Patent No. 5,854,067, U.S. Patent No. 5,851,808, U.S. Patent No.  
5,849,995, U.S. Patent No. 5,849,989, U.S. Patent No. 5,849,708, U.S. Patent  
5 No. 5,849,572, U.S. Patent No. 5,849,571, U.S. Patent No. 5,849,553, U.S.  
Patent No. 5,844,079, U.S. Patent No. 5,843,744, U.S. Patent No. 5,843,742,  
U.S. Patent No. 5,843,694, U.S. Patent No. 5,840,540, U.S. Patent No.  
5,837,844, U.S. Patent No. 5,837,242, U.S. Patent No. 5,834,202, U.S. Patent  
No. 5,830,729, U.S. Patent No. 5,830,698, U.S. Patent No. 5,830,461, U.S.  
10 Patent No. 5,817,492, U.S. Patent No. 5,814,618, U.S. Patent No. 5,814,500,  
U.S. Patent No. 5,814,300, U.S. Patent No. 5,807,995, U.S. Patent No.  
5,807,708, U.S. Patent No. 5,801,030, U.S. Patent No. 5,800,998, U.S. Patent  
No. 5,795,734, U.S. Patent No. 5,795,726, U.S. Patent No. 5,792,833, U.S.  
15 Patent No. 5,792,632, U.S. Patent No. 5,789,156, U.S. Patent No. 5,777,194,  
U.S. Patent No. 5,776,449, U.S. Patent No. 5,773,697, U.S. Patent No.  
5,770,384, U.S. Patent No. 5,767,376, U.S. Patent No. 5,763,240, U.S. Patent  
No. 5,756,671, U.S. Patent No. 5,744,343, U.S. Patent No. 5,744,336, U.S.  
20 Patent No. 5,736,377, U.S. Patent No. 5,733,744, U.S. Patent No. 5,733,743,  
U.S. Patent No. 5,733,733, U.S. Patent No. 5,731,182, U.S. Patent No.  
5,723,765, U.S. Patent No. 5,723,333, U.S. Patent No. 5,723,287, U.S. Patent  
No. 5,721,367, U.S. Patent No. 5,721,118, U.S. Patent No. 5,700,470, U.S.  
25 Patent No. 5,686,595, U.S. Patent No. 5,679,523, U.S. Patent No. 5,677,177,  
U.S. Patent No. 5,658,772, U.S. Patent No. 5,656,438, U.S. Patent No.  
5,654,182, U.S. Patent No. 5,654,168, U.S. Patent No. 5,650,491, U.S. Patent  
No. 5,650,308, U.S. Patent No. 5,650,298, U.S. Patent No. 5,643,727, U.S.  
30 Patent No. 5,641,866, U.S. Patent No. 5,641,748, U.S. Patent No. 5,639,726,  
U.S. Patent No. 5,635,381, U.S. Patent No. 5,629,179, U.S. Patent No.  
5,629,159, U.S. Patent No. 5,614,389, U.S. Patent No. 5,612,205, U.S. Patent  
No. 5,596,089, U.S. Patent No. 5,591,609, U.S. Patent No. 5,589,362, U.S.  
Patent No. 5,539,094, U.S. Patent No. 5,530,191, U.S. Patent No. 5,527,695,

U.S. Patent No. 5,510,099, U.S. Patent No. 5,478,731, U.S. Patent No. 5,441,884, U.S. Patent No. 5,434,066, U.S. Patent No. 5,378,618, U.S. Patent No. 5,354,668, U.S. Patent No. 5,334,515, U.S. Patent No. 5,300,431, and U.S. Patent No. 4,959,317.

5       **1. Use of Variants Recombinases in Plants and Plant Cells**

Methods for introducing a DNA sequence into plant cells are known in the art. Nucleic acids can generally be introduced into plant protoplasts, with or without the aid of electroporation, polyethylene glycol, or other processes known to alter membrane permeability. Nucleic acid constructs can also be 10 introduced into plants using vectors comprising part of the Ti- or Ri-plasmid, a plant virus, or an autonomously replicating sequence. Nucleic acid constructs can also be introduced into plants by microinjection or by high-velocity microprojectiles, also termed "particle bombardment" or "biolistics" (Sanford, J. C., *Tibtech* 6: 299 (1988)), directly into various plant parts. The preferred 15 means of introducing a nucleic acid fragment into plant cells involves the use of *A. tumefaciens* containing the nucleic acid fragment between T-DNA borders either on a disarmed Ti-plasmid (that is, a Ti-plasmid from which the genes for tumorigenicity have been deleted) or in a binary vector in trans to a disarmed Ti-plasmid. The Agrobacterium can be used to transform plants by inoculation of 20 tissue explants, such as stems, roots, or leaf discs, by co-cultivation with plant protoplasts, or by inoculation of seeds or wounded plant parts.

Foreign genes can be introduced into a wide range of crop species. Thus, the disclosed variant recombinases and method are applicable to a broad range of agronomically or horticulturally useful plants. The particular method 25 which is employed to introduce the DNA sequence into a selected plant cell is not critical. In a preferred embodiment, DNA sequences are introduced into plant cells by co-cultivation of leaf discs with *A. tumefaciens* essentially as described by Horsch et al., *Science*, 227: 1229-1231 (1985) omitting the nurse cultures.

In the present method, the recombination sites are contacted with a variant recombinase, thereby producing the site specific recombination. In one embodiment, a variant recombinase, or messenger RNA encoding a variant recombinase, is introduced into the cells directly by micro-injection, biolistics, or other protein or RNA introduction procedure. In a preferred embodiment, DNA encoding the variant recombinase is introduced into the plant cell under the control of a promoter that is active in plant cells. Suitable regulatory nucleotide sequences are known in the art. The promoter which is employed with a selected plant cell is not critical to the method of the invention. A partial list of suitable promoters include the 35S promoter of cauliflower mosaic virus described by Odell et al., *Nature*, 313: 810-812 (1985); the promoter from the nopaline synthase gene of *A. tumefaciens* described by Depicker et al., *J. of Mol. Appl. Genet.*, 1: 561-573 (1982); the promoter from a Rubisco small subunit gene described by Mazur and Chui, *Nucleic Acids Research* 13: 2373-2386 (1985); the 1' or 2' promoter from the TR-DNA of *A. tumefaciens* described by Velten et al., *EMBO J.* 12: 2723-2730 (1984); the promoter of a chlorophyll a/b binding protein gene described by Dunsmuir et al., *J. Mol. Appl. Genet.* 2: 285-300 (1983); the promoter of a soybean seed storage protein gene described by Chen et al., *Proc. Natl. Acad. Sci. USA*, 83: 8560-8564 (1986); and the promoter from the wheat EM gene described by Marcotte et al., *Nature* 335: 454-457 (1988). Variant recombinases can be expressed throughout the plant generally in all cells at all stages of development, or expression of variant recombinases can be more specifically controlled through the use of promoters or regulatory nucleotide sequences having limited expression characteristics. Variant recombinases can be expressed in a tissue specific manner, for example only in roots, leaves, or certain flower parts. Variant recombinases can be expressed in a developmentally specific time period, for example only during seed formation or during reproductive cell formation. Expression of variant recombinases can also be placed under the control of a promoter that can be regulated by application of an inducer. In this case expression is off or very low until the

external inducer is applied. Promoters active in plant cells have been described that are inducible by heat shock (Gurley et al., *Mol. Cell. Biol.* 6: 559-565 (1986)), ethylene (Bfoglie et al., *Plant Cell* 1: 599-607 (1989)), auxin (Hagan and Guilfoyle, *Mol. Cell. Biol.* 5: 1197-1203 (1985)), abscisic acid (Marcotte et al., *Nature* 335: 454-457 (1988)), salicylic acid (EPO 332104A2 and EPO 337532A1), and substituted benzenesulfonamide safeners (WO 90/11361).  
5 Control of expression of variant recombinases by the safener-inducible promoter 2-2, or its derivatives, allows the expression to be turned on only when the inducing chemical is applied and not in response to environmental or  
10 phytohormonal stimuli. Thus expression can be initiated at any desired time in the plant life cycle. Preferably, the regulatory nucleotide sequence is a 35S promoter or a 2-2 promoter. The above techniques and materials can also be used to express wild type recombinase in plant cells if required by the particular recombination pattern to be accomplished.  
15

One application of the disclosed variant recombinases is in controlling male fertility in a method for producing hybrid crops. Hybridization of a crop involves the crossing of two different lines to produce hybrid seed from which the crop plants are grown. Hybrid crops are superior in that more of the desired traits can be introduced into the production plants. For instance, quality traits such as oil content, herbicide resistance, disease resistance, adaptability to environmental conditions, and the like, can be hybridized in offspring so that the latter are invested with the most desirable traits of its parents. In addition, progeny from a hybrid cross may possess new qualities resulting from the combination of the two parental types, such as yield enhancement resulting from the phenomenon known as heterosis. Controlled cross-fertilization to produce hybrid seeds has been difficult to achieve commercially due to competing self-fertilization, which occurs in most crop plants.  
20  
25  
30

Hybrid seed production is typically performed by one of the following means: (a) mechanically removing or covering the male organs to prevent self-fertilization followed by exposing the male-disabled plants to plants with male

organs that contain the trait(s) desired for crossing; (b) growing genetically male-sterile plants in the presence of plants with fertile male organs that contain the trait that is desired for crossing; or (c) treating plants with chemical hybridizing agents (CHA) that selectively sterilize male organs followed by 5 exposing the male-disabled plants to plants with fertile male organs that contain the trait that is desired for crossing. Some disadvantages to each of these methods include: (a) applicability only to a few crops, such as corn, where the male and female organs are well separated; and it is labor intensive and costly; (b) genetically male sterile lines are cumbersome to maintain, requiring crosses 10 with restorer lines; (c) all CHAs exhibit some degree of general phytotoxicity and female fertility reduction. Also CHAs often show different degrees of effectiveness toward different crop species, or even toward different varieties within the same species.

A molecular genetic approach to hybrid crop production applicable to a 15 wide range of crops and involves genetic male sterility is described in EPA 89-344029. This system involves the introduction of a cell disruption gene that is expressed only in the tapetal tissue of anthers thereby destroying the developing pollen. The resulting genetically male sterile plants serve as the female parents in the cross to produce hybrid seed. This system could be highly effective and desirable. However one disadvantage is that since the male sterile parent is 20 heterozygous for the sterility gene which acts as a dominant trait, only 50% of the plants grown from the hybrid seed are fertile, the rest retain the sterility gene. This situation will result in reduced pollen shed in the production field which may lead to reduced seed set and yield. Addition of recombinase 25 technology to this hybrid scheme allows restoration of fertility to a much higher percentage of plants in the production field, as well as elimination of the cell disruption gene. Placing the male sterility gene between recombination sites allows it to be deleted following introduction of a variant recombinase into the hybrid from the male parent.

RECOMBINASES  
AND THEIR USE IN  
GENETIC ENGINEERING

Another application of the disclosed variant recombinases is in making seedless produce. Seedlessness is desirable in consumed produce for convenience and taste. Currently "seedless" watermelon is sold that actually contains some developed seed and a large number of immature seed that varies in size up to that of fully mature seed. To produce these watermelon first a hybrid cross is made between a tetraploid maternal parent and a diploid pollinator. The resulting triploid seed produces self-infertile plants that are crossed with a diploid pollinator to produce seedless fruit (Kihara, *Proc. Soc. Hort. Sci.*, 58: 217-230, (1951)). This production scheme suffers the following problems: (i) Creating a tetraploid plant, which is accomplished by a chromosome duplication method, is difficult. Also the number of seeds per fruit on this tetraploid plant must be low since this has a positive correlation with seed number in the final product (Andrus, Production of Seedless Watermelons, USDA Tech. Bull. No. 1425 (1971)); (ii) good combining ability of the diploid pollinator and the tetraploid plant is difficult to achieve (Henderson, *J. Amer. Soc. Hort. Sci.*, 102: 293-297 (1977)); (iii) the triploid seeds are much inferior to regular diploid seeds in vigor and germinability (Maynard, *Hort. Sci.*, 24: 603-604 (1989)). These problems, together with incomplete seedlessness in the final product, make the development of seedless watermelon slow and difficult. This ploidy-based approach to seedlessness is possible only in those few species where unusual euploid plants (tetraploid and triploid for watermelon, for example) are viable.

A molecular genetic approach to seedlessness involving the disclosed variant recombinases is much more efficient, resulting in a more reliably seedless product and does not involve changes in ploidy. Thus it is more generally applicable to a wider range of species. A recombination site/polyA-inactivated cell disruption gene regulated by a seed-specific promoter is introduced into a plant. When this plant is crossed to a plant expressing a variant recombinase, the disruption gene is activated and expressed in the seed, thereby disrupting seed development. The certainty of endosperm failure

(caused by the cell disruption gene product) leading to the abortion of the whole seed is very high. In most dicots, the endosperm supplies the nutrients needed for early embryo development. Endosperm abortion invariably leads to seed abortion (Brink and Cooper, *Bot. Rev.* 8: 423-541 (1947)).

- 5       The seed-specific promoter used can be selected from the group of promoters known to direct expression in the embryo and/or the endosperm of the developing seed, most desirably in the endosperm. Examples of seed-specific promoters include but are not limited to the promoters of seed storage proteins. The seed storage proteins are strictly regulated, being expressed almost exclusively in seeds in a highly tissue-specific and stage-specific manner (Higgins et al., *Ann. Rev. Plant Physiol.* 35: 191-221 (1984); Goldberg et al., *Cell* 56: 149-160 (1989)). Also, different seed storage proteins may be expressed at different stages of seed development and in different parts of the seed.
- 10      There are numerous examples of seed-specific expression of seed storage protein genes in transgenic dicotyledonous plants. These include genes from dicotyledonous plants for bean  $\beta$ -phaseolin (Sengupta-Gopalan et al., *Proc. Natl. Acad. Sci. USA* 82: 3320-3324 (1985) and Hoffman et al., *Plant Mol. Biol.* 11: 717-729 (1988)), bean lectin (Voelker et al., *EMBO J* 6: 3571-3577 (1987), soybean lectin (Ocamuro et al., *Proc. Natl. Acad. Sci. USA* 83: 8240-8344 (1986)), soybean kunitz trypsin inhibitor (Perez-Grau and Goldberg *Plant Cell* 1: 1095-1109 (1989)), soybean  $\beta$ -conglycinin (Beachy et al., *EMBO J* 4: 3047-3053 (1985), Barker et al., *Proc. Natl. Acad. Sci.* 85: 458-462 (1988), Chen et al., *EMBO J* 7: 297-302 (1988), Chen et al., *Dev. Genet.* 10: 112-122 (1989), Naito et al., *Plant Mol. Biol.* 11: 683-695 (1988)), pea vicillin (Higgins et al., *Plant Mol. Biol.* 11: 109-123 (1988)), pea convicillin (Newbigin et al., *Planta* 180: 461 (1990)), pea legumin (Shirsat et al., *Mol. Gen. Genetics* 215: 326 (1989)), rapeseed napin (Radke et al., *Theor. Appl. Genet.* 75: 685-694 (1988)), as well as genes from monocotyledonous plants such as for maize 15-kd zein (Hoffman et al., *EMBO J* 6: 3213-3221 (1987)), barley  $\beta$ -hordein (Marris et al.,

*Plant Mol. Biol.* 10: 359-366 (1988)), and wheat glutenin (Colot et al., *EMBO J* 6: 3559-3564 (1987)). Moreover, promoters of seed-specific genes operably linked to heterologous coding regions in chimeric gene constructions also maintain their temporal and spatial expression pattern in transgenic plants.

5 Such examples include *Arabidopsis thaliana* 2S seed storage protein gene promoter to express enkephalin peptides in *Arabidopsis* and *Brassica napus* seeds (Vandekerckhove et al., *Bio/Technology* 7: 929-932 (1989)), bean lectin and bean  $\beta$ -phaseolin promoters to express luciferase (Riggs et al., *Plant Sci.* 63: 47-57 (1989)), and wheat glutenin promoters to express chloramphenicol acetyl

10 transferase (Colot et al., *EMBO J.* 6: 3559-3564 (1987)). Promoters highly expressed early in endosperm development are most effective in this application. Of particular interest is the promoter from the a subunit of the soybean  $\beta$ -conglycinin gene (Walling et al., *Proc. Natl. Acad. Sci. USA* 83: 2123-2127 (1986)) which is expressed early in seed development in the endosperm and the

15 embryo.

The cell disruption gene used can be selected from a group of genes encoding products that disrupt normal functioning of cells. There are many proteins that are toxic to cells when expressed in an unnatural situation. Examples include the genes for the restriction enzyme EcoRI (Barnes and Rine,

20 *Proc. Natl. Acad. Sci. USA* 82: 1354-1358 (1985)), diphtheria toxin A (Yamaizumi et al., *Cell* 15: 245-250 (1987)), streptavidin (Sano and Cantor, *Proc. Natl. Acad. Sci. USA* 87: 142-146 (1990)), and barnase (Paddon and Hartley, *Gene* 53: 11-19 (1987)). Most preferred for this system is the coding region of barnase which has been shown to be highly effective in disrupting the

25 function of plant cells (EPA 89-344029).

A highly desirable seedless system is one in which fully fertile F1 seed develops, that can then be grown into plants that produce only seedless fruit. This system is economically favorable in that for each cross pollination, a large number of seedless fruits result: the number of F1 seed from one cross X the number of fruits produced on an F1 plant. Also incorporated in this scheme are

30

the advantages of growing a hybrid crop, including the combining of more valuable traits and hybrid vigor. This is accomplished in the same manner as described above except that the recombination site/polyA-inactivated disruption gene is expressed from a seed maternal tissue (seed coat or nucellus)-specific promoter. For example, the seed coat is the outgrowth of the integuments, a strictly maternal tissue. Therefore the hybrid cross that brings the recombination site/polyA-inactivated disruption gene together with the recombinase gene does not involve this seed coat tissue. The seed coat of the F1 seed has either recombination sites or recombinase, depending on which is used as the female parent, and thus F1 seed develop normally. After the F1 seed gives rise to a fruit-bearing F1 plant, all vegetative cells (including seed coat cells) inherit both recombination sites and recombinase from the embryo. Thus the seed coat of the F1 plant has an activated cell disruption gene.

The seed coat is an essential tissue for seed development and viability. When the seed is fully matured, the seed coat serves as a protective layer to inner parts of the seed. During seed development, the seed coat is a vital nutrient-importing tissue for the developing embryo. The seed is nutritionally "parasitic" to the mother plant. All raw materials necessary for seed growth must be imported. In seeds of dicotyledonous plants, the vascular tissue enters the seed through the funiculus and then anastamoses in the seed coat tissue. There is no vascular tissue connection or plasmodesmata linkage between the seed coat and the embryo. Therefore, all nutrient solutes delivered into the developing seed must be unloaded inside the seed coat and then move by diffusion to the embryo. Techniques have been developed to study the nutrient composition in the seed coat (Hsu et al., *Plant Physiol.* 75: 181 (1984); Thorne & Rainbird, *Plant Physiol.* 72: 268 (1983); Patrick, *J. Plant Physiol.* 115: 297 (1984); Wolswinkel & Ammerlaan, *J. Exp. Bot.* 36: 359 (1985)), and also the detailed cellular mechanisms of solute unloading (Offler & Patrick, *Aust. J. Plant Physiol.* 11: 79 (1984); Patrick, *Physiol. Plant* 78: 298 (1990)). It is

obvious that the destruction of this vital nutrient-funnelling tissue causes seed abortion.

The disclosed tissue-specific and site-directed DNA recombination can be used to obtain seedless fruit production. This method is useful for the 5 production of seedless watermelon, for example. A combination of gene expression specific for maternally inherited seed tissue and the disclosed recombinase system can be used for the production of seedless watermelon. The system can be universally applied to any horticultural crop in which the presence of seeds is undesirable and difficult to be eliminated through conventional 10 breeding methods. The system also allows the normal production of F1 seeds. The ability to maintain heterosis is an advantage of producing F2 seedless fruits.

The existing production of seedless watermelon indicates that seed development is not essential for the watermelon fruit development. However, conventional production of seedless watermelon using the ploidy imbalance 15 trick has never been very popular due to the difficulty of overcoming the yield and production problems. Creating and maintaining the tetraploid (4n) female germline, and producing the triploid (3n) seeds have made the seed cost high. Cross-pollination is needed for the production of triploid seeds (4n X 2n) and 20 seedless fruits (3n X 2n). Also triploid seed germination is usually poor due to ploidy imbalance.

The present approach eliminates the dependence on polyploid germlines and provides an efficient system for producing seedless fruit. The products of double fertilization of higher plants are the embryo and endosperm. The seed coat (including the integumentary tapetum) and nucellus (the tissue 25 encompassing the embryo sac) are the remaining seed tissues that are maternally inherited. In addition to general protection, the seed coat and nucellus also play an important role in importing nutrients into the developing embryo and endosperm. Seed development will be aborted if this vital nutrient-importing mechanism of the seed coat/nucellus is debilitated. This will be accomplished 30 by using the recombinase system to activate a cell-damaging gene only in these

tissues. Controlling the gene activation in a maternal tissue-specific manner allows production of normal F1 seed, but abortion of F2 seed. A seed coat or nucellus promoter is coupled to a tissue-destructive (lethal) gene in order to prevent seeds from forming. The destructive gene is inactive in the seed parent  
5 due to the presence of a blocking transcription terminator. The terminator is flanked by recombination sites for subsequent excision by a recombinase-mediated recombination event. Expression of the recombinase is also controlled by the seed coat/nucellus-specific promoter. When plants carrying the separate recombinase and recombination site constructs are crossed, the F1 seed will be  
10 viable because seed coat/nucellus is maternal tissue, and in that tissue recombinase and recombination sites are not combined. When the F1 seed is used as planting seed, the self-pollinated or out-crossed plants will produce seedless fruits or vegetables, since in seed coat/nucellus tissues recombinase and recombination sites are combined, and the lethal gene is activated.  
15

## **2. Use of Variant Recombinases for Phage Packaging**

The disclosed variant recombinases can also be used to aid in phage packaging. The cloning system described herein utilizes a headful in vitro packaging system to clone foreign DNA fragments as large as 95 kb which permits the isolation of DNA fragments that are at least twice the size of those that can be obtained by lambda cosmid cloning. This increased cloning capacity has the following utility:

- (1) Genes in the 45-95 kb size range and, more particularly, in the 70-95 kb size range can now be directly cloned and genes in the 25-45 kb size range can be cloned more easily.
- 25 (2) Chromosomal "walking" and "jumping" techniques can be speeded up by a factor of at least two and should be more accurate because of the reduced number of contiguous segments that need to be linked together.
- (3) The cloning system of the invention is useful as a means for the delivery of DNA efficiently to bacteria which otherwise do not take up DNA  
30 from solution well.

Specifically, the headful packaging system of this invention for cloning foreign DNA fragments as large as 95 kb comprises:

- (a) modifying vector DNA by inserting a stuffer fragment into a blunt end producing site which is proximal to a pac site;
- 5 (b) digesting the product of step (a) to produce two vector arms each of which contains (i) a blunt end, (ii) another end which is compatible with the foreign DNA fragment which is to be cloned, and (iii) a recombination site;
- (c) ligating the foreign DNA to the product of step (b) without generating concatemers;
- 10 (d) reacting the product of step (c) with pac cleavage proficient extract and head-tail proficient extract wherein the ratio of large heads to small heads in the head-tail extract is at least 5:1;
- (e) infecting a bacterial strain expressing a variant recombinase with the product of step (d); and
- 15 (f) recovering the cloned DNA.

The term pac is a generic name which refers to the site needed to initiate packaging of DNA. The pac cleavage proficient extract contains the recognition proteins necessary to cleave the pac site and, thus, initiate packaging. The head-tail proficient extract contains the heads and tails needed to package the cloned DNA into a virus particle. The term concatemer means a DNA molecule consisting of repeating units arranged in a head-to-tail configuration. The term stuffer fragment refers to a DNA fragment which is inserted into the vector DNA at a unique site, and within which headful packaging is terminated. The terms bacteriophage and phage are used interchangeably herein.

25 Although many of the elements described herein pertain to the P1 bacteriophage cloning system, those skilled in the art will appreciate that, with the exception of the components needed to package DNA (pac and packaging extracts), many of the elements discussed below, such as plasmid replicon and a multicopy or lytic replicon, pertain to the recovery of packaged DNA and can be

used to recover DNA in bacteria, such as *E. coli*, with other cloning systems, for example, bacteriophage, yeast, etc.

Bacteriophages which are suitable to practice the invention must have a large head capacity and the elements necessary for packaging DNA must be defined. For example, for phages P22 and T1, which utilize headful packaging, the necessary packaging elements are defined. However, P22 and T1 do not have a very large head capacity. On the other hand, for phage T4, which has a large head capacity, the necessary packaging elements have not been defined.

The elements necessary for packaging DNA (i.e., an in vitro headful packaging system) are the following:

- (1) a unique site, pac, which is cleaved by recognition proteins; it is the pac cleavage proficient extract which contains the recognition proteins necessary to cleave the pac site; and
- (2) empty phage heads into which the DNA is packaged until the head has been completely filled, then a cleavage event is triggered (the "headful" cut) which separates the packaged DNA away from the remaining components; it is the head-tail proficient extract which contains the heads and tails needed to package the cloned DNA into virus particle.

Although initiation of packaging is site-specific (cleavage of pac site initiates packaging), termination of packaging is not site-specific. In other words, no unique site is recognized, as packaging will terminate at whatever point the head has been filled.

In the case of P1, the DNA substrate used in the packaging reaction during the viral life cycle is a concatemer consisting of individual units of the P1 chromosome arranged in a head-to-tail manner. Headful packaging, using either P1 phage or any other phage, is a four step process: (1) In the first step a unique site, pac, is recognized and cleaved by the pac recognition proteins (PRPs); (2) DNA on one side of the cleavage is packaged into an empty phage head until the head has been completely filled; (3) a second cleavage event is then triggered (the "headful" cut) that separates the packaged DNA away from the rest of the

concatemer; and (4) initiation of a second round of DNA packaging from the free end generated by the previous "headful" cut--hence the term processive headful cutting. However, if a concatemer is not generated then processive headful packaging does not occur.

5       The ends of the packaged P1 DNA do not contain complementary single-stranded sequences, as do the ends of packaged bacteriophage lambda DNA, and consequently after P1 DNA is injected into a bacterium its cyclization does not occur by strand annealing but rather by recombination between homologous sequences present at the ends of the molecule. Because of this circumstance,  
10      any vector that uses P1 packaging, or for that matter any headful packaging mechanism, must devise a means of cyclizing the linear packaged DNA by recombination. Cyclizing is accomplished by incorporating recombination sites into the vector and using a disclosed variant recombinase to cyclize the DNA  
15      after injection into gram-negative bacterial strains expressing the variant recombinase.

P1 produces two head sizes, a big head that can accommodate 105-110 kb of DNA, and a small head that can accommodate no more than 45 kb of DNA. Normally the ratio of big to small heads in a P1 wild-type infection is 10:1, however, in the cm-2 mutant of P1 used to prepare some of the packaging  
20      lysates described herein, the ratio of head sizes is 1:1. The head-tail packaging lysate prepared from the cm mutant of P1 contained the usual ratio of big to small heads which is about 10:1. This is the preferred lysate for preparing head-tail packaging extract. To ensure packaging of DNA exclusively into the big phage heads, the DNA must be bigger than that which can be accommodated by  
25      the small heads. It is generally desired that there be a large excess of big heads. However, the ratio of large heads to small heads should not fall below a ratio of about 5:1.

### Illustration

The following illustration describes an example of how the disclosed  
30      method can be used to generate variant FLP recombinases with altered site

specificity. As with other recombinase, the method preferably uses the following components:

1. An in vitro mutagenesis system;
2. A recombinase expression plasmid that allows varying levels of expression by a simple environmental control (for example, by the presence of varying amounts of an inducer substance in the growth media, by temperature, or by osmolarity);
3. An indicator/selector bacterial strain. The strain carries both an indicator recombination substrate for detection of recombination at the wild type recombination site and a second recombination substrate that allows selection for recombinase mutants that have gained the ability to recognize and perform recombination at a target mutant recombination site (that is, a variant recombination site). Importantly, the wild type and target mutant sites are designed so that recombination between the mutant and wild type sites is blocked even with a mutant recombinase that can recognize both the wildtype site and also the target mutant site. This design prevents unwanted recombination between the wildtype and target mutant recombination sites that could interfere with either selection or detection of desired recombinational outcomes. The block is imposed by designing the wildtype and mutant sites to have different spacer regions (that is, different compatibility sequences), for example, the normal "wt" spacer for the wildtype recombination site, and an alternative spacer "A1" for the other recombination substrate. In an otherwise nonmutant recombination site DNA recombination proceeds efficiently both for recombination sites having the wt spacer (that is, a recombination between two wt sites) and also for sites having the A1 spacer (that is, a recombination between two A1 sites). Yet, recombination between the A1 site and the wt site is blocked (that is, recombination between a wt site and an A1 does not occur). This strategy is applicable to all recombinases that have a recombination target site displaying one or more recombinase binding sites (repeat elements) on each side of a spacer region in which recombination occurs (Nunes-Döby et al., *Nucl.*

*Acids Res.*, 26:391-406 (1998)). Such sites display a requirement for homology in the spacer elements for optimal recombination activity and has been shown to be the case for members of the Int family of recombinases, including Cre, lambda Int, and FLP (Craig, *Ann. Rev. Genet.* 22:77-105 (1988)).

5       The preferred in vitro mutagenesis system is that of Stemmer (Stemmer, *Nature* 370:389-391 (1994)), or a variant of that strategy. After mutagenesis and assembly of fragments into a full-length FLP gene, it is cloned into the expression vector.

The expression plasmid to be used can be any of the "inducible" 10 expression plasmids available in bacteria. For this illustration one of the pBAD plasmids for *E. coli* was chosen that allows expression of recombinase by growth on arabinose (Guzman et al., *J. Bacteriol.* 177:4121-4130 (1995)), and which can be turned off by growth on glucose (and no arabinose). For this 15 illustration the expression plasmid carries the replication origin of pACYC , and the FLP recombinase gene is under the control of the *E. coli* ara promoter region. In addition, the plasmid carries the selectable marker Cm<sup>r</sup> which confers resistance to the antibiotic chloramphenicol. Because the pACYC replicon is low copy, its use may be advantageous in preventing excessive expression of FLP. Alternatively, a higher copy replicon could be used, such as that of ColE1. 20 In that case the expression level of FLP must also be carefully controlled using the inducer substance arabinose.

The indicator/selector bacteria carries two different reporter constructs 25 for FLP-mediated recombination. The first reporter construct consists of two FRT sites (FLP recombination target; that is, the recombination site recognized by FLP recombinase) in direct orientation (an excision substrate) and resides on a low copy replicon that is compatible with the FLP expression construct. In this example the first substrate is integrated into the *E. coli* genome. This can be done by incorporating the FRT substrate onto phage lambda and then constructing a lambda lysogen. Alternatively the FRT substrate could reside on 30 a low-copy replicon that is compatible with that of the FLP expression vector

and which has an additional selectable marker, for example resistance to bleomycin. This FRT substrate carries two FRT sites in direct orientation flanking a gene whose presence can be easily monitored. In this illustration a constitutively expressing lacZ gene was used whose presence can be determined 5 simply by growing colonies plates containing X-gal, upon which they will become blue in color. Loss of the lacZ gene by FLP-mediated recombination results in white colony formation on X-gal plates.

The indicator/selector bacterial strain also carries a second FRT-like substrate. This is a plasmid element having two FRT-M sites in direct 10 orientation flanking DNA sequences (STOP) that disallow expression of a downstream selectable marker. In this example, nonexpression of the selectable marker is achieved by placing genetic elements in the following order: constitutive promoter – FRT-M – STOP – FRT-M – ‘neo, where ‘neo indicates the promoterless neo gene of Tn5. Hence this cassette cannot express neo and 15 cells are sensitive to the antibiotic kanamycin. Excision of STOP by recombination at FRT-M is designed to permit expression of neo so that cells now become resistant to kanamycin. The plasmid carries an additional selectable marker, Ap<sup>r</sup> conferring resistance to ampicillin, to maintain presence of the plasmid in *E. coli*. The STOP sequence here is the strong transcriptional 20 terminator rrnBT1T2 (Liebke et al., *Nucleic Acids Res.* 13:5515-5525 (1985)).

Figure 17 shows wt FRT, FRT-A1, and FRT-M sites used in this 25 illustration. Although the wildtype FRT site displays three inverted repeat elements, recombination proceeds efficiently with sites carrying two of these repeats in the inverted configuration shown (Jayaram, *Proc. Natl. Acad. Sci. USA* 82:5875-5879 (1985)). Either the full or minimal site can be used since both are recombinationally functional. The FRT-A1 site is designed to have an altered spacer but which is still functional for self X self recombination (Senecoff et al., *J. Biol. Chem.* 261:7380-7386 (1986)). The target FRT-M site is designed to carry symmetrical mutations in the repeat elements that disallow

efficient FLP-mediated recombination (Senecoff et al., *J. Mol. Biol.* 201:405-421 (1988)), and also the spacer mutation of FRT-A1.

Importantly, the FRT-M site differs from the FRT site in two ways. First, both of the 13 bp inverted repeat elements (that is the recognition sequences) are mutated in a symmetrical manner such that the wt FLP enzyme does not catalyze recombination between two FRT-M sites, or does so only extremely poorly (< 0.1%). Second, the spacer region (that is, the compatibility sequence; the 8 bp region between the 13 bp inverted repeats) is replaced with an alternate spacer A1. The alternate spacer when present in an otherwise wt FRT site, which we will call FRT-A1, is permissive for FLP-mediated recombination between two FRT-A1 sites, but does not permit recombination between FRT-A1 and FRT. Use of the FRT-M site which contains the heterologous spacer prevents FLP-mediated recombination between FRT and FRT-M by FLP or a mutant FLP protein that might otherwise catalyze recombination between the wt FRT substrate and the mutant target FRT-M substrate. Unwanted recombination between the wildtype and target mutant recombination sites would decrease efficiency of the selection procedure by (a) not limiting recombination at the target mutant site specifically to these sites and thus compromising the selection (at FRT-M sites) for mutant FLP recombinases, (b) affecting the accuracy of the specific indication of activity at the wt FRT sites, and (c) decreasing either the plasmid stability of the FRT-M selector substrate or the integrity of bacterial chromosome (or compatible plasmid) carrying the wt FRT sites.

Procedure (Figure 18): the FLP gene is mutagenized *in vitro* and then cloned into the inducible expression vector, in this case a pBAD derivative that places FLP under the control of the arabinose-inducible pBAD promoter. The pool of mutagenized FLP genes is transformed into the FRT indicator/selector strain which is pre-induced with arabinose and/or induced with arabinose during DNA transformation. Bacterial colonies are then selected to be simultaneously resistant to chloramphenicol (to retain the FLP expression plasmid), ampicillin

or carbenicillin (to retain the selector plasmid) and kanamycin (to select for cells in which FRT-M X FRT-M recombination has occurred) on agar plates containing either arabinose (for continued FLP expression) or glucose (to prevent prolonged FLP expression). In some instances it may be advantageous 5 to limit FLP expression to better enrich for those FLP mutants that either have more avidity for recombination at the FRT-M sites or to better exclude those FLP mutants that retain activity at the wildtype FRT sites. This is because prolonged or high-level FRT expression can lead to inefficient but detectable recombination at mutant sites.

10        Either all Kan<sup>r</sup> colonies or only those that are blue on X-gal plates are then pooled and harvested for DNA preparation. A second round of FRT gene mutagenesis and selection is then initiated by PCR amplification. Multiple rounds of mutagenesis and selection are used to obtain FRT mutants with altered site-specificity. Comparison of various individual isolates allows determination 15 of critical amino acid residues that contribute to the desired mutant phenotype.

The same rationale and procedure can be used to generate a second class of altered FLP recombinases. The target mutant FRT site used is, however, different. In this case the target is the FRT-M2 site (Figure 19) which carries a different binding site mutation(s) than does the FRT-M site as described above.

20                  **Examples**

**Example 1: Selection of Variant Cre Recombinases**

The following example describes the production and analysis of some examples of the disclosed variant recombinases. Cre mutants characterized by a wider substrate recognition were created, applying a technique called directed 25 molecular evolution: Multiple rounds of a random mutagenesis procedure (DNA shuffling; Stemmer, W. P. C., *Proc. Natl. Acad. Sci. USA*, 91:10747-10751 (1994)) and a sensitive selection for the desired phenotypes allow to accumulate candidate mutants within the generated pools of mutated sequences. The Cre mutants created in this example showed wt-like activity on *loxP* sites. 30 In addition, they performed on an altered substrate, called *loxK2*, that is no

- recognized by the wt enzyme. Two transversions from adenine (*loxP*) to thymine (*loxK2*) at positions 11' and 12' of the *lox* sequence are the barriers that inhibit wt Cre from recognizing *loxK2*: The two thymines are believed to cause repulsive forces with the acidic side chain of a glutamate residue in the J helix of wt Cre (position 262). This glutamate was found to be replaced by a glycine in all mutants with remarkably increased activity on *loxK2*. Additional site-directed mutagenesis experiments, confined to the glutamate at position 262 of Cre, could confirm that E262G but also E262W mutations alone are sufficient to increase *loxK2* activity by a factor of 10<sup>3</sup> without affecting *loxP* recognition.
- 5 Other point mutations identified in the analyzed mutants may however be responsible for increasing the newly obtained specificity even further (10 fold compared to E262G alone).
- 10

## MATERIALS AND METHODS

### General Procedures

15 Standard Reagents

The following reagents were used in all experiments: 10x' TBE (Tris-Borate-EDTA, pH 8.3) was purchased from Biofluids, Inc. (Rockville, MD) and diluted to 1x with deionized water prior to use. TE (Tris-HCl 10 mM, EDTA 1 mM, pH 8.0 and pH 7.5) and Tris-HCl (1 M, pH 7.5 and 8.0) came from Quality Biological, Inc. (Gaithersburg, MD), as well as autoclaved LB (Luria-Bertani) and SOC broth. L-(+)-arabinose (>99%) was ordered from Sigma-Aldrich Fine Chemicals (St. Louis, MO) and anhydrous D-glucose from Mallinckrodt Laboratory Chemicals (Phillipsburg, NJ).

20

### Gel Electrophoresis

25 For DNA electrophoresis, 0.8% agarose TBE gels were used (GTG Sea Kem Agarose (FMC, Rockland, ME)). Gels were prestained with 0.25 µg/ml EtBr (Ethidium Bromide, 10 mg/ml (Life Technologies, Inc., Grand Island, NY)). The used electrophoresis apparatus was a DNA SUB CELL™ (BioRad, Hercules, CA) with an OSP 105 (OWL, Woburn, MA) powersupply. Gels were run at 60 V (5 V/cm) as recommended by Sambrook et al., Cold Spring Harbor,

30

New York: Cold Spring Harbor Laboratory Press (Second Edition) (1989). Occasionally, for small amounts of samples, 50 ml minigels were used under similar conditions (Hoefer HE33, Hoefer Scientific Instruments, San Francisco, CA). Molecular weight standards were  $\lambda$  / *Hind* III digest (Research Genetics, 5 Huntsville, AL) and Ready-Load<sup>TM</sup> 100 bp DNA ladder (Life Technologies), providing a standard size range from 100 bp to 23130 bp (Figure 4). For standard fragment purification from gel, the Geneclean II® Kit (BIO 101, Inc., La Jolla, CA (11/98) was used, following the manufacturer's instructions.

### **Minipreps and Plasmids**

10 Plasmids for diagnostics, cloning, and sequence analysis were prepared using the Wizard<sup>TM</sup> Minipreps Plus Kit (Promega, Wizard<sup>TM</sup> Minipres *Plus* DNA Purification System. Instruction Manual (Madison, WI) (1/96)). Useful ones were assigned a pBS number and stored in TE pH 8.0 at +4°C.

### **Oligonucleotides**

15 All oligonucleotides used as PCR primers, for plasmid construction, or in the mutagenesis procedure, were ordered from Midland, Inc. (Midland, TX) in gel filtration (GF) quality. The lyophilized oligonucleotides were assigned a BSB number, suspended in HPLC grad water (Sigma-Aldrich) at a final concentration of 300  $\mu$ M, and stored at -20°C.

### **DNA Digests and Ligations**

20 All enzymes used for DNA manipulations (restriction enzymes, T4 ligase, etc.) were purchased from New England Biolabs, Inc., Catalog. (Beverly, MA) (1998/99) and used as recommended in the manufacturer's catalog (1998/99). Briefly, for restriction enzyme digests the total reaction volume was 20  $\mu$ l with approximately 10 units (U) of enzyme. For DNA fragment ligations, 10  $\mu$ l with 200 U of T4 DNA ligase were used.

### ***E. coli* Strains**

All *E. coli* strains, except otherwise mentioned, were derived originally from DH5 $\alpha$ : *endA1 hsdR17* ( $r_{KM}^+$ ) *supE44 thi-1 recA1 gyrA* ( $Nal^R$ ) *relA1* 30  $\Delta(lacIZYA-argF)$  U169 *deoR* (M80 *dlac*  $\Delta(lacZ)$ M15) (Woodcock et al., *Nucl.*

*Acids Res.*, 17:3469-3478 (1989); Raleigh et al., In *Current Protocols in Molecular Biology*, eds. Ausubel, F.M. et. al. (New York: Publishing Associates and Wiley Interscience). Unit 1.4 (1989). After modification with  $\lambda$  prophages or plasmids, strains were catalogued by assigning them a BS number and stored 5 at -80°C with 10% DMSO (Dimethylsulfoxide) after overnight culture in appropriate selection medium.

#### **Transformation of *E. coli***

For all plasmid transformations of *E. coli* strains, electroporation was preferred over chemical protocols. Electroporated cells were made and used 10 for electroporation as described by Smith et al., *Focus*, 12:38-40 (1990). The appropriate cell porator and cuvettes were from Life Technologies. Depending on the selection procedure after electroporation, the time in SOC medium (Smith et al., *Focus*, 12:38-40 (1990) at 37°C under agitation (Lab-Line® Orbit 15 Environ-Shaker, Lab Line Instruments, Inc., Melrose Park, IL) prior to plating on selection medium was 1 h for ampicillin (Ap) and 2 h or more h for kanamycin (Kan) selection. For induction of *cre* expression (as described below), the transformants were cultivated in SOB (Smith et al., *Focus*, 12:38-40 20 (1990)) supplemented with 0.2% of L-(+)-arabinose (Sigma-Aldrich) plus 20mM of MgCl<sub>2</sub> (referred to as induction medium) for 2.5 h and 4 h before plating on the appropriate selection media (see below). Resulting colony numbers were counted after overnight incubation at 37°C in a gravity convection incubator (Precision Scientific, Chicago, IL).

#### ***E. coli* Cultures**

LB (as mentioned above) was used as the standard medium for all *E. coli* 25 cultures (liquid or solid). For selection and screening, the appropriate reagents at the following concentrations were added:

Table 1: List of reagents used for selection and screening of *E. coli* cultures.

<u>Reagent</u>	<u>Concentration</u>	<u>Stock Solution</u>
Ampicillin (Ap)	100 µg/ml	50 mg/ml in H <sub>2</sub> O
Chloramphenicol (Cm)	27 µg/ml	34 mg/ml in EtOH
Kanamycin (Kan)	16 µg/ml	10 mg/ml in H <sub>2</sub> O
X-gal	0.003%	2% in DMF (w/v)
Z-ara	0.006%	2% in DMF (w/v)

The concentration of stock solutions, stored at -20°C and their dilutions in liquid LB medium or LB-agar plates is given. X-gal stands for 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, and Z-ara for 5-bromo-3-indolyl-α-L-arabinofuranoside. All reagents, except Z-ara, were purchased from Life Technologies and aliquoted in the desired stock concentration for storage. Z-ara (Berlin and Sauer, *Anal. Biochem.*, 243:171-175 (1996)) was a generous gift from W. Berlin.

Ready-to-use solid LB-agar plates (2%) plain, or supplemented with Ap (100 µg/ml) were purchased from Digene, Inc. (Beltsville, MD). For all other reagent combinations in solid medium, plates were poured according to the needs using autoclaved 2% LB agar purchased from Biofluids.

#### 20           **Polymerase Chain Reaction (PCR)**

Standard PCR reactions were carried out in 50 µl total volume with the following reagents (all, except noted, from Perkin Elmer, Foster City, CA): 1x PE buffer II (without MgCl<sub>2</sub>), 2 mM MgCl<sub>2</sub>, 250 µM of each dNTP, 0.8 µM of each primer, ca. 50 ng of template DNA, qsp. H<sub>2</sub>O (HPLC grade, Sigma-Aldrich) to 49.5 µl. For mutagenic PCR reactions (also referred to as error-prone PCR), the amount of each dNTP was reduced to 20 µM and 0.25 mM of MnCl<sub>2</sub> added. After denaturation at 95°C for 5 min, 0.5 µl of 5 U/µl PE Amlpi Taq Polymerase was added at approximately the annealing temperature of the primers. After mixing, the appropriate thermal cycles were carried out (as indicated individually below), using a PTC 200 thermal cycler (DNA Engine,

MJ Research, Cambridge, MA). When finished, all PCR products immediately were loaded on an agarose gel, or separated from enzyme, nucleotides and primers by applying the Wizard™ PCR Preps Kit (Promega, Wizard™ Miniprep Plus DNA Purification System. Instruction Manual (Madison, WI) (1/96)).

5 PCR products were recovered using deionized water and stored frozen at -20°C.

### **Sequence Analysis**

Sequence analysis of plasmid constructions and *cre* mutants were carried out on a PE ABI PRISM™ 310 Genetic Analyzer (Perkin Elmer) according to recommendations in the manufacturer's protocol P/N 402078 Revision A (1995) 10 for the ABI PRISM™ Dye Terminator Cycle Sequencing Kit (Perkin Elmer). Briefly, a cycle sequencing reaction contained ca. 50 ng of template DNA in miniprep quality, 4 pmol of primer, and 8 µl of the ABI Terminator Ready Reaction Mix (Perkin Elmer), in a total volume of 20 µl, and subjected to the following conditions: (96°C, 10 s; melting temperature of primer, 15 s; 60°C., 4 15 min) 26 times on a PTC 200 thermal cycler (MJ Research). After removal of residual primers and dye by ethanol precipitation, the DNA was resuspended in 25 µl of ABI Template Suppression Reagent (Perkin Elmer) and denatured at 95°C for 5 min before loading the ABI Genetic Analyzer. The obtained data files were examined using ABI PRISM™ Sequencing Analysis Version3.0 20 Software (1996, Perkin Elmer). Gene Jockey II (1996, Biosoft, Cambridge, UK) software was used for sequence comparison, translation, and alignments.

### **Mutagenesis Procedure**

#### **Substrate Preparation by PCR**

The *cre* gene for the following DNase I shuffling reaction was amplified 25 by PCR using 5' forward primer BSB436 (5'  
AAATAATCTGACTGAAATGTCC 3') and 3' reverse primer  
BSB376 (5' ATATATAGCTTATCTTACGCGTAATGG 3'),  
introducing an *Xba* I and *Hind* III cloning site, respectively (underlined).

Mutagenic and non-mutagenic PCR's were carried out: (94°C, 30 s; 52°C, 30 s; 30 72°C, 90 s) 45 or 30 times, respectively. The 5' primer was designed to include

the endogenous Shine-Dalgarno (SD) of *cre*, whereas its three endogenous promoters were excluded (position -17, 6; positions refer to the adenine of the start codon of the *cre* coding sequence as position 1). Thus, after introducing the resulting *cre* genes into pBAD33 (see below), expression was exclusively under control of the pBAD promoter without interference or background expression due to endogenous promoters. Including the SD sequence of *cre* was necessary, since pBAD33 does not contain this sequence 5' of its multiple-cloning-site (MCS). The 3' reverse primer was designed to be homologous to the 3' untranslated region (UTR) of *cre* (position 1057, 1032). Mutagenic events were therefore permitted in 1020 bp of the entire 1026 bp *cre* coding sequence, excluding the first two codons. For the first round of the directed evolution procedure, the wt *cre* expression plasmid pBS185 (Sauer and Henderson, *The New Biologist*, 2:441-449 (1990)) served as template. In following cycles, the pool of mutated *cre* genes from the previous round was used. In all experiments, both, mutagenic and non-mutagenic PCR's were carried out in parallel using the appropriate template.

#### **Homologous Recombination *in Vitro***

##### *DNase I digest*

Approximately 5 µg of the *cre* PCR product (ca. 1.1 kb) were digested with 0.03 U of DNase I, type IV (Sigma-Aldrich) in 20 µl total volume of 50 mM Tris-HCl pH 7.5 plus 1 mM MgCl<sub>2</sub> for 2 to 3 minutes at room temperature. After digestion, samples immediately were loaded on a 2% minigel to separate the generated fragments (Figure 5). Fragments of 25 bp to 300 bp were purified from the gel by DE81 (Whatman, Maidstone, GB) extraction and ethanol precipitation (Sambrook et al., Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press (Second Edition) (1989)), before suspending in 5 µl of TE pH 8.0.

##### *Self-Printing PCR*

A 60 cycle non-mutagenic PCR (as described above) was carried out without added primers, allowing the fragments to prime themselves and thereby

to undergo shuffling while reassembling. Conditions for PCR were: 94°C, 90 s; (94°C, 30 s; 45°C, 30 s; 72°C, 90 s) 60 times; 72°C, 10 min.

#### *Reassembling of cre*

Since the self-priming step never yielded a single size product but rather  
5 a range of fragments between 300 bp to 2000 bp (Figure 5), the self-priming  
PCR mixture was diluted 1/40 in a non-mutagenic PCR mix with primers  
BSB376 and BSB436 (see above), and subjected to an additional 20 cycles  
(94°C, 30 s; 52°C, 30 s; 72°C, 90 s). This additional step lead to one product of  
1.1 kb size (Figure 5).

#### 10      *cre Expression*

After digesting the linkers of the generated mutant *cre* pool with *Xba* I  
and *Hind* III, the fragments were ligated into the identical sites of the MCS of  
the *cre* expression vector pBAD33 (Figure 6). Two features favored the choice  
of pBAD33 as the vector to express the mutant *cre* pool for the selection  
procedure (see below): First, its pACYC184 derived origin of replication is  
15 compatible with the ColE1 derived ones of the plasmids used in the selection  
procedure. Second, pBAD33 contains the promoter of the arabinose operon  
(pBAD), as well as expresses the regulatory protein AraC. It is therefore  
possible to regulate the expression of a gene cloned into the MCS and under  
20 PBAD control, from moderately high levels to nearly complete regression, by  
simply changing 0.2% L-(+)-arabinose in the medium to 0.2% D-glucose  
(Guzman et al., *J. Bacteriol.*, 177:4121-4130 (1995) and Miyada et al., *Proc.  
Natl. Acad. Sci. USA*, 81:4120-4124 (1984)). As indicated above, the primers for  
*cre* PCR were designed in order to include the endogenous SD sequence but to  
25 exclude the three *cre* promoters. *cre* expression therefore will be under  
complete control of the pBAD promoter. This is important for the selection  
procedure (see below) that was intended for few Cre molecules acting on  
different *lox* sites. High concentrations or long term background expression of  
*cre* could eventually defeat the selection since wt Cre also catalyzes at very low  
30 frequencies recombination events between altered *lox* sites.

## Plasmids and *E. coli* Strains Used for Selection and Screen

### *Mutant lox sites*

Figure 1 compares the original *loxP* site to the two mutant sites, *loxK1* and *loxK2*, used during the described experiments. The *lox* sites with 5' *Sal* I and *Xho* I compatible, and 3' *Xba* I and *Nhe* I compatible ends were received as single stranded oligonucleotides from Midland and annealed by heating the appropriate ones together at 70°C, followed by a gradual cool down.

### *Plasmids for Selection and Screening*

Plasmid pBS561 was constructed using three fragments: (i) the 5' modified *neo* gene derived from pBS398 (Sauer et al., *Methods*, 4:143-149 10 (1992), (ii) the RSVneo (Gorman et al., *Science*, 221:551-553 (1983) backbone without the *neo* gene, and (iii) the oligonucleotide-derived MCS (Figure 7). The EGFP gene derived from pEGFP-N1 (Clontech, Palo Alto, CA) was then inserted into the MCS along with 5' and 3' *lox* sites orientated in the same 15 direction to produce plasmids pBS568 (*loxK1*<sup>2</sup>) and pBS569 (*loxK2*<sup>2</sup>). Figure 8 summarizes the procedures used to construct plasmids pBS583 and pBS584. To restore the original *neo* reading frame without the 5' extension, the *loxK*<sup>2</sup> cassettes containing *Mlu* I/*Kpn* I-fragments from pBS568 and pBS569 were ligated into the RSV neo backbone that contains *Mlu* I and *Bgl* II sites. The *Bgl* II – *Kpn* I junction was achieved by filling the 3' recessed end of *Bgl* II with Klenow (NEB) followed by a blunt-end ligation to the *Kpn* I end. This junction also was checked by sequencing and found to be correct. A transcriptional terminator, *rrn*BT<sub>1</sub>T<sub>2</sub>, derived from pBAD33 by non-mutagenic PCR with primers BSB425 (5' ATAAGCGGCCGCTGAGCTTGGCTGTT TTGGCGG 20 3') and BSB426 (5' GCCGTCTCGAGAGAGTTGTAG AAACGCAAAAAGGC 3'), was inserted into the *loxK*<sup>2</sup> cassette 3' of the EGFP gene after digest of the its *Not* I and *Xho* I linkers (underlined). With this construct, it could be predicted that a catalyzed recombination by K1<sup>+</sup> or K2<sup>+</sup> Cre mutants between the *lox* sites would result in the excision of EGFP and the 25 transcriptional terminator, and thereby permit the transcription of the *neo* gene 30

due to the RSV promoter, located 5'. Expression of *neo* would no longer be impaired, because it is placed under control of 5' promoter elements present in RSVneo (a Kan<sup>R</sup> rendering plasmid in *E. coli*).

A similar *loxP*<sup>2</sup> cassette selection plasmid also was designed (pBS613, 5 Figure 9), to be used as a control. Using this plasmid, the frequency of *loxP* recombination by Cre mutants could be determined in the same manner as used to evaluate *loxK1* or *loxK2* recombination by pBS583 and pBS584.

Finally, a completely different set of *loxK1*<sup>2</sup>/*loxK2*<sup>2</sup> cassette plasmids was created. These plasmids were no longer used for selecting mutants that 10 recognize *loxK1* or *loxK2*, but rather were used to screen for these mutants in conjunction with a different bacterial background (see below). Figure 10 summarizes the construction process for pBS601 (*loxK1*<sup>2</sup>) and pBS602 (*loxK2*<sup>2</sup>): In a first step, the *neo* resistance marker of pBS581 and pBS582 (intermediates in the construction of pBS583 and pBS584) was removed by 15 deleting the *Pvu* II fragment and thus restoring the possibility to use *neo* for a different selection procedure. Following this, the *EGFP* gene between the *lox* sites was replaced by the pUC19 (Yanish-Perron, *et. al.*, 1985) derived *lac* promoter with its 3' MCS. This pUC19 fragment was obtained by non-mutagenic PCR with primers BSB448 (5' GTCAAGCTAGCTAGCAGGTTT 20 CCCGACTGG 3') and BSB449 (5' ACATTGCGGCCGAGATCTCCTCTA GAGTCGACCTG 3'). An *Nhe* I site 5', and a *Bgl* II and a *Not* I site 3' (underlined) were introduced thereby, which made it possible to replace the *Nhe* I – *Not* I *EGFP* fragment after linker digestion. The newly generated polylinker between the two *lox* sites permitted insertion of the *Xba* I – *Bam*H I fragment of 25 pBS481 (that carries the *abfA.st* marker gene) into its *Xba* I and *Bgl* II sites. As shown recently, *E. coli* strains expressing a recombinant α-L-arabinofuranosidase gene from *Streptomyces lividans*. (*abfA.st*), can be detected by eye on LB plates containing 5-bromo-3-indolyl-α-L-arabinofuranoside (Zara) Berlin and Sauer, *Anal. Biochem.*, 243:171-175 (1996). This leads to the 30 formation of an indigo blue pigment, that is similar to the classical *lacZ/5-*

bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-gal) marker system. It could therefore be expected that *E. coli* strains expressing mutant Cre recombinases which allow recombination of *loxK1* or *loxK2* should lose the *abfA.st* gene and should form white colonies on Z-ara plates. All other clones, however, should be dark blue. Using *abfA.st* instead of the well established *lacZ* screen was necessary, because the *E. coli* strain (see below) used for this construct expresses  $\beta$ -galactosidase endogenously.

#### *E. coli Strains for Selection and Screen*

The *E. coli* strain BS583, DH5  $\Delta$ lac ( $\lambda$ D69 *loxP*<sup>2</sup>[*lacZ* LEU2]), was chosen as the bacterial background for the selection procedure for K1<sup>+</sup> or K2<sup>+</sup> Cre mutants by plasmids pBS583 or pBS584. Due to the *loxP*<sup>2</sup>[*lacZ*] containing  $\lambda$  prophage, Cre activity on *loxP* can be evaluated simply by using X-gal plates. The selection strains BS1493 and BS1494 were made by introducing the selection plasmids pBS583 and pBS584 into BS583 (Table 2). The *loxP*2 plasmid pBS613, to be used as a control, needed to be in BS583 cells as well, becoming the strain BS1541 (Table 2).

For the screening plasmids pBS601 and pBS602, *E. coli* strain NS2300 (Sternberg et al., *J. Mol. Biol.*, 187:197-212 (1986)) was selected as host: K12 *recA*::Tn10 ( $\lambda$ i<sup>434</sup> *loxP*2[*neo*]). This strategy combines a kanamycin selection for Cre enzymes, that are no longer active on *loxP* (P<sup>-</sup>), with a screen for K1<sup>+</sup> or K2<sup>+</sup> enzymes. By transforming pBS601 and pBS602 into NS2300, the P<sup>-</sup> selection strains BS1523 and BS1524 were formed (Table 2).

#### **Selection and Screen for CRE Mutants**

##### *Selection for K1<sup>+</sup>/K2<sup>+</sup> and Screen for P<sup>-</sup>*

After ligation of the generated mutant *cre* pool into pBAD33 for 3 h, BS1493 or BS1494 electrocompetent cells were transformed with 2  $\mu$ l of the microdialyzed reaction mixture (VS membrane, Millipore<sup>TM</sup>, Bedford, MA). To induce expression of the *cre* pool, the transformed cells were incubated at 37°C in induction medium for 2.5 h and/or 4 h under agitation (as mentioned before). Cultures were diluted 1/500 or 1/5000 and grown on LB plates with the

following formulation: Ap, Cm, glucose, and X-gal for determining the transformation efficiency, referred to as non-selection plates. Dilutions of 1/5 and occasionally 1/50 were grown on plates with addition of Kan, used to select for K1<sup>+</sup> or K2<sup>+</sup> mutants and called selection-plates. The formulation of the  
5 plates served the following purposes: (i) Ap and Cm were added to assure that all clones contained both, selection and expression plasmid, (ii) X-gal to distinguish between P<sup>+</sup> and P<sup>-</sup> clones (Table 2). After overnight incubation at 37°C, blue and white colonies were counted and pools prepared for the next round of DNA shuffling. Alternatively, certain mutants were chosen for further  
10 analysis (see below).

*Selection for P<sup>-</sup> and Screen for K1<sup>+</sup> or K2<sup>+</sup>*

After 2.5 h and/or 4 h of expression of the mutant *cre* pool in the transformed BS1523 and BS1524 cells, usually dilutions of 10<sup>-3</sup> or 10<sup>-4</sup> were grown on LB agar plates supplemented with the same reagents as listed above,  
15 except, that Z-ara replaced X-gal to allow the K1<sup>+</sup>/K2<sup>+</sup> screen. Non-selection plates were used for determining the transformation efficiency, and Kan containing plates for the P<sup>-</sup> selection (Table 2).

**Mutant Analysis**

**wt *cre* Expression Plasmid**

With fewer cycles (15) of non-mutagenic PCR on the *cre* expression plasmid pBS185 and after linker digestion, the *cre* pool obtained was cloned into pBAD33 and transformed into BS583 cells. After 2 h of *cre* expression, the transformed cells were grown on X-gal plates. After overnight incubation at 37°C, two white colonies (indicating *loxP* recombination) were picked for  
20 plasmid preparation and complete sequencing. No point mutation was found in either one, so that each could be used as a control plasmid for wt Cre expression.  
25 One of the two was selected for further use and named pBS606.

**Functional Testing**

In order to determine the frequency of *lox* recombination of isolated  
30 mutant Cre enzymes by the described selection procedure, it is necessary to

separate the *cre* candidate expression plasmid (pBAD33) from the selection plasmid of the chosen Kan<sup>R</sup> candidate. Then, the cleaned expression vector can be used to retransform the appropriate selection and screening strain BS1494, as well as BS1493 and BS1541 to determine the candidate's capacity for *loxK2*,  
5 *loxK1* and *loxP* recombination under identical conditions. By comparing the resulting frequencies of Kan<sup>R</sup> of different Cre mutants and wt Cre, all treated identically, one can determine quantitatively how well each chosen mutant candidate really performs on the altered *lox* sites.

Therefore, overnight cultures of candidates were grown in liquid LB  
10 supplemented with Cm and Kan for plasmid minipreps yielding a mixture of both the mutant Cre expressing plasmid pBAD33 and the newly Kan<sup>R</sup> selection plasmid. In order to eliminate the latter, minipreps were digested with the restriction enzyme *Aat* II which only cuts the selection plasmid. After transformation of BS583 cells with this digestion mixture and approximately 2 h  
15 *cre* expression, different dilutions were grown on LB agar plates supplemented with Cm and X-gal to select for pBAD33. Plates with Ap plus Cm were used to determine the background of contamination with uncut selection plasmid. The next day, clones obtained by the Cm selection were tested for Ap<sup>s</sup> and Kan<sup>s</sup> to confirm the elimination of the selection plasmid. A final overnight culture,  
20 followed by a miniprep procedure, yielded the unique plasmid for functional testing, as described above.

#### Sequencing

To obtain the DNA sequence of candidate *cre* genes in pBAD33, eight primers (BSB454 to BSB461, Table 3), four for each strand, were designed so  
25 that the entire gene could be sequenced in both directions.

#### Site-Directed Mutagenesis

After identifying one essential mutation for the decrease in substrate specificity, the Stratagene QuickChange™ Site-Directed Mutagenesis Kit (Stratagene Cloning Systems, La Jolla, CA) was used to create *cre* mutants with  
30 mutations at the determined location, only. Using three different mutant primer

sets (BSB 465 to BSB 470, Table 4), all steps were carried out as detailed in the manufacturer's instruction manual, except that electrocompetent BS1494 cells were used for transformation and mutant selection, replacing the provided XL1 blue cells. The made mutant candidates were subjected to functional testing and

5 sequencing as detailed before.

In a different experiment, the DNA shuffling mutagenesis procedure was repeated on wt *cre* by adding one 5' phosphorylated strand of each set of mutant oligonucleotides (BSB465, BSB467 and BSB469) to the pool of small fragments prior to reassembly. This allowed to incorporate them into the

10 resulting *cre* pool. The desired mutations should consequently be introduced at much higher frequency than without the addition of oligonucleotides.

## RESULTS

### Establishment of the Selection Procedure

#### Selection Plasmids (pBS583 and pBS584)

15 To test the generated plasmids pBS583 and pB584, a recombination event between their *lox* sites was mimicked by digesting pBS566 and pBS567 (intermediates of the pBS583/584 construction, containing only the 3' *lox* site) with *Sal* I and *Xho* I, followed by religation. This lead to excision of the *EGFP* gene and terminators. After deletion of *EGFP* and rrnBT<sub>1</sub>T<sub>2</sub>, the Kan<sup>R</sup>

20 phenotype was observed as anticipated. In addition, the frequency of spontaneously occurring Kan<sup>R</sup> clones carrying the original plasmids was approximately 10<sup>-7</sup>. This background is inconsequential, since the transformation efficiency of BS583 cells was determined as 10<sup>7</sup> per µg of pBAD33.

25 The equivalent *loxP* control plasmid pBS613 was tested directly with the wt *cre* expression plasmid pBS606. After 2.5 h of *cre* expression, 94% of all clones were determined Kan<sup>R</sup> and about 6% showed blue color. Without *cre* expression, no Kan<sup>R</sup> and no white colonies were observed. This confirms that the control cell line BS1541 (Table 2) permits the combined P<sup>+</sup> selection and P<sup>-</sup> screen.

## Screening Plasmids pBS601 and pBS602

Only pBS602 was tested before use by expression of wt Cre and a K2<sup>+</sup>/P<sup>+</sup> Cre mutant (see below). On non-selection medium, wt Cre expression resulted in more than 95%, whereas expression of the mutant Cre resulted in less than 3% of blue colonies. This indicates that excision of the *loxK2* flanked *abfA.st* marker by K2<sup>+</sup> Cre is possible. On selection medium, very few colonies could be found, since both types of *cre* have shown activity on *loxP* before (see below).

### Mutagenic vs. Non-Mutagenic PCR

The frequency of P<sup>-</sup> Cre mutants obtained after non-mutagenic and after error-prone PCR was determined by the following experiment: After one mutagenic or one non-mutagenic PCR on the wt Cre expression plasmid pBS185, the resulting *cre* pools were inserted into the expression vector pBAD33 and transformed into BS583 cells. After 2.5 h of arabinose-mediated induction or glucose-mediated repression (by SOC medium) or *cre* expression, dilutions were transferred to LB plates with Ap, Cm, glucose and X-gal. The results are presented in Table 5: Under glucose repression, exclusively blue colonies could be identified (first line in Table 5), indicating that *cre* expression is insufficient for *loxP* recombination and excision of *lacZ* of BS583. Induction with L-(+)-arabinose, however, lead to the formation of white colonies at the presented frequencies (second line), indicating that (i) the described control of *cre* expression by pBAD33 is functioning, and (ii) the mutagenic PCR conditions cause three times more impaired Cre enzymes for *loxP* recombination than the non-mutagenic conditions (60% blue colonies vs. 30%). It is worth mentioning that ligation reactions lacking *cre* insertion resulted in 50 to 100 times less blue colonies than obtained with the ligations with *cre* insertion. This phenotypically blue background of empty pBAD33 was subtracted before calculating the presented data.

Leung et al., *Technique*, 1:11-15 (1989) reported that the frequency of point mutations created by error-prone PCR is about 0.5%. If this is true, in

average five point mutations should occur in each 1 kb *cre* coding sequence subjected to an error-prone PCR. By extrapolating this data to the three times less P<sup>-</sup> enzymes after a non-mutagenic PCR, one can conclude that the frequency for point mutations should also be reduced by a factor of three to 0.18%.

- 5 Experiments made by Zhou et. al. (1991) showed 11% of a 633 bp marker gene phenotypically impaired after non-mutagenic PCR. About 37% of all genes in the pool, however, carried at least one point mutation. Even though the conditions for the non-mutagenic PCR were similar, the observed discrepancy between 11% and 20% of phenotypical mutants may be due to a variety of  
10 reasons, among which: (i) the size difference between the two genes (633 bp vs. 1020 bp), (ii) different elongation times during PCR, and (iii) different sensibility of the two proteins for disabling point mutations.

#### **Testing wt Cre on *loxK1*<sup>2</sup> vs. *loxK2*<sup>2</sup> Substrates**

- The level of *loxK1* and *loxK2* recombination due to wt *cre* expression  
15 was determined using the wt Cre control plasmid pBS606. After transformation of the cell lines BS1493 and BS1494 with pBS606 and 2.5 h and 4 h of *cre* expression, cells were grown on selection and non-selection plates (as described previously). The recombination frequency between the altered *lox*<sup>2</sup> sites was considered equal to the observed frequency of Kan<sup>R</sup> phenotype: for *loxK1*, it  
20 was about 10<sup>-5</sup> after 2.5 h and 2 X 10<sup>-5</sup> after 4 h of wt *cre* expression, for *loxK2*, it changed from about 2 X 10<sup>-5</sup> to 2 X 10<sup>-3</sup>. All colonies found were white, indicating effective *loxP* recombination by wt Cre within the allowed expression time. This result shows that long term expression of the wt enzyme permits a slight increase in recombination between the altered *lox* sites. The use of  
25 pBAD33 to avoid background *lox* recombination by suppressing *cre* expression is therefore justified. Because *loxK2* was eventually 100 fold better recognized by wt Cre than *loxK1* (but still at low frequency), first the creation of novel Cre recombinases with *loxK2* specificity was attempted.

## Mutagenesis on *loxK2*

### First Rounds of Directed Evolution

The result of the first four rounds of the described mutagenesis procedure on *loxK2* with selection plasmid pBS584 are presented in Table 6.

5 The following symbols are used to describe the status of the DNA shuffling procedure for *cre*: "o" indicates a non-mutagenic PCR, "m" a mutagenic PCR, and "x" stands for the *in vitro* reassortment event. For example, mxoxox *cre* represents a *cre* pool subjected to three rounds of the directed evolution process, with a mutagenic PCR followed by *in vitro* shuffling in the first, and non-

10 mutagenic PCRs and shuffling as mutagenic and recombinogenic events in the following two rounds. The phenotypically blue background due to empty pBAD33 was subtracted from all results by control ligations without *cre* insertion. In every round, error-prone and non-mutagenic PCR served as the necessary mutagenic event on the template pool of the previous round. After *in*

15 *vitro* reassortment and selection, always the larger Kan<sup>R</sup> population of the two parallel experiments was chosen as template for the next round (as indicated in the last column of Table 6). Only in the first round the error-prone PCR could lead to more candidates, whereas in all following rounds the reduced mutagenic frequency of the non-mutagenic PCR turned out to be more beneficial. The

20 density of point mutations resulting out of two mutagenic PCR's was obviously too high to allow efficient elimination of deleterious mutations from advantageous ones during the *in vitro* shuffling step. This is confirmed by the high frequencies of blue colonies found within any pool in any round subjected to mutagenic PCR's twice. Error-prone PCR in the context of the applied

25 selection therefore appears to be useful in the first round only, where its three times higher mutagenic frequency increases the amount of beneficial mutations compared to a non-mutagenic PCR. With increasing cycle numbers non-mutagenic PCR's should be preferred to avoid high densities of deleterious mutations.

The established directed molecular evolution process allows effective evolution of *cre*. Column five of Table 6 shows that with every round the number of Kan<sup>R</sup> colonies is increasing, while the time for *cre* expression could be lowered from 4 h to 2.5 h (column three). After only three rounds, Cre 5 mutants capable for *loxK2* recombination at decreased concentrations due to the reduced expression time were found. However, it was not possible to isolate any blue colony on the selection plates. All identified K2<sup>+</sup> mutants therefore are also P<sup>+</sup>. As mentioned above, high densities of deleterious mutations in the *cre* pool subjected to error-prone PCR's twice could explain why no blue colonies 10 were seen on selection plates, even with over 90% of P<sup>+</sup> candidates on non-selection plates.

### Evaluation of Six K2<sup>+/P<sup>+</sup> cre Mutants</sup>

#### *Functional Test*

As indicated in Table 6, 36 white Kan<sup>R</sup> colonies could be isolated from 15 the mxoxox *cre* pool after only 2.5 h of *cre* expression with an 1/5 dilution grown on selection plates. This result indicated that competent Cre mutant capable of *loxK2* recombination were produced. Six were selected for further analysis. After elimination of the selection plasmid from the minipreps (as described in Materials and Methods), all six of them, as well as wt Cre (pBS606) 20 were subjected to the described functional test on *loxK2*, but also on *loxK1* and *loxP* recombination with plasmids pBS584, pBS583 and pBS613. The results are presented in Table 7.

Briefly, by selecting for *loxK2* recombination, all mutants except mxoxox 4, showed significantly increased percentages of Kan<sup>R</sup> (between 3% 25 and nearly 70%), compared to wt Cre (0.002%), as indicated in column three of Table 7. This indicates a 10<sup>3</sup> to over 10<sup>4</sup> fold increase in activity on *loxK2*.

On *loxP*, all (including mxoxox 4) showed recombination frequencies between 80% and 100% after 2.5 h of *cre* expression (column 4). This was expected from the results obtained with the X-gal screen for *loxP* recombination 30 during the selection procedure. 2.5 h of induction for wt *cre* expression is

therefore sufficient for almost complete *loxP* recombination, justifying 2.5 h of expression of mutant *cre* pools for selecting competent K2<sup>+</sup> Cre mutants. The observed slight decrease in *loxP* recombination with the mutants mxoxox 3 to 6 either derived from usual variations during experiments, or may indicate a 5 slightly reduced *loxP* activity. With BS1541 blue colonies on both selection and non-selection plates were found in approximately the same frequency (2% to 20%) as kanamycin sensitivity (Kan<sup>S</sup>). This indicates competition between the *loxP*<sup>2</sup>[*lacZ*] site on the genome and the *loxP*<sup>2</sup>[EGFP-*rrnBT*<sub>1</sub>T<sub>2</sub>] sites on pBS613. Since the same Cre mutants never resulted in blue colonies during selection for 10 *loxK2* recombination in cell line BS1494, it is possible to conclude that *loxP* is still preferred over *loxK2*. This argument is supported by higher frequencies of *loxP* recombination, close to 100%, compared to the *loxK2* recombination frequencies of 3% to 70%.

15 All frequencies found for *loxK1* recombination, determined by using cell line BS1493, lie below 0.01% after 2.5 h, as well as after 4 h of induction of *cre* expression (column five). This indicates that no analyzed mutant developed an increased activity on *lox K1* compared to wt Cre.

20 To summarize, five out of the six analyzed mutants showed a significant decrease in specificity, resulting in the possibility for *loxP* and *loxK2* recombination.

#### *Sequencing*

25 The six described mutants have been completely sequenced in both directions to determine the mutations which lead to the observed decrease in specificity. The resulting aligned *cre* coding and aa sequences of all mutants and wt Cre are represented in Tables 10 and 11. Each mutant showed between 3 and 8 point mutations, altogether 31, as listed in column two of Table 8. The overall mutagenic frequency can therefore be calculated at 0.5% (31 mutations in 6 clones of 1020 bp), which is similar to only one round of error-prone PCR (Leung et al., *Technique*, 1:11-15 (1989)). The reason for the low frequency of 30 point mutations after three rounds of the mutagenesis procedure (i.e. nine

PCR's) is the applied selection after each round, cre mutants with low density of point mutations seem to be favored by the stringent kanamycin selection.

26 of the 31 identified point mutations resulted in aa changes compared to the wt sequence, as indicated in column three. No deletions or frame-shift 5 mutations, as well as no codons affected by more than one point mutation at the same time could be identified. All possible transition events could be observed, but only half of all possible transversion events (shown in Table 12). Adenine to guanine and vice versa transition events represented almost 30% of all identified point mutations. All other events occurred less frequent (10%, 7%, or 10 never). The represented statistic may however be biased, either since only six mutants were analyzed, or due to the directed molecular evolution technique itself: The types of point mutations observed less often, may more frequently be deleterious in *cre* and were consequently removed from the pools. With more mutants to be sequenced, this question could be addressed further.

15 Only one point mutation, a transition event from adenine to guanine at position 785 in the *cre* coding sequence is common for all 5 mutants with remarkably increased *loxK2* activity. This mutation leads to a replacement of a glutamate residue at position 262 in the J helix of wt Cre by a glycine (indicated in column five of Table 8). This glutamate is believed to contact the *loxP* sequence at positions 11 or 12 with its acidic side chain (Guo et al., *Nature*, 389:40-46 (1997)). Another point mutation, resulting in a conservative 20 threonine to serine exchange at position 316 was identified in three mutants. Five point mutations were found independently in two of the six mutants, among which two types of silent mutations. Finally, eleven point mutations occurred 25 only once (indicated in column four). Therefore, the critical mutation for *loxK2* activity appears to be E262G. Some of the additional mutations could be responsible for the observed ten fold difference in *loxK2* recombination frequency among the five E262G carrying mutants.

## Site-Directed Mutagenesis to Verify Results

### Site-Directed Mutagenesis Procedures

To determine whether the E262G mutation alone is responsible for the increase of *loxK2* activity of the Cre mutants by at least a factor of  $10^3$ , two  
5 different experiments were made:

First, the described directed evolution procedure was repeated in three different sets on wt *cre*, by adding three 5' phosphorylated mutant oligonucleotides prior to reassembly: Incorporation of the first oligonucleotide (BSB465) into *cre* should lead to the E262G mutation, incorporation of the  
10 second one (BSB467) to a E262A mutation, and the equimolar mixture of random oligonucleotides (represented by BSB469) to  $20^3$  ( $= 8000$ ) possible aa combinations at positions 261 to 263 of Cre. According to Stemmer, W. P. C.,  
15 *Proc. Natl. Acad. Sci. USA*, 91:10747-10751 (1994), these oligonucleotides should be incorporated during reassembly and cause the desired mutations at a frequency of about 8%. After insertion of the resulting *cre* pools into pBAD33 and 2.5 h of expression, 0.8% of white Kan<sup>R</sup> colonies were found with BSB465. Therefore, the frequency of the Kan<sup>R</sup> phenotype due to *loxK2* recombination is ten times lower than the expected frequency for the E262G mutation to occur.  
This indicates that the E262G mutation increases the specificity for *loxK2* from  
20 0.002% of wt Cre (see above) to approximately 10% of recombination during the standard expression experiment (2.5 h of *cre* expression prior to selection). By using the second oligonucleotide (BSB467) only 0.09% of the total white colonies showed Kan<sup>R</sup>. Thus, E262A still favors *lox K2* recombination but by almost a factor ten less efficiently than the E262G mutation. With the random  
25 oligonucleotide mixture (BSB469), the frequency of *loxK2* recombination shrunk to 0.02%. Compared to a control experiment with no oligonucleotides added, resulting in 0.003% Kan<sup>R</sup> (consistent with the results obtained below), still some of the possible 8000 aa combinations at positions 261 to 263 of Cre are expected to favor *loxK2* recombination. Since the frequency of blue  
30 colonies on non-selection plates was about 30%, a clear indication for additional

mutations, it cannot be completely excluded that some of the occurred Kan<sup>R</sup> mutants of this experiment have been carrying some additional beneficial mutations. Nevertheless, this experiment indicated that the E262G mutation is probably the basis for significant increase in *loxK2* activity.

5       For better defined mutations, a second experiment was done: The same oligonucleotides, now in sets for both DNA strands, were used with the Stratagene QuckChange™ Site-Directed Mutagenesis Kit as described in Materials and Methods. After transformation of the *loxK2* selection strain BS1494, the percentage of white Kan<sup>R</sup> colonies in the three different experiments could be determined as 6.2% for E262G, 0.8% for E262A and 0.6% for the 8000 different ten (10) days combinations as positions 261 to 263. Due to the QuickChange™ procedure, which eliminates parental DNA, one could expect that the desired mutations occurred in at least 50% of all clones of the three different pools. This assumption indicates that the E262G mutation alone results in approximately 12% or less recombination frequency on *loxK2* (6% out of 50% or more carrying the mutation) and the E262A exchange in 1.6% or less (under standard conditions). This calculation is not valid for the third set of oligonucleotides, because no defined mutation is introduced but rather a mixture of 8000 different ones. Blue colonies were not found during this experiment, confirming that the frequency of additional mutations altering Cre activity on *loxP* was very low.

10      The results of both experiments indicate consistently, that the E262G mutation alone is sufficient to increase *loxK2* recognition by approximately a factor of 10<sup>3</sup> compared to wt Cre. The ten times higher frequency observed with three of the six analyzed mutants after three rounds of the mutagenesis procedure can only be explained with additional beneficial mutations. The E262A mutation increases the frequency of *loxK2* recombination also, but approximately by a factor of ten less effectively than E262G.

## **Sequencing and Elimination of Possible Additional Mutations**

Two white Kan<sup>R</sup> colonies of each pool derived from the site-directed mutagenesis procedure were selected and the entire *cre* gene was sequenced. Both E262G and E262A candidates showed the desired sequence with no additional mutations. The random candidates surprised: One of them did not reveal any point mutation, representing an artifact which managed to survive the selection, whereas the other one showed nucleotide alterations from position 783 to 786. The wt sequence (<sub>781</sub>CTG GAA<sub>786</sub>) was found to be changed to (<sub>783</sub> CTT TGG<sub>786</sub>), resulting in one silent mutation, conserving L261, and a E262W exchange. To exclude possible mutations in pBAD33 due to the PCR involved site-directed mutagenesis procedure, the three defined *cre* mutants (E262G, E262A, and E262W) were excised by *Hind* III and *Xba* I and reinserted into the MCA of fresh pBAD33.

## **Functional Testing**

The three defined Cre mutants for the amino acid position 262 were subjected to a functional test for *loxK2*, *loxK1* and *loxP* recombination activity, as mentioned before. The results are summarized in Table 9. First, the results described previously for the E262G and E262A mutations were confirmed: As indicated in column three, the *loxK2* recombination frequency increased 10<sup>3</sup> fold with the E262G mutant compared to the wt enzyme, whereas the E262A mutant shows only an increase of 200 fold. Surprisingly, the E262W mutant also achieved a similar activity on *loxK2* as seen with the E262G mutant. The test for *loxP* recombination frequency with cell line BS1541 (column four) showed that the ability for *loxP* recognition is at best slightly impaired by the three different mutations (as already seen with the analyzed mxoxox mutants). Again, blue colonies could only be found with this cell line, indicating that *loxP* is preferred over *loxK2* (as described before). As expected, none of the three mutants performed significantly better on *loxK1* than wt Cre (column five). To conclude, this final experiment provides the necessary evidence that the E262G mutation presents the basis for the observed decrease in specificity of Cre.

However, additional mutations seem to be helpful to increase the newly obtained activity further. In addition, glycine at position 262 is not the only possible residue to permit a remarkable increase in *loxK2* activity.

## DISCUSSION

### 5 K2<sup>+</sup>/P<sup>+</sup> Cre Mutants

The chosen random mutagenesis procedure linked to the described selection in *E. coli* allowed the identification of Cre mutants, characterized by a wider substrate recognition. The evolved enzymes showed wt-like activity on *loxP* sites and in addition had almost the same activity on altered *lox*<sup>2</sup> sites,  
10 referred to as *loxK2*. By contrast, the wt enzyme showed only marginal activity on *loxK2*<sup>2</sup> substrates.

#### 15 *lox* Sites

*loxP* and *loxK2* differ at several locations as illustrated in Figure 1: First, the three outermost bp of the inverted repeats are altered, facilitating the  
construction of the various plasmids used for selection. Second, the entire non-canonical 8 bp spacer is completely exchanged, and third, two transversion events (thymine to adenine) are introduced at positions 11 and 12 of the *lox* site.  
Only the two transversion events are considered important for inhibiting wt Cre from recognizing the site. Other investigations have shown before, that the two  
20 alterations of *loxP* mentioned first are without inhibiting effect on wt Cre (B. Sauer, unpublished results). The design of *loxK2* was based in part on so-called cryptic *lox* sites, that were identified previously in the yeast genome (Sauer, B., *J. Mol. Biol.*, 233:911-928 (1992)). Another consideration was the choice of a good starting sequence for the described mutagenesis procedure. Starting with  
sites that contained several and/or widespread alterations of *loxP* was avoided, because the greater the number of alterations in the substrate, the more the  
enzyme would have to be altered. Consequently, to most effectively use the  
25 mutagenesis procedure, the two sites presented in Figure 1, *loxK1* and *loxK2*, were designed to have only two critical alterations. In initial experiments, wt  
*loxK2* was found to recombine *loxK2*<sup>2</sup> substrate pBS584 slightly better than  
30 Cre was found to recombine *loxK2*<sup>2</sup> substrate pBS584 slightly better than

*loxK1*<sup>2</sup> pBS583. This difference may depend on the fact that in *loxK2* the two alternations are located next to each other, while in *loxK1* they are separated by 3 bp (positions 14 and 10). Thus, *loxK1* could interfere with wt Cre binding at two distinct DNA-protein interaction sites as compared to *loxK2*, where only one location of incompatibility is available. For this reason, *loxK2* was chosen for the initial set of experiments, described in this work.

#### Cre Mutants after Three Rounds of Directed Evolution

Three iterations of the *in vitro* evolution procedure were necessary to identify 36 candidates, expressing Cre mutants that could process *loxK2* (based on the applied selection procedure in *E. coli*). Tests showed that five out of six selected ones had 10<sup>3</sup> and 10<sup>4</sup> fold increased activity on *loxK2* when compared to wt Cre. On *loxP* and *loxK1*, however, there was almost no difference between wt and the mutant enzymes. The mutants therefore had developed an increased tolerance from transversions at positions 11 and 12 (*loxK2*) of the *lox* sequence, but not for other positions like 10 and 14 (*loxK1*). To indicate this phenotype they were referred to as K2<sup>+/P<sup>+</sup></sup>.

#### The E262G Mutation

Sequence analysis identified that the five mutants with remarkably enhanced *loxK2* activity (10<sup>3</sup> to 10<sup>4</sup> fold compared to wt Cre) had in common only one point mutation, leading to the aa change E262G. Site-directed mutagenesis experiments confirmed, that the E262G mutation is sufficient to increase *loxK2* activity by a factor of 10<sup>3</sup> compared to wt Cre.

Based on the recently described crystal structure (Guo et al., *Nature*, 389:40-46 (1997)) glutamate at position 262, located in the J helix of the enzyme, may be a DNA contacting residue and permit the formation of a hydrogen bond between the carboxyl group of its side chain and an amino group of one of the two adenines at positions 11' or 12' in the *loxP* sequence (Figure 1). However, changing these two bases to thymines in the *loxK2* sequence should lead to an electrostatic repulsion between their oxygens and the acidic side chain of glutamate. This could explain the observation that wt Cre is

CONFIDENTIAL

unable to catalyze a recombination between two *loxK2* sites. Exchanging glutamate for a glycine, that does not have a side chain, should remove the electrostatic repulsion and thereby permit *loxK2* binding. On the other hand, this alteration could affect *loxP* binding because an electropositive DNA-protein interaction may be lost. Results from the mentioned experiments support this proposition: The E262G mutation alone lead to an increase in *loxK2* recombination from 0.002% to about 2% and to a slight decrease in *loxP* recombination from 94% to about 80%. The 50 times lower frequency of *loxK2* compared to *loxP* recombination may depend on the second thymine or more likely on the complementary adenine (position 11 in *loxK2*) that could contribute to sterical repulsion between the J helix and the *loxK2* site. To prove this hypothesis, the role of arginine at position 258, located one helix turn away from the glutamate, should be further investigated by site-directed mutagenesis. As proposed by Guo et al., *Nature*, 389:40-46 (1997), R258 is a DNA contacting residue that forms hydrogen bonds with the guanine at position 10' of *loxP* and may also interact with the bp at position 11. There is yet no confirmatory experimental evidence for this proposal.

Results from three initially isolated mutants (mxoxox 1 to 3) indicated about 50% of recombination frequency on *loxK2*. This is about ten fold higher than that obtained with the E262G mutation alone. It is therefore likely that some of the additional point mutations identified in these three mutants account for this increase in activity. Table 8 lists all point mutations that were found. If silent and conservative mutations are considered not to influence specificity, only a limited number of candidates to account for the phenotype remains. Among these, S254G and Q255R of mxoxox 2 and 3, because of their location close to the amino-terminus of the J helix, could be expected to influence DNA contacts with positions 11 or 12 of the *lox* site. The other mutations are scattered in the N- and C-terminal domain of Cre. All, except R101Q of mxoxox 5, affect aa that are not located within the proximity of DNA contacting areas. Some appear independently in two mutants, e.g. D29A or D189N, that

could influence protein folding or the interactions among the four Cre enzymes necessary for recombination. Such alterations could influence for example the orientation of the J helix and thereby reduce remaining interference between the *loxK2* site and the enzyme. Alternatively, some mutations, also silent ones,  
5 could influence protein expression, leading to a faster accumulation of enzymes and consequently to higher recombination frequency. This possibility should however also influence *loxP* recombination. In fact, after 2.5 h of *cre* expression, the mutants mxoxox 1 and 2 showed a slightly higher frequency of *loxP* recombination compared to wt *cre* (98% vs. 94%). This difference, on the  
10 other hand, may be attributed to the variations that occur normally within experiments. To address this question further, shorter *cre* expression times on *loxP* would be required.

When the coordinates of the crystal structure (Guo et al., *Nature*, 389:40-46 (1997)) are available (protein data bank, Brookhaven National Laboratory), it  
15 will be possible to confirm many of the tenets discussed.

Finally, the increase in *loxK2* tolerance between the E262G mutation alone and the isolated mutants carrying additional point mutations justifies the use of the DNA shuffling procedure linked to selection: Not only has it permitted the elimination of deleterious mutations from the sequence pool, but it  
20 helped to accumulate various more or less beneficial aa alterations as well.

### The E262A and E262W Mutations

The mentioned site-directed mutagenesis procedure was used to generate two more defined Cre mutants, E262A and E262W. Compared to the E262G mutation, E262A permitted *loxK2* recombination ten fold less effectively. The  
25 E262W mutation however resulted in similar activity on *loxK2*.

The aliphatic side chain (a methyl group) of A262 could be the reason for slight sterical interference. This would explain the observed reduced frequency of *loxK2* activity with E262A. *loxP* recognition, however, could not be found to be affected compared to E262G. The lowered *loxK2* activity  
30 explains why no E262A mutation was identified in the small pool of six

analyzed mutants: With a ten fold decrease in activity, one would expect to encounter the corresponding mutation ten times less often during selections as well.

In contrast to the small side chain of alanine, the large aromatic side chain of W262, was expected to inhibit recombination between any *lox* sites due to sterical interference. Surprisingly, this seems not to be true. A possible explanation for the observed activity on *loxP* and *loxK2* could be that the aromatic and planar structure of the tryptophan side chain, fits better into the J helix – *lox* interface than does a methyl group. Different influences of A262 and W262 on folding of the J helix could also contribute to the observed phenotypes. The reason why the E262W mutation was not identified among the six analyzed mutants is the genetic code. Whereas for the E262G and E262A mutations only one bp in the glutamate encoding GAA codon needs to be mutated to GGA or GCA, for E262W the whole codon must be exchanged to TGG. This is unlikely to occur during the applied random mutagenesis procedure with a mutation frequency of 0.5%. Other amino acid changes due to two or three mutations of the glutamate encoding codon therefore cannot be considered to have occurred during the random mutagenesis procedure.

When the coordinates of the crystal structure are public, it will be interesting to confirm and further investigate the discussed hypothesis.

#### ABBREVIATIONS

5-BI-ara a.k.a Z-ara	5-bromo-3-indoyl- $\alpha$ -L-arabinofuranoside
aa	amino acid
Ap(Ap <sup>R</sup> , Ap <sup>S</sup> )	ampicillin
25 bp	base pairs
Cm(Cm <sup>R</sup> , Cm <sup>S</sup> )	chloramphenicol (resistant, sensitive)
cre – Cre	cyclization recombination ( <i>gene</i> – Protein)
Da	Dalton
DMSO	dimethylsulfoxide
30 ds	double stranded

	GF	gel filtration
	K1 <sup>+</sup> or K2 <sup>+</sup>	Cre mutant capable for <i>lox</i> K1 or <i>lox</i> K2 recombination
	Kan (Kan <sup>R</sup> , Kan <sup>S</sup> )	kanamycin (resistant, sensitive)
5	<i>lox</i>	locus of crossover
	MCS	multiple cloning site
	mRNA	messenger RNA
	<i>neo</i> – Neo	neophosphotransferase ( <i>gene</i> – Protein)
10	P <sup>-</sup> or P <sup>+</sup>	Cre mutant defective or capable for <i>lox</i> P recombination
	PCR	Polymerase Chain Reaction
	SD	Shine-Dalgarno sequence
	ss	single stranded
	TK	thymidine kinase
15	wt	wildtype
	X-gal	5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside

### Example 2: Analysis of Variant Cre Recombinases

This example describes analysis the activity of several specific variant  
20 Cre recombinases.

#### Vectors

*pBS606, 614, 626, 627, 628 and 650:* pBAD33 with wt, E262G,  
E262G/D29A, E262G/D189N, E262G/T316S, and R3M3 *cre* insertion used for  
expression of the corresponding Cre proteins in DH5 $\alpha$  for *in vivo* testing.  
25 *pBS632 to pBS641:* pUC19 based plasmids for *in vivo* tests of different  
Cre mutants on a variety of different *lox* sites and combination of *lox* sites, all  
bearing the FAS1 spacer (Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996)).  
Recombination between two *lox* sites leads to excision of a *neo* cassette to give  
kanamycin sensitive *E. coli*. The same plasmids were also used for *in vitro*  
30 recombination experiments.

*pRH200*: wt Cre expression plasmid (a generous gift from Ron Hoess, DuPont, Wilmington, DE) used to overexpress wt Cre in BL21(DE3) (Novagen, Madison, WI) strain.

*pBS654 to pBS658*: wt *cre* of *pRH200* was replaced with different *cre* mutants (E262G, E262G/D29A, E262G/D189N, E262G/T316S, and R3M3) using *Age* I and *Ml*  $\mu$  I restriction sites.

#### ***E. coli* Strains**

*BS583*: The *E. coli* strain BS583, DH5  $\Delta$ lac ( $\lambda$ D69 *loxP*<sup>2</sup>[*lacZ* LEU2]), was chosen as the bacterial background for the selection procedure using 10 plasmid pBS584. Due to the *loxP*<sup>2</sup>[*lacZ*] containing  $\lambda$  prophage, Cre activity on *loxP* can be evaluated simply by using X-gal plates.

*BS1494*: The *E. coli* strain for selection was established by introducing the selection plasmid pBS584 into BS583. Thus, BS1494 allows a kanamycin-selection for *loxK2* and in parallel a blue/white-screen for *loxP* recombination 15 with 5-bromo-4chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-gal). Note that the spacer region of the *loxK2* site (FAS1) is different from the original one of *loxP*. Thus, recombination events between *loxP* of the  $\lambda$  prophage and *loxK2* of the selection plasmid pBS584 catalyzed by potent Cre mutants are excluded in BS1494.

20 *BS1576 to BS1581*: For the *in vivo* recombination experiments wt and mutant Cre expressing strains were generated by introducing plasmids pBS606, 614, 626, 627, 628, and 650 into DH5 $\alpha$ .

#### **Transformation of *E. coli***

For plasmid transformations of *E. coli* strains, electroporation was 25 preferred over chemical protocols. Electrocompetent cells were made and used for electroporation as described by Smith et al., *Focus*, 12:38-40 (1990). The appropriate cell porator and cuvettes were from Life Technologies (Bethesda, MD).

## Site-Directed Mutagenesis

The QuickChange™ Site-Directed Mutagenesis Kit (Stratagene Cloning Systems, La Jolla, CA) (1997) was used to generate defined single and double mutations in the *cre* gene.

### 5 Overexpression and Purification of Candidate Mutants

Wild-type and five different mutant Cre proteins were overexpressed using plasmids pRH200, and pBS654 to pBS658 in conjunction with Novagen BL21 (DE3) cells. After induction for 2.5 h cells were harvested, sonicated, and Cre partially purified after DNase I digest with a single step Whatman® P11 10 resin (Whatman Inc., Fairfield, NJ) as described before by Wierzbicki et al., *J. Mol. Biol.*, 195:785-794 (1987). The obtained Cre preps were about 80% pure and protein concentrations ranged between 100 and 200 ng/μl.

### Mutant Analysis

15 *In Vivo*: Plasmids pBS632 to pBS641 were transformed into Cre-expressing *E. coli* strains BS1576 (wt), BS1577 (E262G), BS1578 (E262G/D29A), BS1579 (E262G/D189N), BS1580 (E262G/T316S), and BS1581 (R3M3). After 1 hour of induction of *cre* expression with 0.2% L-(+)-arabinose, 10<sup>-5</sup> dilutions were plated on non-selection medium containing 0.2% D-glucose. After overnight incubation at 37°C, colonies were transformed to 20 kanamycin-selection plates for the described negative selection for *neo* excision.

25 *In Vitro*: Purified Cre mutants were used for both *in vitro* recombination and gel retardation experiments as described before by Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996) and Wierzbicki et al., *J. Mol. Biol.*, 195:785-794 (1987), respectively. For the recombination reactions plasmids pBS632 to pBS641 served as substrates, whereas for the DNA binding reactions  $\gamma[^{33}\text{P}]$ -dATP (Amersham Pharmacia Biotech, Piscataway, NJ) end-labeled 35 bp oligonucleotides were used, each encoding a *lox*-halfsite and one half of the FAS1 spacer.

### Evaluation of Six K2<sup>+</sup>/P<sup>+</sup> cre Mutants

Six of the 36 identified single Kan<sup>R</sup> colonies of the third round were chosen for further analysis and referred to as R3M1 to 6 (Round 3 Mutants 1 to 6). Retesting them in the indicator strain revealed that all but one (R3M4) show significant *loxK2* recombination and all are unbiased in their activity on *loxP* (Table 14). Sequencing analysis revealed one amino acid change common to all five mutants having increased *loxK2* activity: a glutamate to glycine exchange at position 262 (E262G) in the J helix of the Cre protein (Figure 13). A second point mutation, a conservative threonine to serine exchange at position 316 (T316S), was identified in three of the mutants with enhanced *loxK2* activity. Two non-conservative mutations (D29A and D189N) were found in two of the five mutants. In addition, ten mutations occurred only once. Therefore, the critical mutation for *loxK2* activity appears to be E262G.

### Site-Directed Mutagenesis

To address the question of the influence of the different point mutations further, the QuickChange™ Site-Directed Mutagenesis Kit (Stratagene) was applied to generate the following Cre mutants, each confirmed by sequencing: E262G, E262G/D29A, E262G/D189N, and E262G/T316S.

### In Vivo Characterization

To elucidate the contribution of specific amino acid changes in conferring altered recombinational specificity to Cre, recombination assays with different *lox* sites were carried out with the following Cre enzymes: the wt enzyme, one of the originally sequenced third round mutants (R3M3), and the generated single and double mutants. All *lox* sites used for the *in vivo* tests were designed to have the same 8 bp spacer region (FAS1) so that recombinational specificity was completely dependent on Cre's recognition of the symmetrical inverted repeats of the *lox* sites. Note that wt Cre-dependent recombination between *loxP* sites bearing the FAS1 spacer does not differ from recombination between original *loxP* sites (Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996)).

Figure 14 presents the recombination frequencies of various mutant *lox*<sup>2</sup> substrates and combination of sites (*loxP* with *loxK2* and as control with *loxK1*) from the marker excision assay. Mutant *lox* sites with symmetric nucleotide substitutions at positions 11 and 12 of the *loxP* sequence were tested with the wt enzyme and the five variant Cre mutants, including the multiple mutant R3M3(A). All enzymes showed a maximum in recombination (close to 100%) with thymines at these positions, i.e. with *loxP*<sup>2</sup>. Adenines, i.e. *loxK2*<sup>2</sup>, lowered the recombination frequencies drastically for the wt enzyme, whereas the single and double mutants performed approximately 50% to 70% less effectively.

10 R3M3, however, showed nearly *LoxP*-like activity on the *loxK2*<sup>2</sup> substrate, as seen before with the selection strain (Table 14). Altering the two thymines to guanines resulted in similar recombination frequencies as seen with adenines at these positions. Cytosines, on the other hand, did not result in similar recombination frequencies as seen with thymines, but were surprisingly the least

15 efficiently recognized substitutions of positions 11 and 12. To conclude, it appears that the E262G mutation is necessary and sufficient to significantly increase recombination frequencies on *lox* sequences which are symmetrically altered at positions 11 and 12. Of the additional mutations tested, D29A seems to be slightly beneficial, whereas D189N and T316S appear indifferent or even

20 slightly deleterious for recombination on the variant sites. Thus, additional mutations of R3M3 (Figure 13) must be responsible for its further increased performance on the mutant substrates *in vivo*.

Figure 14B shows the observed recombination frequencies on mixed substrates (e.g. *loxP* with *loxK2*). For both *loxK2* and the control substrate, *loxK1*, recombination with *loxP* by wt enzyme was substantially less than for *loxP*<sup>2</sup> recombination. This recombination frequency was increased dramatically with all of the mutant Cre protein. These results hint that not only a cooperativity in binding of two Cre molecules to one *lox* site exists but moreover also cooperativity between Cre molecules binding to different sites which then are synapsed and recombined. This finding is especially useful for

genomic targeting: It suggests that a targeting vector carrying a *loxP* site will be effectively recombined with the endogenous *lox*-like site by the Cre mutants as long as the spacers are compatible.

Noteworthy also is R3M3-Cre's increased ability to recombine *loxK1* by itself, whereas all the mutants, like wt, did not. Again, some additional mutations found in R3M3 (Figure 13) seem to be responsible not only for increased recombination frequencies on *loxK2* but also on *loxK1* compared to Cre bearing the E262G mutation alone or in conjunction with the D29A mutation.

## 10           ***In Vitro Characterization***

*In Vitro Recombination Assays.* For the *in vitro* recombination experiments the same substrates as *in vivo*--that is, pBS632 to pBS641--were used. An *in vitro* recombination experiment using wt, E262G, and R3M3 Cre preps on *loxP<sup>2</sup>*, *loxK2<sup>2</sup>*, and *loxK1<sup>2</sup>* substrate showed that, as seen *in vivo* before, 15 wt Cre is capable to recombine *loxP<sup>2</sup>* substrates only. No recombination products are visible when *loxK2<sup>2</sup>* or *loxK1<sup>2</sup>* substrates were used. By introducing the E262G mutation into Cre, however, recombination of *loxK2<sup>2</sup>* substrates becomes possible at elevated frequencies, and even for *loxK1<sup>2</sup>* substrate recombination products become weakly visible *in vitro*. E262G-Cre activity on the *loxK1* control site *in vitro* but not *in vivo* probably derives from differences in ionic strength and/or enzyme concentration between the assays. Finally, with R3M3 Cre the ability for both *loxK2<sup>2</sup>* and *loxK1<sup>2</sup>* recombination is further increased, as expected from the *in vivo* assays. As mentioned in the *in vivo* results before, guanines at positions 11 and 12 of the *lox* sequence were 20 recognized at similar frequencies as seen with adenines (i.e. *loxK2*), whereas cytosines were clearly less tolerated by all Cre mutants. Slight differences between *in vivo* and *in vitro* recombination frequencies are probably due to differences in ionic strength, temperature, DNA condensation, enzyme concentration, etc. In general, the pattern of the *in vitro* recombination

frequencies of the different Cre enzymes on the different *lox* sites mirrors the one seen *in vivo*.

*Gelshift Experiments.* Gelshift experiments were applied to address the question of *in vitro* DNA-affinities of the different Cre mutants. As expected from the previous results, all three Cre enzymes bind with similar efficiency to *loxP*, whereas to *loxK2*, only E262G and R3M3 show binding affinity.  
5 Surprisingly, R3M3 binding appears less efficient on the *loxK2* half-site than binding of E262G, and on the *loxK1* half-site only E262G does bind weakly whereas R3M3 does not.

## 10 DISCUSSION

### *lox sites*

*loxP* and *loxK2* differ at several locations as illustrated in Figure 1: First, the three outermost bp of the inverted repeats are altered (positions 15, 16, 17, 15', 16' and 17'). Second, the entire non-canonical 8 bp spacer is completely exchanged (positions 4 to 4'), and third, two transversion events (thymine to adenine) are introduced at positions 11 and 12 (and mirrored at 11' and 12') of the *lox* site, mimicking potential recombination targets in eukaryotes. Only the two mutations at positions 11 and 12 are considered important for inhibiting wt Cre from recognizing the site. Thus, they were the only alterations in the *lox* sites used for the *in vivo* and *in vitro* characterization experiments. Other investigations have shown that the two alterations of *loxP* mentioned first are without inhibiting effect on wt Cre (Sauer, B., *Mol. Cell. Biol.*, 7:2087-2096 15 (1987) and Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996)). Noteworthy is however that the altered 8 bp spacer region (FAS1 spacer) does not allow *loxP* - 20 *loxK2* recombination, since the regions where the single-strand cleavages and exchanges take place are not compatible. To allow simultaneous monitoring of Cre-mediated recombination both at the wt *loxP*<sup>2</sup> and at a mutant *lox*<sup>2</sup> substrate (*loxK2*<sup>2</sup>), incompatible spacer elements were used to prevent recombination 25 between the two types of *lox* sites by a candidate Cre mutant with altered specificity. Such recombination might easily compromise ready detection of 30

desired Cre specificity mutants. Incompatible spacers (original *loxP* and FAS1) formed the basis for the simultaneous selection for *loxK2* recombination and screen for *loxP* recombination with *E. coli* strain BS1494 which led to the disclosed variant Cre recombinases.

5        *LoxK1*, the other lox sequence used in this study, bears two critical bp exchanges per arm as well, however at different positions: 10 and 14. It was used as a control *lox* site, addressing the question whether the generated Cre mutants with novel specificity for *loxK2* can also tolerate adjacent alterations within the *lox* sequence.

10        **Cre Mutants after Three Rounds of Directed Evolution**

Three iterations of the *in vitro* evolution procedure were used to identify 36 candidates which express Cre mutants that could process *loxK2* (based on the selection), as well as *loxP* (based on the simultaneous screen). wt Cre, on the other hand, only shows marginal activity on *loxK2* when expressed at very high 15 levels.

15        **Characterization**

Sequence analysis revealed that five mutants with significant *loxK2* activity had in common only one point mutation, leading to the amino acid change E262G. However, several other point mutations occurred independently 20 twice or thrice, among which D29A, D189N, and T316S. To investigate the influence of the mentioned mutations on the observed phenotype, specific single and double mutants were generated by site-directed mutagenesis. *In vivo* and *in vitro* assays were then carried out with wt-Cre and five different mutants (R3M3, E262G, E262G/D29A, E262G/D189N, E262G/T316S) to compare their 25 performance on a variety of different alterations of the *loxK2* site.

The *in vivo* and *in vitro* recombination assays showed a similar pattern in recombination frequencies for the different enzymes on the different sites tested. In general, recombination frequencies on mutant substrates were distinctively the highest with R3M3. The double mutant E262G/D29A was about half as 30 effective as R3M3, whereas the other double mutants and the single mutant

E262G showed slightly further decreased recombination frequencies on the altered sites. The wt enzyme did not recombine any of the mutant substrates presented here, neither *in vivo* nor *in vitro*. With previous results showing that single D29A, D189N, and T316S mutants of Cre perform like the wt enzyme on 5 *loxK2* and *loxK1* *in vivo* and the fact that the E262G point-mutation was the only one found independently in all the originally isolated Cre mutants with *loxK2* specificity, it is clear that E262G is a critical mutation that allows Cre to recognize *loxK2*. However, in combination with E262G, D29A permits still higher recombination frequencies on *lox* sites altered at positions 11 and 12.

10 Since R3M3 shows even further increased recombination frequencies on the altered sites compared to E262G/D29A, other of the point mutations identified in this Cre mutant (see Figure 14) must account for this increase in activity. Because of its location close to the amino-terminus of the J helix, the Q255R mutation of R3M3 could be expected to influence DNA contacts. Other 15 mutations may influence protein folding or protein-protein interactions which could result in a higher flexibility within the Cre-*lox* interface and thus allowing a better tolerance of alterations of the *lox* sequence. This hypothesis is also supported by the observation that R3M3 recognizes the *loxK1* site at frequencies similar to E262G recognizing *loxK2*. The double and single Cre mutants, on the 20 other hand, did not show activity on *loxK1*. In addition, the gel-shift experiments showed that R3M3-Cre's binding affinity for *loxK2* and *loxK1* half-sites is less than E262G-Cre's and the three double mutant's. Taking these 25 results together, other mutations of R3M3 must further influence Cre-*lox* interactions to allow enhanced recombination on *loxK2*. On the one hand, this results in less efficient binding to *lox* half-sites, on the other hand, when complete *lox* sites are available, the cooperativity phenomenon between Cre enzymes binding to the same and different *lox* sites may compensate for this loss in binding activity. Then the postulated increased flexibility between DNA and protein seems to become advantageous for recognizing and recombining altered 30 *lox* sites, as seen with the *in vivo* and *in vitro* recombination assays.

Alternatively, some mutations, also silent ones, could influence protein expression, leading to a faster accumulation of enzymes and consequently to higher recombination frequency. An *E. coli* codon usage table suggested, however, that none of the identified mutations should improve Cre expression in *E. coli* remarkably.

5

### **Modeling**

With the published crystal structure of four Cre molecules bound to two synapsed *loxA* sites after the first single strand cleavage (Guo et al., *Nature*, 389:40-46 (1997)) the identified point mutations were analyzed for being involved in DNA and/or protein interactions. All of them, including the E262 position in the J-helix of Cre were found to be not involved in either interactions in this state of the reaction. This observation indicates that the mutations which were found to account for the described novel substrate recognition *in vivo* and *in vitro* lead to this new phenotype in a less direct and obvious manner. As mentioned earlier, they may influence protein folding, resulting in a higher flexibility within the Cre-*lox* interface. This hypothesis is especially well supported with the described differences between binding to *lox* halfsites and recombination. Alternatively, they may still be involved in protein-protein (D29A) or protein-DNA (E262G) contacts before or after the formation of the clamp-like strand-exchange state.

10

15

20

### ***In Vivo* and *In Vitro* Recombination**

Some additional variations of the *loxK2* site were tested also. The list in Table 17 shows all the sequences of *lox* sites which were tested and assigns them a name, as well as their plasmid (pBS) number. In Figure 15 the obtained *in vivo* recombination frequencies on all the variants of *loxK2* are indicated. The additional results indicate that alterations at position 12 of the *lox* halfsite are of more importance for Cre-based recombination than ones at position 11.

25

30

The *in vitro* recombination frequencies of all six Cre enzymes tested on the *lox* sites listed above are given in table 15. The frequencies were calculated after quantitation of the brightness of fluorescence of the Ethidium-Bromide-

stained DNA fragments on agarose-gels. Differences in temperature, ionic strength, medium composition, and enzyme concentration probably account for the observed differences between *in vivo* and *in vitro* recombination results.

5 Most strikingly, *loxP* is no longer recognized with the highest frequencies *in vitro*. However, when the ionic strength in the *in vitro* assay was increased results began to resemble the ones seen *in vivo*. Thus, efficiency of recombination with variant *lox* sites by each of the Cre mutant and the wt enzyme can be further controlled *in vitro* by adjusting ionic strength and other *in vitro* conditions.

10 Qualitatively, however, the *in vivo* and *in vitro* recombination frequencies mirror each other. These novel Cre mutants thus possess a specificity for substrates (*loxK2* and its derivatives) which are not recognized by the wt enzyme.

#### Gelshift Assays

15 DNA binding (gelshift) experiments were also done with the generated Cre double-mutants (E262G with D29A, D189N, or T316S) to analyzing binding of the variant Cre recombinases to various recombination sites. In table 16 the observed mean percentages of binding to *loxP*, *loxK2*, and *loxK1* halfsites with the five different Cre mutants and the wt enzyme are given. As shown, all 20 mutants - in contrast to the wt enzyme - do bind to *loxK2* with similar frequencies, except R3M3 which shows surprisingly low retardation. As discussed above, this phenomenon may be explained with an increased tolerance, i.e., flexibility, of R3M3 for altered *lox* sites. On halfsites which precludes the cooperativity between Cre molecules in binding R3M3 cannot 25 bind as tight as wt or the single and double mutants. With the *loxK1* halfsite this 'binding versus recombination' difference is even more strikingly. Whereas wt and the R3M3 mutant cannot bind to the halfsite, all the other mutants can. Yet, recombination of *loxK1* substrates was seen with R3M3 Cre, only. These results show clearly that simple DNA affinity does not correlate in a one-to-one fashion

with recombination. Thus, inappropriate DNA binding by recombinases likely can lead to a block in recombination.

### Conclusions

The *in vivo* data show that:

- 5      1.      The E262G mutation confers a generally elevated level of recombination at a number of variant *lox* sites, those having any of a large number of alterations at positions 11 and 12 (and mirroring 11' and 12' alterations).
- 10     2.      The D189N mutation in conjunction with the E262G mutation appears to fine tune the broadened specificity of the E262G mutation by reducing recombination at the *loxK2* variants 'GG', 'TC' and 'CC' without decreasing recombination at *loxK2* and the 'GT' variant. This mutation is thus useful to limit the broadened specificity of E262G.
- 15     3.      The T316S mutation when in conjunction with E262G provides a slight boost in recombination frequency with the *loxK2* variants 'GT' and 'CC', and has no deleterious effect on recombination at the other variant *loxK2* sites.
- 20     4.      The D29A mutation together with E262G boosts recombination at *loxK2* and the variants 'CC' and 'GG'. D29A does not reduce recombination at the other variant *lox* sites or at *loxP*.
- 25     5.      Some of the additional mutations of R3M3 must account for the further increased recombination frequency on any of the tested mutant *lox* sites, including *loxK1* but do not compromise *loxP* recognition.

The disclosed variant recombinases have a number of useful features and applications. By recognizing an altered, user-defined target site, they were designed to allow both genetic targeting events in prokaryotes and eukaryotes like wt Cre but on different sites and *in vitro* recombination strategies. With a wider variety of possible target sequences being now accessible, multiple and defined genomic alterations will now become feasible. This opens more possibilities in designing genomic manipulations in all DNA-based organisms by site-specific recombination.

With the various genome projects under way today, there will be more and more applications for site-specific recombination to study the impact of genes or genetic control elements by genomic engineering. In addition, genome manipulations are also more frequently used to express recombinant proteins

5 within the organism of choice.

**Table 13.** Presented are the results of the first four rounds of the described mutagenesis procedure for *loxK2* specificity. Column one indicates the round of the mutagenesis procedure (round 0 indicates that no mutagenesis event has taken place yet, wt enzyme, only) and column two the allotted time for

10 *cre* expression in induction medium. Column three presents the observed frequencies of Kan<sup>R</sup>, indicating *loxK2* recombination by a mutant candidate. Of note, all Kan<sup>R</sup> colonies found during this experiment were white, indicating

15 effective *loxP* recombination. In column four the actual number of Kan<sup>R</sup> colonies found in each round of 1000 to 10<sup>4</sup> plated is given, and the last column presents the frequency of white colonies on non-selection plates which is

decreasing with every round.

**Table 14.** Presented are the frequencies of Kan<sup>R</sup> of six chosen candidate mutants from round three of the mutagenesis procedure (R3M1 to 6) when retesting them in the indicator strain. Also, they were tested for their performance on *loxP* sites in identical fashion. The obtained Kan<sup>R</sup> frequencies indicate the percentages of recombination within the allotted induction time of 2.5 hours.

It is understood that the disclosed invention is not limited to the particular methodology, protocols, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context

clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to "the antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

5        Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials  
10      are as described. Publications cited herein and the material for which they are cited are specifically incorporated by reference. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

15      Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

**Table 2****Table 2:** List of Strains Used for Selection and Screen

BS #	Description	Substrates	Selection and Screen
1493	BS583 [pBS583]	<i>loxK1</i> <sup>2</sup> / <i>loxP</i> <sup>2</sup>	<i>neo</i> selection and <i>lacZ</i> screen, respectively
1494	BS583 [pBS584]	<i>loxK2</i> <sup>2</sup> / <i>loxP</i> <sup>2</sup>	<i>neo</i> selection and <i>lacZ</i> screen, respectively
1541	BS583 [pBS613]	<i>loxP</i> <sup>2</sup> / <i>loxP</i> <sup>2</sup>	<i>neo</i> selection and <i>lacZ</i> screen, respectively
1523	NS2300 [pBS601]	<i>loxK1</i> <sup>2</sup> / <i>loxP</i> <sup>2</sup>	<i>abfA.st</i> screen and <i>neo</i> selection, respectively
1524	NS2300 [pBS602]	<i>loxK2</i> <sup>2</sup> / <i>loxP</i> <sup>2</sup>	<i>abfA.st</i> screen and <i>neo</i> selection, respectively

List of the *E. coli* strains used for the described selection and screening procedures for the desired Cre mutants. BS1493 and BS1494 served as selection strains for K1<sup>+</sup> or K2<sup>+</sup> Cre mutants, respectively. BS1541 was used as a control strain to determine *loxP* activity. BS1523 and BS1524 were used to select for P<sup>+</sup> mutants. Construction and application of the different selection procedures are explained in detail in the text.

### Tables 3 and 4

Table 3: Sequencing Primers for *cre*

Primer BSB#	Sequence 5' - 3'	Position (5', 3') in <i>cre</i>
454	TTT GGG CTA GCG AAT TCG AG	-55, -36
455	TTT GGG CCA GCT AAA CAT GC	273, 292
456	CGG TGG GAG AAT GTT AAT CC	567, 586
457	GGA CAC AGT GCC CGT GTC	862, 879
458	TCT GCG TTC TGA TTT AAT CTG	1117, 1097
459	CCA GGC CAG GTA TCT CTG	858, 841
460	GTA CGT GAG ATA TCT TTA ACC C	563, 542
461	TTG CTG GAT AGT TTT TAC TGC C	270, 249

Presented are the eight sequencing primers used for sequencing of the entire *cre* gene in both directions and their positions within the *cre* coding sequence. Primers BSB 454 to BSB457 allow sequencing of the coding strand, whereas the four remaining primers have been designed for the non-coding strand. In order to achieve a complete sequence information in both directions, about 350 bases have to be read out of each sequencing reaction. The positions given for each primer refer to its 5' and 3' end, with position 1 referring to the adenine of the ATG start codon of *cre*.

Table 4: Primers Used in the QuickChange™ Site-Directed Mutagenesis Kit (Stratagene)

Primer BSB#	Sequence 5' - 3'	Position (5', 3' in <i>cre</i> )
465	GCTATCAACTCGGCCCTGGGAGGGATTGGAAAGCAACTCATCG	765, 809
466	GAGTTGCTTCAAAAATCCCTCCCAGGGCGCGAGTTGATAGCTGGC	805, 761
467	GCTATCAACTCGGCCCTGGCAGGGATTGGAAAGCAACTCATCG	765, 809
468	GAGTTGCTTCAAAAATCCCTGCCAGGGCGCGAGTTGATAGCTGGC	805, 761
469	GCTATCAACTCGGCCNNNNNNNNNATTGGAAAGCAACTCATCG	765, 809
470	GAGTTGCTTCAAAAATNNNNNNNNNGCGCGAGTTGATAGCTGGC	805, 761

Illustrated are the mutant oligonucleotides used in the QuickChange™ Site-Directed Mutagenesis Kit (Stratagene) to introduce single point mutations (mismatches with the wt sequence are highlighted by bold letters). With BSB465/466 a E262G mutation, and with BSB467/468 a E262A mutation is introduced in Cre. The last set of primers (BSB469/470), as indicated by the bold N, represent an equimolar mixture of all possible bases at the assigned positions. This mixture results in all possible aa combinations at positions 261 to 263 of Cre. As mentioned before, the indicated positions refer to 5' and 3' end of the oligonucleotides in the *cre* coding sequence.

**Table 5****Table 5:** Comparison of Mutagenic and Non-Mutagenic PCR on wt *cre*

Induction of <i>cre</i> Expression	Non-Mutagenic PCR		Mutagenic PCR	
	Blue	White	Blue	White
SOC, 2.5h	> 99.6%	< 0.4%	> 99.5%	< 0.5%
SOB+ara, 2.5h	19.7%	81.3%	60.8%	39.2%

The experiments presented here served two purposes: (*i*) to compare the influence of glucose (SOC medium) and arabinose on *cre* expression with pBAD33, (*ii*) to compare the frequencies of deleterious point mutations occurring during non-mutagenic and error-prone PCR. The first column indicates the medium used for repression (SOC), or induction of *cre* expression (SOB+ara). The second column compares the observed frequencies of blue and white colonies after a non-mutagenic PCR, the third column after a mutagenic PCR. Blue colonies indicate, that the *loxP<sup>2</sup>* flanked *lacZ* gene of BS583 is not excised by Cre, white ones its Cre-mediated excision. Note that the number of blue colonies resulting from empty pBAD33 vector (approximately 1% in all experiments) was subtracted before calculating the presented values. This blue background was determined with a control ligation lacking *cre* insertion. With glucose in the medium, only blue colonies are found, indicating that *cre* is not expressed. With arabinose induction, however, the frequencies of disabled Cre mutants (blue) can be determined, increasing three times under mutagenic conditions.

**Table 6**Table 6: The First Four Rounds on *loxK2*<sup>2</sup>

Round	Status	Induction	% White (Non-Selection)	% Kan <sup>R</sup> (White)	Nb. Kan <sup>R</sup> (White)	Nb. Pooled for the Next Round
1	ox	4 h	83.9%	0.01%	1	none
	mx	4 h	42.4%	0.16%	6	6
2	mxox	2.5 h	88.3%	0.02%	1	none
		4 h	82.5%	0.56%	47	47
	mxmlx	2.5 h	13%	< 0.01%	0	none
		4 h	24%	0.3%	5	none
3	mxoxox	2.5 h	80.7%	0.2%	36	30
		4 h	85%	25%	10 <sup>4</sup>	none
	mxoxmx	2.5 h	25.7%	0.02%	1	none
		4 h	21.8%	5%	250	none
4	mxoxoxox	2.5 h	75%	4.6%	102	none
	mxoxoxmx	2.5 h	< 7.7%	0.3%	3	none

Presented are the results of the first four rounds of the described mutagenesis procedure for *loxK2* specificity. The following symbols for the status of the *cre* pools have been used: "o" indicates a non-mutagenic, "m" a mutagenic PCR, and "x" stands for the shuffling step by DNase I digest and reassembly. Column one indicates the round of the mutagenesis procedure, column two its status as mentioned above, and column three the time permitted for *cre* expression in induction medium. In column four, the calculated percentages of white colonies on non-selection plates is indicated, decreasing with every round, especially when the pools were subjected to mutagenic PCR's twice. Column five presents the observed frequencies of Kan<sup>R</sup>, indicating *loxK2* recombination by a mutant candidate. Of note, that all Kan<sup>R</sup> colonies found during this experiment were white, indicating effective *loxP* recombination. The two last columns give the actual numbers of Kan<sup>R</sup> colonies found in each round (1/5 dilution) and mark the ones used as starting material for the next round.

**Table 7****Table 7: Functional Evaluation of Six Selected mxoxox K2<sup>+</sup> Mutants and wt Cre**

Cre Candidate	Induction Time	% Kan <sup>R</sup> with BS1494 ( <i>loxK2<sup>2</sup></i> )	% Kan <sup>R</sup> with BS1541 ( <i>loxP<sup>2</sup></i> )	% Kan <sup>R</sup> with BS1493 ( <i>loxK1<sup>2</sup></i> )
wt	2.5 h	0.002%	93.9%	0.001%
	4 h	n.d.	n.d..	0.002%
mxoxox 1	2.5 h	66.4%	98.2%	0.004%
	4 h	n.d.	n.d.	0.005%
mxoxox 2	2.5 h	53.6%	98%	0.007%
	4 h	n.d.	n.d.	0.005%
mxoxox 3	2.5 h	66.5%	80.5%	0.007%
	4 h	n.d.	n.d.	0.01%
mxoxox 4	2.5 h	0.05%	80.3%	0.008%
	4 h	n.d.	n.d.	0.006%
mxoxox 5	2.5 h	15.2%	81.2%	0.006%
	4 h	n.d.	n.d.	0.009%
mxoxox 6	2.5 h	3.1%	83.7%	0.003%
	4 h	n.d.	n.d.	0.01%

The results of functional testing of the six chosen K2<sup>+</sup>/P<sup>+</sup> Cre candidates compared to wt Cre are listed. All enzymes were checked on *loxK2*, *loxP* and *loxK1* recombination in the selection strains BS1494, BS1493 and the control strain BS1541. In the first column the Cre candidate is indicated, in the second the allowed time for *cre* expression. The three following columns show the calculated percentages of Kan<sup>R</sup> when subjecting the different Cre mutants and wt Cre to the three selection strains. The frequency of the observed Kan<sup>R</sup> phenotype is considered as an indicator for the frequency of *lox* recombination: On *loxK2*, all mutants, except mxoxox 4, show remarkably increased Kan<sup>R</sup> frequencies compared to wt Cre. On *loxP*, all (including mxoxox 4), show very similar results as wt Cre, indicating, that *loxP* recombination is at best slightly affected. On *loxK1* neither mutant nor wt Cre show more than background activity, even after four hours of *cre* expression. The obtained mutants are therefore characterized by a broader substrate recognition compared to the wt enzyme.

Table 8

Table 8: Sequence Analysis of the Six mxoxox K2<sup>+</sup>/P<sup>+</sup> Mutants

Cre Candidate	Codon Position	Codon Change in <i>cre</i> <u>wt</u> → <u>mut</u>	aa Change	Nb. of Isolates	Position in Cre
<b>mxoxox 1</b>	45	<u>CCG</u> <u>CCT</u>	(P15P)	2	(N-terminal)
	86	<u>GAC</u> <u>GCC</u>	D29A	2	A
	565	<u>GAC</u> <u>AAC</u>	D189N	2	loop I - 2
	642	<u>AGC</u> <u>AGT</u>	(S214S)	1	(N-term. of I)
	679	<u>GTC</u> <u>ATC</u>	V227I	1	I
	785	<u>GAA</u> <u>GGA</u>	E262G*	5	J
<b>mxoxox 2</b>	45	<u>CCG</u> <u>CCT</u>	(P15P)	2	(N-terminal)
	413	<u>GAA</u> <u>GGA</u>	E138G	1	N-term. of F
	760	<u>AGC</u> <u>GCG</u>	S254G	1	loop 5 - J
	785	<u>GAA</u> <u>GGA</u>	E262G*	5	J
	861	<u>TCT</u> <u>TCC</u>	(S287S*)	2	N-term. of K
	946	<u>ACC</u> <u>TCC</u>	T316S	3	loop L - M
<b>mxoxox 3</b>	46	<u>GTC</u> <u>ATC</u>	V16I	1	N-terminal
	565	<u>GAC</u> <u>AAC</u>	D189N	2	loop I - 2
	592	<u>GGC</u> <u>AGC</u>	G198S	1	C-term. of 2
	668	<u>CGA</u> <u>CAA</u>	R223Q	1	I
	764	<u>CAG</u> <u>CGG</u>	Q255R	1	loop 5 - J
	785	<u>GAA</u> <u>GGA</u>	E262G*	5	J
	861	<u>TCT</u> <u>TCC</u>	(S287S*)	2	N-term. of K
	920	<u>CCG</u> <u>CTG</u>	P307L	1	L
<b>mxoxox 4</b>	230	<u>TAT</u> <u>TGT</u>	Y77C	1	C
	412	<u>GAA</u> <u>AAA</u>	E138K	1	N-term. of F
	851	<u>CTG</u> <u>CAG</u>	L284Q	2	loop J - K
<b>mxoxox 5</b>	86	<u>GAC</u> <u>GCC</u>	D29A	2	A
	302	<u>CGG</u> <u>CAG</u>	R101Q*	1	D
	659	<u>CTG</u> <u>CAG</u>	L220Q	1	I
	785	<u>GAA</u> <u>GGA</u>	E262G*	5	J
	946	<u>ACC</u> <u>TCC</u>	T316S	3	loop L - M
<b>mxoxox 6</b>	785	<u>GAA</u> <u>GGA</u>	E262G*	5	J
	851	<u>CTG</u> <u>CAG</u>	L284Q	2	loop J - K
	946	<u>ACC</u> <u>TCC</u>	T316S	3	loop L - M

The point mutations identified by sequence analysis in the six selected K2<sup>+</sup>/P<sup>+</sup> mutants are listed. Column one identifies the mutants, column two the observed point mutations and their position in the *cre* coding sequence. Column three indicates the resulting aa changes and their positions in the Cre enzyme (silent mutations in parenthesis). DNA contacting residues, according to the crystal structure (Guo, *et. al.*, 1997), are marked by an asterisk. Column four indicates how often the different point mutations were independently found in the pool of the six mutants, and column five shows where the aa changes are located in the secondary structure of the protein. Of the altogether 31 point mutations listed, five are silent. Only one aa change, E262G, is common to all mutants with remarkably increased *loxK2* activity (mxoxox 1, 2, 3, 5, and 6), suggesting that this mutation is the essential one for the observed phenotype. Nine point mutations occurred twice or three times in the pool, whereas eleven were found in one mutant only. For further information, see text and appendices A, B, and C.

**Table 9****Table 9:** Functional Evaluation of Three Defined Cre Mutants for Position 262 and wt Cre

Cre Mutant	Induction Time	BS1494 ( <i>loxK2</i> <sup>2</sup> )	% Kan <sup>R</sup> with BS1541 ( <i>loxP</i> <sup>2</sup> )	BS1493 ( <i>loxK1</i> <sup>2</sup> )
wt	2.5 h	0.002%	93.9%	0.001%
E262G	2.5 h	2.2%	84.2%	0.004%
E262A	2.5 h	0.4%	82.3%	0.006%
E262W	2.5 h	2.9%	81.7%	0.003%

The results of functional testing of three defined Cre mutants for position 262 compared to wt Cre are listed. All enzymes were checked on *loxK2*, *loxP* and *loxK1* recombination in the selection strains BS1494, BS1493 and the control strain BS1541. In the first column the Cre candidate is indicated, in the second the allowed time for *cre* expression. The three following columns show the calculated percentages of Kan<sup>R</sup> when subjecting the different Cre mutants and wt Cre to the three selection strains. The frequency of the observed Kan<sup>R</sup> phenotype is considered as an indicator for the frequency of *lox*<sup>2</sup> recombination: On *loxK2*, E262G and E262W show approximately an 10<sup>3</sup> fold increased Kan<sup>R</sup> frequency compared to wt Cre, whereas E262A results in a 200 fold increase. On *loxP*, all show very similar results as wt Cre, indicating, that *loxP* recombination is at best slightly affected. On *loxK1* neither mutant nor wt Cre show more than background activity. This indicates, that E262G and E262W alone are sufficient to remarkably increase Cre's activity on *loxK2*, that these mutations do not increase *loxK1* recognition, and that *loxP* activity may be slightly affected.

DRAFT - DRAFT - DRAFT - DRAFT - DRAFT - DRAFT -

Table 10

## In Vitro Evolution of the Cre recombinase

wtCre	TTTGGGCTAG	CGAATTGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mxo <sub>oxo</sub> 1	TTTGGGCTAG	CGAATTGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mxo <sub>oxo</sub> 2	TTTGGGCTAG	CGAATTGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mxo <sub>oxo</sub> 3	TTTGGGCTAG	CGAATTGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mxo <sub>oxo</sub> 4	TTTGGGCTAG	CGAATTGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mxo <sub>oxo</sub> 5	TTTGGGCTAG	CGAATTGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mxo <sub>oxo</sub> 6	TTTGGGCTAG	CGAATTGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
<b>-55</b>					
wtCre	GTGAAATGTC	CAATTTACTG	ACCGTACACC	AAAATTTGCC	TGCATTACCG
mxo <sub>oxo</sub> 1	GTGAAATGTC	CAATTTACTG	ACCGTACACC	AAAATTTGCC	TGCATTACCT
mxo <sub>oxo</sub> 2	GTGAAATGTC	CAATTTACTG	ACCGTACACC	AAAATTTGCC	TGCATTACCT
mxo <sub>oxo</sub> 3	GTGAAATGTC	CAATTTACTG	ACCGTACACC	AAAATTTGCC	TGCATTACCG
mxo <sub>oxo</sub> 4	GTGAAATGTC	CAATTTACTG	ACCGTACACC	AAAATTTGCC	TGCATTACCG
mxo <sub>oxo</sub> 5	GTGAAATGTC	CAATTTACTG	ACCGTACACC	AAAATTTGCC	TGCATTACCG
mxo <sub>oxo</sub> 6	GTGAAATGTC	CAATTTACTG	ACCGTACACC	AAAATTTGCC	TGCATTACCG
<b>-5</b>					
wtCre	GTCGATGCAA	CGAGTGATGA	GGTTGCAAG	AACCTGATGG	ACATGTTCA
mxo <sub>oxo</sub> 1	GTCGATGCAA	CGAGTGATGA	GGTTGCAAG	AACCTGATGG	CCATGTTCA
mxo <sub>oxo</sub> 2	GTCGATGCAA	CGAGTGATGA	GGTTGCAAG	AACCTGATGG	ACATGTTCA
mxo <sub>oxo</sub> 3	ATCGATGCAA	CGAGTGATGA	GGTTGCAAG	AACCTGATGG	ACATGTTCA
mxo <sub>oxo</sub> 4	GTCGATGCAA	CGAGTGATGA	GGTTGCAAG	AACCTGATGG	ACATGTTCA
mxo <sub>oxo</sub> 5	GTCGATGCAA	CGAGTGATGA	GGTTGCAAG	AACCTGATGG	CCATGTTCA
mxo <sub>oxo</sub> 6	GTCGATGCAA	CGAGTGATGA	GGTTGCAAG	AACCTGATGG	ACATGTTCA
<b>46</b>					
wtCre	GGATCGCCAG	GCGTTTCTG	AGCATAACCTG	GAAAATGCTT	CTGTCGTT
mxo <sub>oxo</sub> 1	GGATCGCCAG	GCGTTTCTG	AGCATAACCTG	GAAAATGCTT	CTGTCGTT
mxo <sub>oxo</sub> 2	GGATCGCCAG	GCGTTTCTG	AGCATAACCTG	GAAAATGCTT	CTGTCGTT
mxo <sub>oxo</sub> 3	GGATCGCCAG	GCGTTTCTG	AGCATAACCTG	GAAAATGCTT	CTGTCGTT
mxo <sub>oxo</sub> 4	GGATCGCCAG	GCGTTTCTG	AGCATAACCTG	GAAAATGCTT	CTGTCGTT
mxo <sub>oxo</sub> 5	GGATCGCCAG	GCGTTTCTG	AGCATAACCTG	GAAAATGCTT	CTGTCGTT
mxo <sub>oxo</sub> 6	GGATCGCCAG	GCGTTTCTG	AGCATAACCTG	GAAAATGCTT	CTGTCGTT
<b>96</b>					
wtCre	GCCGGTCGTG	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTCCCC
mxo <sub>oxo</sub> 1	GCCGGTCGTG	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTCCCC
mxo <sub>oxo</sub> 2	GCCGGTCGTG	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTCCCC
mxo <sub>oxo</sub> 3	GCCGGTCGTG	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTCCCC
mxo <sub>oxo</sub> 4	GCCGGTCGTG	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTCCCC
mxo <sub>oxo</sub> 5	GCCGGTCGTG	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTCCCC
mxo <sub>oxo</sub> 6	GCCGGTCGTG	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTCCCC
<b>146</b>					
wtCre	GCAGAACCTG	AAGATGTTCG	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mxo <sub>oxo</sub> 1	GCAGAACCTG	AAGATGTTCG	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mxo <sub>oxo</sub> 2	GCAGAACCTG	AAGATGTTCG	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mxo <sub>oxo</sub> 3	GCAGAACCTG	AAGATGTTCG	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mxo <sub>oxo</sub> 4	GCAGAACCTG	AAGATGTTCG	CGATTATCTT	CTATGTCITC	AGGCGCGCGG
mxo <sub>oxo</sub> 5	GCAGAACCTG	AAGATGTTCG	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mxo <sub>oxo</sub> 6	GCAGAACCTG	AAGATGTTCG	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
<b>196</b>					

Table 10 (cont.)

*In Vitro Evolution of the Cre recombinase*

wtCre	TCTGGCAGTA	AAAACATATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mxoxox1	TCTGGCAGTA	AAAACATATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mxoxox2	TCTGGCAGTA	AAAACATATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mxoxox3	TCTGGCAGTA	AAAACATATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mxoxox4	TCTGGCAGTA	AAAACATATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mxoxox5	TCTGGCAGTA	AAAACATATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mxoxox6	TCTGGCAGTA	AAAACATATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
246					
wtCre	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mxoxox1	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mxoxox2	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mxoxox3	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mxoxox4	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mxoxox5	ATCGTCAGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mxoxox6	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
296					
wtCre	GTTATGCGGC	GGATCCGAAA	AGAAAAACGTT	GATGCCGGTG	AACGTGCAAA
mxoxox1	GTTATGCGGC	GGATCCGAAA	AGAAAAACGTT	GATGCCGGTG	AACGTGCAAA
mxoxox2	GTTATGCGGC	GGATCCGAAA	AGAAAAACGTT	GATGCCGGTG	AACGTGCAAA
mxoxox3	GTTATGCGGC	GGATCCGAAA	AGAAAAACGTT	GATGCCGGTG	AACGTGCAAA
mxoxox4	GTTATGCGGC	GGATCCGAAA	AGAAAAACGTT	GATGCCGGTG	AACGTGCAAA
mxoxox5	GTTATGCGGC	GGATCCGAAA	AGAAAAACGTT	GATGCCGGTG	AACGTGCAAA
mxoxox6	GTTATGCGGC	GGATCCGAAA	AGAAAAACGTT	GATGCCGGTG	AACGTGCAAA
346					
wtCre	ACAGGCTCTA	GCGTCGAAC	GCACTGATT	CGACCAGGTT	CGTTCACTCA
mxoxox1	ACAGGCTCTA	GCGTCGAAC	GCACTGATT	CGACCAGGTT	CGTTCACTCA
mxoxox2	ACAGGCTCTA	GCGTCGGAC	GCACTGATT	CGACCAGGTT	CGTTCACTCA
mxoxox3	ACAGGCTCTA	GCGTCGAAC	GCACTGATT	CGACCAGGTT	CGTTCACTCA
mxoxox4	ACAGGCTCTA	GCGTCAAAC	GCACTGATT	CGACCAGGTT	CGTTCACTCA
mxoxox5	ACAGGCTCTA	GCGTCGAAC	GCACTGATT	CGACCAGGTT	CGTTCACTCA
mxoxox6	ACAGGCTCTA	GCGTCGAAC	GCACTGATT	CGACCAGGTT	CGTTCACTCA
396					
wtCre	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCTGGG
mxoxox1	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCTGGG
mxoxox2	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCTGGG
mxoxox3	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCTGGG
mxoxox4	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCTGGGG
mxoxox5	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCTGGGG
mxoxox6	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCTGGGG
446					
wtCre	ATTGCTTATA	ACACCCCTGTT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mxoxox1	ATTGCTTATA	ACACCCCTGTT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mxoxox2	ATTGCTTATA	ACACCCCTGTT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mxoxox3	ATTGCTTATA	ACACCCCTGTT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mxoxox4	ATTGCTTATA	ACACCCCTGTT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mxoxox5	ATTGCTTATA	ACACCCCTGTT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mxoxox6	ATTGCTTATA	ACACCCCTGTT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
496					

Table 10 (cont.)

## In Vitro Evolution of the Cre recombinase

wtCre	TAAAGATATC	TCACGTACTG	ACGGTGGAG	AATGTTAAC	CATATTGGCA
mxo <sub>oxo</sub> 1	TAAAGATATC	TCACGTACTA	ACGGTGGAG	AATGTTAAC	CATATTGGCA
mxo <sub>oxo</sub> 2	TAAAGATATC	TCACGTACTG	ACGGTGGAG	AATGTTAAC	CATATTGGCA
mxo <sub>oxo</sub> 3	TAAAGATATC	TCACGTACTA	ACGGTGGAG	AATGTTAAC	CATATTAGCA
mxo <sub>oxo</sub> 4	TAAAGATATC	TCACGTACTG	ACGGTGGAG	AATGTTAAC	CATATTGGCA
mxo <sub>oxo</sub> 5	TAAAGATATC	TCACGTACTG	ACGGTGGAG	AATGTTAAC	CATATTGGCA
mxo <sub>oxo</sub> 6	TAAAGATATC	TCACGTACTG	ACGGTGGAG	AATGTTAAC	CATATTGGCA
546					
wtCre	GAACGAAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mxo <sub>oxo</sub> 1	GAACGAAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mxo <sub>oxo</sub> 2	GAACGAAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mxo <sub>oxo</sub> 3	GAACGAAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mxo <sub>oxo</sub> 4	GAACGAAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mxo <sub>oxo</sub> 5	GAACGAAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mxo <sub>oxo</sub> 6	GAACGAAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
596					
wtCre	GGGGTAACTA	AACTGGTCGA	CCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mxo <sub>oxo</sub> 1	GGGGTAACTA	AACTGGTCGA	CCGATGGATT	TCCATCTCTG	GTGTAGCTGA
mxo <sub>oxo</sub> 2	GGGGTAACTA	AACTGGTCGA	CCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mxo <sub>oxo</sub> 3	GGGGTAACTA	AACTGGTCGA	CCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mxo <sub>oxo</sub> 4	GGGGTAACTA	AACTGGTCGA	CCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mxo <sub>oxo</sub> 5	GGGGTAACTA	AACTGGTCGA	CCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mxo <sub>oxo</sub> 6	GGGGTAACTA	AACTGGTCGA	CCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
646					
wtCre	TGATCCGAAT	AACTACCTGT	TTTGC <sub>CCCC</sub> GT	CAGAAAAAAAT	GGTGTGCGG
mxo <sub>oxo</sub> 1	TGATCCGAAT	AACTACCTGT	TTTGC <sub>CCCC</sub> GT	CAGAAAAAAAT	GGTGTGCGG
mxo <sub>oxo</sub> 2	TGATCCGAAT	AACTACCTGT	TTTGC <sub>CCCC</sub> GT	CAGAAAAAAAT	GGTGTGCGG
mxo <sub>oxo</sub> 3	TGATCCGAAT	AACTACCTGT	TTTGC <sub>CCCC</sub> GT	CAGAAAAAAAT	GGTGTGCGG
mxo <sub>oxo</sub> 4	TGATCCGAAT	AACTACCTGT	TTTGC <sub>CCCC</sub> GT	CAGAAAAAAAT	GGTGTGCGG
mxo <sub>oxo</sub> 5	TGATCCGAAT	AACTACCTGT	TTTGC <sub>CCCC</sub> GT	CAGAAAAAAAT	GGTGTGCGG
mxo <sub>oxo</sub> 6	TGATCCGAAT	AACTACCTGT	TTTGC <sub>CCCC</sub> GT	CAGAAAAAAAT	GGTGTGCGG
696					
wtCre	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGA	AGGGATTTTT
mxo <sub>oxo</sub> 1	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
mxo <sub>oxo</sub> 2	CGCCATCTGC	CACCGGCCAG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
mxo <sub>oxo</sub> 3	CGCCATCTGC	CACCAGCCGG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
mxo <sub>oxo</sub> 4	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGA	AGGGATTTTT
mxo <sub>oxo</sub> 5	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
mxo <sub>oxo</sub> 6	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
746				785↑	
wtCre	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mxo <sub>oxo</sub> 1	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mxo <sub>oxo</sub> 2	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mxo <sub>oxo</sub> 3	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mxo <sub>oxo</sub> 4	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mxo <sub>oxo</sub> 5	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mxo <sub>oxo</sub> 6	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
796					

Table 10 (cont.)

*In Vitro Evolution of the Cre recombinase*

wtCre	ATACCTGGCC	TGGTCTGGAC	ACAGTCCCCG	TGTCGGAGCC	GCGCGAGATA
mxo <sub>oxo</sub> 1	ATACCTGGCC	TGGTCTGGAC	ACAGTCCCCG	TGTCGGAGCC	GCGCGAGATA
mxo <sub>oxo</sub> 2	ATACCTGGCC	TGGTCCGGAC	ACAGTCCCCG	TGTCGGAGCC	GCGCGAGATA
mxo <sub>oxo</sub> 3	ATACCTGGCC	TGGTCCGGAC	ACAGTCCCCG	TGTCGGAGCC	GCGCGAGATA
mxo <sub>oxo</sub> 4	ATACCAGGCC	TGGTCTGGAC	ACAGTCCCCG	TGTCGGAGCC	GCGCGAGATA
mxo <sub>oxo</sub> 5	ATACCTGGCC	TGGTCTGGAC	ACAGTCCCCG	TGTCGGAGCC	GCGCGAGATA
mxo <sub>oxo</sub> 6	ATACCAGGCC	TGGTCTGGAC	ACAGTCCCCG	TGTCGGAGCC	GCGCGAGATA
846					
wtCre	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mxo <sub>oxo</sub> 1	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mxo <sub>oxo</sub> 2	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mxo <sub>oxo</sub> 3	TGGCCCGCGC	TGGAGTTTCA	ATACTGGAGA	TCATGCAAGC	TGGTGGCTGG
mxo <sub>oxo</sub> 4	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mxo <sub>oxo</sub> 5	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mxo <sub>oxo</sub> 6	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
896					
wtCre	ACCAATGTAA	ATATTGTCAT	GAACATATATC	CGTAACCTGG	ATAGTGAAAC
mxo <sub>oxo</sub> 1	ACCAATGTAA	ATATTGTCAT	GAACATATATC	CGTAACCTGG	ATAGTGAAAC
mxo <sub>oxo</sub> 2	TCCAATGTAA	ATATTGTCAT	GAACATATATC	CGTAACCTGG	ATAGTGAAAC
mxo <sub>oxo</sub> 3	ACCAATGTAA	ATATTGTCAT	GAACATATATC	CGTAACCTGG	ATAGTGAAAC
mxo <sub>oxo</sub> 4	ACCAATGTAA	ATATTGTCAT	GAACATATATC	CGTAACCTGG	ATAGTGAAAC
mxo <sub>oxo</sub> 5	TCCAATGTAA	ATATTGTCAT	GAACATATATC	CGTAACCTGG	ATAGTGAAAC
mxo <sub>oxo</sub> 6	TCCAATGTAA	ATATTGTCAT	GAACATATATC	CGTAACCTGG	ATAGTGAAAC
946					
wtCre	AGGGGCAATG	GTGCGCCTGC	TGGAAGATGG	CGATTAGCCA	TTAACCGCGTA
mxo <sub>oxo</sub> 1	AGGGGCAATG	GTGCGCCTGC	TGGAAGATGG	CGATTAGCCA	TTAACCGCGTA
mxo <sub>oxo</sub> 2	AGGGGCAATG	GTGCGCCTGC	TGGAAGATGG	CGATTAGCCA	TTAACCGCGTA
mxo <sub>oxo</sub> 3	AGGGGCAATG	GTGCGCCTGC	TGGAAGATGG	CGATTAGCCA	TTAACCGCGTA
mxo <sub>oxo</sub> 4	AGGGGCAATG	GTGCGCCTGC	TGGAAGATGG	CGATTAGCCA	TTAACCGCGTA
mxo <sub>oxo</sub> 5	AGGGGCAATG	GTGCGCCTGC	TGGAAGATGG	CGATTAGCCA	TTAACCGCGTA
mxo <sub>oxo</sub> 6	AGGGGCAATG	GTGCGCCTGC	TGGAAGATGG	CGATTAGCCA	TTAACCGCGTA
996				1032	
wtCre	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCCTGAT
mxo <sub>oxo</sub> 1	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCCTGAT
mxo <sub>oxo</sub> 2	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCCTGAT
mxo <sub>oxo</sub> 3	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCCTGAT
mxo <sub>oxo</sub> 4	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCCTGAT
mxo <sub>oxo</sub> 5	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCCTGAT
mxo <sub>oxo</sub> 6	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCCTGAT
1046					
wtCre	ACAGATTAAA	TCAGAACGCA	GA		
mxo <sub>oxo</sub> 1	ACAGATTAAA	TCAGAACGCA	GA	ATG	- Start Codon
mxo <sub>oxo</sub> 2	ACAGATTAAA	TCAGAACGCA	GA		
mxo <sub>oxo</sub> 3	ACAGATTAAA	TCAGAACGCA	GA	TAG	- Stop Codon
mxo <sub>oxo</sub> 4	ACAGATTAAA	TCAGAACGCA	GA		
mxo <sub>oxo</sub> 5	ACAGATTAAA	TCAGAACGCA	GA		
mxo <sub>oxo</sub> 6	ACAGATTAAA	TCAGAACGCA	GA	T	- Point Mutation
1096					

Table 11

In Vitro Evolution of the Cre recombinase

wtCre	MSNLLTVHQN	LPALPVDATS	DEVRKNLMDM	FRDRQAFSEH	TWKMLLSVCR
mxoxox1	MSNLLTVHQN	LPALPVDATS	DEVRKNLMAM	FRDRQAFSEH	TWKMLLSVCR
mxoxox2	MSNLLTVHQN	LPALPVDATS	DEVRKNLMDM	FRDRQAFSEH	TWKMLLSVCR
mxoxox3	MSNLLTVHQN	LPALPIDATS	DEVRKNLMDM	FRDRQAFSEH	TWKMLLSVCR
mxoxox4	MSNLLTVHQN	LPALPVDATS	DEVRKNLMDM	FRDRQAFSEH	TWKMLLSVCR
mxoxox5	MSNLLTVHQN	LPALPVDATS	DEVRKNLMAM	FRDRQAFSEH	TWKMLLSVCR
mxoxox6	MSNLLTVHQN	LPALPVDATS	DEVRKNLMDM	FRDRQAFSEH	TWKMLLSVCR
1					
			A		B
wtCre	SWAAWCKLNN	RKWFPAEPED	VRDYL <del>L</del> YLQA	RGLAV <del>K</del> TIQQ	HLGQLNMLH <del>R</del>
mxoxox1	SWAAWCKLNN	RKWFPAEPED	VRDYL <del>L</del> YLQA	RGLAV <del>K</del> TIQQ	HLGQLNMLH <del>R</del>
mxoxox2	SWAAWCKLNN	RKWFPAEPED	VRDYL <del>L</del> YLQA	RGLAV <del>K</del> TIQQ	HLGQLNMLH <del>R</del>
mxoxox3	SWAAWCKLNN	RKWFPAEPED	VRDYL <del>L</del> YLQA	RGLAV <del>K</del> TIQQ	HLGQLNMLH <del>R</del>
mxoxox4	SWAAWCKLNN	RKWFPAEPED	VRDYL <del>L</del> CLQA	RGLAV <del>K</del> TIQQ	HLGQLNMLH <del>R</del>
mxoxox5	SWAAWCKLNN	RKWFPAEPED	VRDYL <del>L</del> YLQA	RGLAV <del>K</del> TIQQ	HLGQLNMLH <del>R</del>
mxoxox6	SWAAWCKLNN	RKWFPAEPED	VRDYL <del>L</del> YLQA	RGLAV <del>K</del> TIQQ	HLGQLNMLH <del>R</del>
51					
			C		D
wtCre	RSGLPRPSDS	NAVSLVM <del>R</del> RI	RKENVDAGER	AKQALAFERT	DFDQVRSLME
mxoxox1	RSGLPRPSDS	NAVSLVM <del>R</del> RI	RKENVDAGER	AKQALAFERT	DFDQVRSLME
mxoxox2	RSGLPRPSDS	NAVSLVM <del>R</del> RI	RKENVDAGER	AKQALAFGRT	DFDQVRSLME
mxoxox3	RSGLPRPSDS	NAVSLVM <del>R</del> RI	RKENVDAGER	AKQALAFERT	DFDQVRSLME
mxoxox4	RSGLPRPSDS	NAVSLVM <del>R</del> RI	RKENVDAGER	AKQALAFKRT	DFDQVRSLME
mxoxox5	QSGLPRPSDS	NAVSLVM <del>R</del> RI	RKENVDAGER	AKQALAFERT	DFDQVRSLME
mxoxox6	RSGLPRPSDS	NAVSLVM <del>R</del> RI	RKENVDAGER	AKQALAFERT	DFDQVRSLME
101					
			E		F
wtCre	NSDRCQDIRN	LAFLGIAYNT	LLF <del>I</del> AEIARI	RVKDISRTDG	GRMLIHIGRT
mxoxox1	NSDRCQDIRN	LAFLGIAYNT	LLF <del>I</del> AEIARI	RVKDISRTNG	GRMLIHIGRT
mxoxox2	NSDRCQDIRN	LAFLGIAYNT	LLF <del>I</del> AEIARI	RVKDISRTDG	GRMLIHIGRT
mxoxox3	NSDRCQDIRN	LAFLGIAYNT	LLF <del>I</del> AEIARI	RVKDISRTNG	GRMLIHISRT
mxoxox4	NSDRCQDIRN	LAFLGIAYNT	LLF <del>I</del> AEIARI	RVKDISRTDG	GRMLIHIGRT
mxoxox5	NSDRCQDIRN	LAFLGIAYNT	LLF <del>I</del> AEIARI	RVKDISRTDG	GRMLIHIGRT
mxoxox6	NSDRCQDIRN	LAFLGIAYNT	LLF <del>I</del> AEIARI	RVKDISRTDG	GRMLIHIGRT
151			G	H	1 2

Table II (cont.)

*In Vitro Evolution of the Cre recombinase*

wtCre	KTLVSTAGVE	KALSLGVTKL	VERWISVSGV	ADDPNNYLFC	<u>RVRKNGVAAP</u>
mxo <sub>oxo</sub> 1	<u>KTLVSTAGVE</u>	KALSLGVTKL	VERWISISGV	ADDPNNYLFC	<u>RVRKNGVAAP</u>
mxo <sub>oxo</sub> 2	KTLVSTAGVE	KALSLGVTKL	VERWISVSGV	ADDPNNYLFC	<u>RVRKNGVAAP</u>
mxo <sub>oxo</sub> 3	KTLVSTAGVE	KALSLGVTKL	VEQWISVSGV	ADDPNNYLFC	<u>RVRKNGVAAP</u>
mxo <sub>oxo</sub> 4	KTLVSTAGVE	KALSLGVTKL	VERWISVSGV	ADDPNNYLFC	<u>RVRKNGVAAP</u>
mxo <sub>oxo</sub> 5	KTLVSTAGVE	KALSLGVTKQ	VERWISVSGV	ADDPNNYLFC	<u>RVRKNGVAAP</u>
mxo <sub>oxo</sub> 6	KTLVSTAGVE	KALSLGVTKL	VERWISVSGV	ADDPNNYLFC	<u>RVRKNGVAAP</u>
201					
		3                    I                    4                    5			
wtCre	SATSQLSTRA	<u>L</u> EGLIFEATHR	LIYGAKDDSG	<u>Q</u> RYLAWSGHS	A <del>F</del> VGAARDMA
mxo <sub>oxo</sub> 1	SATSQLSTRA	LGGIFEATHR	LIYGAKDDSG	<u>Q</u> RYLAWSGHS	A <del>F</del> VGAARDMA
mxo <sub>oxo</sub> 2	SATGQLSTRA	LGGIFEATHR	LIYGAKDDSG	<u>Q</u> RYLAWSGHS	A <del>F</del> VGAARDMA
mxo <sub>oxo</sub> 3	SATSRLSTRA	LGGIFEATHR	LIYGAKDDSG	<u>Q</u> RYLAWSGHS	A <del>F</del> VGAARDMA
mxo <sub>oxo</sub> 4	SATSQLSTRA	<u>L</u> EGLIFEATHR	LIYGAKDDSG	<u>Q</u> RYQAWSGHS	A <del>F</del> VGAARDMA
mxo <sub>oxo</sub> 5	SATSQLSTRA	LGGIFEATHR	LIYGAKDDSG	<u>Q</u> RYLAWSGHS	A <del>F</del> VGAARDMA
mxo <sub>oxo</sub> 6	SATSQLSTRA	LGGIFEATHR	LIYGAKDDSG	<u>Q</u> RYQAWSGHS	A <del>F</del> VGAARDMA
251					
		J                    K			
wtCre	RAGVSIPEIM	QAGGW <del>T</del> NVNI	VMN <del>T</del> IRNLDS	ETGAMVRLLE	DGD-
mxo <sub>oxo</sub> 1	RAGVSIPEIM	QAGGW <del>T</del> NVNI	VMN <del>T</del> IRNLDS	ETGAMVRLLE	DGD-
mxo <sub>oxo</sub> 2	RAGVSIPEIM	QAGGW <del>T</del> SNVNI	VMN <del>T</del> IRNLDS	ETGAMVRLLE	DGD-
mxo <sub>oxo</sub> 3	RAGVSILEIM	QAGGW <del>T</del> NVNI	VMN <del>T</del> IRNLDS	ETGAMVRLLE	DGD-
mxo <sub>oxo</sub> 4	RAGVSIPEIM	QAGGW <del>T</del> NVNI	VMN <del>T</del> IRNLDS	ETGAMVRLLE	DGD-
mxo <sub>oxo</sub> 5	RAGVSIPEIM	QAGGW <del>T</del> SNVNI	VMN <del>T</del> IRNLDS	ETGAMVRLLE	DGD-
mxo <sub>oxo</sub> 6	RAGVSIPEIM	QAGGW <del>T</del> SNVNI	VMN <del>T</del> IRNLDS	ETGAMVRLLE	DGD-
301					
		L                    M                    N			

G - mutated residue

T - catalytic residue

E - DNA contacting residue

— —  $\alpha$ -helix→ -  $\beta$  sheet

Table 12

Transition	Frequency	Transversion	Frequency
A - G	29 % (9)	A - C	6.5 % (2)
G - A	26 % (8)	C - A	< 3 % (0)
C - T	6.5 % (2)	A - T	9.7 % (3)
T - C	6.5 % (2)	T - A	9.7 % (3)
		C - G	< 3 % (0)
		G - C	< 3 % (0)
		G - T	6.5 % (2)
		T - G	< 3 % (0)

31 point mutations could be identified in the six analyzed mutants. The mutagenic frequency can therefore be calculated as 0.5%. No frame-shift mutations, or more than one point mutation per codon of the *cre* sequence were found. The table classifies these mutations into the different types of transition and transversion events. Given are the frequencies and in parenthesis the actual numbers which were found. Interestingly, the A to G and vice versa transisiton occurred much more often than all other possible events. On the other hand, half of the possible transversions were not identified at all.

**Table 13**

Round	Induction	% Kan <sup>R</sup>	Nb. Kan <sup>R</sup>	% White
0	4 h	< 0.01%	-	100%
1	4 h	0.16%	6	84%
2	4 h	0.56%	47	82%
3	2.5 h	0.2%	36	80%
4	2.5 h	4.6%	102	75%

**Table 14**

Mutant	<i>loxK2</i> <sup>2</sup>	<i>loxP</i> <sup>2</sup>	% Kan <sup>R</sup>
wt	<0.01%	94%	
R3M1	66%	98%	
R3M2	54%	98%	
R3M3	65%	91%	
R3M4	0.02%	93%	
R3M5	15%	91%	
R3M6	3%	94%	

Table 15

In Vitro Recombination Results

997358v1

% of recombination is calculated from the obtained fluorescence intensity of substrate and product on an agarose gel.

Cre	% of lox/lox recombination <i>in vitro</i>					
	loxP	ATAACCTTCGTATA	loxK2	loxK1	loxP-K2	loxP-K1
TT	TG	GT	GG	TC	CC	AA
R3M3	25.4	32.1	36.8	29.7	8.5	23.9
E262G/D29A	25.4	30.4	21.4	48.4	16.6	20.4
E262G/T316S	36.4	37.6	38.6	47.3	19.6	23.2
E262G/D189N	35.3	33.8	34.0	59.9	16.4	24.0
E262G	30.9	32.1	27.5	49.2	-	15.2
wt	28.7	0	45.8	0	0	0

Table 16

DNA Binding to lox halfsites (Gelshift)

997358v1

% of gel retardation is calculated from the obtained intensity of the shifted band (Cre bound to *lox* halfsite) and free *lox* halfsites (labeled oligonucleotides). The values given here were all obtained with 0.2 pmol of *lox* halfsites. Without enzyme added, no retardation of either halfsite could be observed. The obtained data was normalized for better comparability to 100% retardation on *loxP* halfsite, for each enzyme tested.

		% of <i>lox</i> halfsites retarded on the gel due to Cre binding	
		<i>loxP</i>	<i>loxK1</i>
		<i>loxK2</i>	<i>loxP</i>
R3M3	100	14.8 ± 5.2	0.3 ± 0.2
E262G/D29A	100	36.6 ± 6.4	14.1 ± 2.7
E262G/T316S	100	40.7 ± 19.3	13.6 ± 1.7
E262G/D189N	100	44.2 ± 8.1	16.1 ± 2.9
E262G	100	34 ± 7.2	15.8 ± 6.4
wt	100	6 ± 1.3	0.8 ± 1.1
		ATTAACCTTCGTATA	ATAACAAACGATA
		ATACACCTTTGTATA	

Table 17

Name	pBS#	Sequence: Halfsite - FAS1 Spacer - Inverted Halfsite
Positions in lox:	17 12 5 4 1/1'4' 5' 11' 17'	
loxP	632	ATAACTTCGTATA TACC/TTTC TATAGCAAGTTAT
loxK2	633	ATAACAAACGTATA TACC/TTTC TATAGCTTGTAT
loxK1	634	ATACCTTGTATA TACC/TTTC TATAGAAAGGTAT
loxK2 'GG'	638	ATAAACGGCGTATA TACC/TTTC TATAGCCC GTAT
loxK2 'CC'	639	ATAAACCCGTATA TACC/TTTC TATAGCGGGTAT
loxK2 'TC'	635	ATAAACTCCGTATA TACC/TTTC TATAGCGAGTTAT
loxK2 'GT'	636	ATAAACGTCGTATA TACC/TTTC TATAGCACGTTAT
loxK2 'TG'	637	ATAAACTGCGTATA TACC/TTTC TATAGCCAGTTAT

CLAIMS

We claim:

1. A method of identifying variant recombinases that mediate recombination at variant recombination sites, the method comprising,

(a) bringing into contact

a mutant recombinase,

a first nucleic acid sequence comprising a first reporter gene and first and second recombination sites, wherein the first and second recombination sites are variant recombination sites, and

a second nucleic acid sequence comprising a second reporter gene and third and fourth recombination sites, wherein the third and fourth recombination sites can be recombined by a non-mutant recombinase,

(b) determining if recombination occurs between the first and second recombination sites, and determining if recombination occurs between the third and fourth recombination sites,

wherein recombination between the first and second recombination sites indicates that the mutant recombinase is a variant recombinase that mediates recombination at variant recombination sites,

wherein recombination between the third and fourth recombination sites indicates that the mutant recombinase retains the ability to mediate recombination at non-variant recombination sites.

2. The method of claim 1 wherein the recombination sites comprise recognition sequences and compatibility sequences,

wherein the recognition sequences of the first and second recombination sites differ from the recognition sequences of the third and fourth recombination sites,

wherein the compatibility sequences of the first and second recombination sites are sufficiently similar to allow recombination between the first and second recombination sites, and wherein the compatibility sequences of the third and fourth recombination sites are sufficiently similar to allow recombination between the third and fourth recombination sites, and

wherein the compatibility sequences of the first and second recombination sites differ from the compatibility sequences of the third and fourth recombination sites such that neither the first nor the second recombination site can be recombined with either the third or the fourth recombination site.

3. The method of claim 1 wherein the first and second recombination sites cannot be recombined by non-mutant recombinase to a significant extent.

4. The method of claim 1 or 2 wherein the first and second recombination sites have identical sequences, and wherein the third and fourth recombination sites have identical sequences.

5. The method of claim 1 wherein recombination between the first and second recombination sites alters the expression of the first reporter gene, wherein recombination between the first and second recombination sites is determined by determining if expression of the first reporter gene is altered, and

wherein recombination between the third and fourth recombination sites alters the expression of the second reporter gene, wherein recombination between the third and fourth recombination sites is determined by determining if expression of the second reporter gene is altered.

6. The method of claim 5 wherein recombination between the first and second recombination sites allows the first reporter gene to be expressed.

7. The method of claim 6 wherein the first nucleic acid sequence further comprises a spacer sequence flanked by the first and second recombination sites, wherein the spacer sequence interrupts the first reporter gene such that the first reporter gene is not expressed, wherein recombination of the first and second recombination sites excises the spacer sequence which allows the first reporter gene to be expressed.

8. The method of claim 6 wherein a portion of the first reporter gene is inverted, wherein the inverted portion of the first reporter gene is flanked by the first and second recombination sites, wherein recombination of the first and second recombination sites inverts the inverted portion of the first reporter gene which allows the first reporter gene to be expressed.

9. The method of claim 5 wherein recombination between the first and second recombination sites prevents expression of the first reporter gene.
10. The method of claim 9 wherein the first reporter gene is flanked by the first and second recombination sites, wherein recombination of the first and second recombination sites excises the first reporter gene which prevents expression of the first reporter gene.
11. The method of claim 9 wherein a portion of the first reporter gene is flanked by the first and second recombination sites, wherein recombination of the first and second recombination sites inverts the flanked portion of the first reporter gene which prevents expression of the first reporter gene.
12. The method of claim 5 wherein recombination between the third and fourth recombination sites allows the second reporter gene to be expressed.
13. The method of claim 12 wherein the second nucleic acid sequence further comprises a spacer sequence flanked by the third and fourth recombination sites, wherein the spacer sequence interrupts the second reporter gene such that the second reporter gene is not expressed, wherein recombination of the third and fourth recombination sites excises the spacer sequence which allows the second reporter gene to be expressed.
14. The method of claim 13 wherein the spacer sequence interrupts the second reporter gene such that the second reporter gene is not transcribed.
15. The method of claim 13 wherein the second reporter gene encodes a protein, wherein the spacer sequence interrupts the second reporter gene such that the protein encoded by the second reporter gene is not translated.
16. The method of claim 13 wherein the spacer sequence interrupts the second reporter gene such that the second reporter gene produces an inactive expression product.
17. The method of claim 12 wherein a portion of the second reporter gene is inverted, wherein the inverted portion of the second reporter gene is flanked by the third and fourth recombination sites, wherein recombination of the third and fourth

recombination sites inverts the inverted portion of the second reporter gene which allows the second reporter gene to be expressed.

18. The method of claim 5 wherein recombination between the third and fourth recombination sites prevents expression of the second reporter gene to be expressed.

19. The method of claim 18 wherein the second reporter gene is flanked by the third and fourth recombination sites, wherein recombination of the third and fourth recombination sites excises the second reporter gene which prevents expression of the second reporter gene.

20. The method of claim 18 wherein a portion of the second reporter gene is flanked by the third and fourth recombination sites, wherein recombination of the third and fourth recombination sites inverts the flanked portion of the second reporter gene which prevents expression of the second reporter gene.

21. The method of claim 1 wherein the first nucleic acid sequence is a first nucleic acid construct and the second nucleic acid sequence is on a second nucleic acid construct.

22. The method of claim 21 wherein the first nucleic acid construct is an extrachromosomal vector and the second nucleic acid construct is in the genome of a host cell.

23. The method of claim 1 wherein the first and second nucleic acid constructs are on the same nucleic acid construct.

24. A method for producing site-specific recombination of DNA, comprising,

contacting a variant recombinase identified by the method of claim 1 with first and second DNA sequences,

wherein the first DNA sequence comprises a first recombination site and the second DNA sequence comprises a second recombination site,

wherein the variant recombinase mediates recombination between the first and second recombination sites thereby producing the site specific recombination.

25. The method of claim 24 wherein the first recombination site, the second recombination site, or both, are variant recombination sites.
26. The method of claim 24, wherein the first and second DNA sequences are connected by a pre-selected DNA segment.
27. The method of claim 26, wherein the first and second recombination sites have the same orientation and the site-specific recombination of DNA is a deletion of the pre-selected DNA segment.
28. The method of claim 27, wherein the pre-selected DNA segment is a gene for a structural protein, an enzyme, or a regulatory molecule.
29. The method of claim 27 further comprising contacting the variant recombinase with a fourth DNA sequence comprising a third recombination site, wherein the second and fourth DNA sequences are connected by a second pre-selected DNA segment.
30. The method of claim 29 wherein the first recombination site is a variant recombination site recognized by the variant recombinase and not by wild type recombinase, and wherein the second and third recombination sites are recombination sites recognized by wild type recombinase and by the variant recombinase.
31. The method of claim 30 further comprising, prior to contacting the variant recombinase with the first, second, and third recombination sites, contacting the recombination sites with wild type recombinase, thereby producing site specific recombination between the second and third recombination sites resulting in a deletion of the second pre-selected DNA segment.
32. The method of claim 29, wherein the second pre-selected DNA segment is a gene for a structural protein, an enzyme, or a regulatory molecule.
33. The method of claim 26, wherein the first and second recombination sites have opposite orientations and the site-specific recombination is an inversion of the nucleotide sequence of the pre-selected DNA segment.
34. The method of claim 33, wherein the first and second recombination sites are variant recombination sites recognized by the variant recombinase.

35. The method of claim 33, wherein the pre-selected DNA segment is a gene for a structural protein, an enzyme, or a regulatory molecule.
36. The method of claim 24, wherein the second and third DNA sequences are introduced into two different DNA molecules and the site-specific recombination is a reciprocal exchange of DNA segments proximate to the recombination sites.
37. The method of claim 36, wherein the first and second recombination sites are variant recombination sites recognized by the variant recombinase.
38. The method of claim 24 wherein the second DNA sequence includes a label, wherein recombination between the first and second recombination sites associates the label with the first DNA sequence.
39. The method of claim 38 wherein the first DNA sequence is a large circular DNA molecule.
40. The method of claim 24 wherein recombination occurs in a cell.
41. The method of claim 40 wherein the variant recombinase is contacted with the first and second DNA sequences by introducing into the cell a third DNA sequence comprising DNA encoding the variant recombinase.
42. The method of claim 41, wherein the third DNA sequence further comprises a regulatory nucleotide sequence and expression of the variant recombinase is produced by activating the regulatory nucleotide sequence.
43. The method of claim 40, wherein the cell is a eukaryotic cell, a mammalian cell, a yeast cell, a fungal cell, a prokaryotic cell, a bacterial cell, an archae bacterial cell, or a cell in a multicellular organism.
44. The method of claim 43 wherein the multicellular organism is a plant, an animal, or a mammal.
45. The method of claim 40, wherein the first and second DNA sequences are connected by a pre-selected DNA segment, wherein the first and second recombination sites have the same orientation and the site-specific recombination of DNA is a deletion of the pre-selected DNA segment.
46. The method of claim 45 wherein the cell is in a multicellular organism.

47. The method of claim 45, wherein the pre-selected segment is an undesired marker or trait gene.

48. The method of claim 24 wherein the variant recombinase is contacted with the recombination sites *in vitro*.

49. The method of claim 48 wherein the method further comprises introducing the recombined DNA into a cell.

50. A method for cloning large DNA fragments, the method comprising concatenating DNA fragments to be cloned with vector arms, wherein each vector arm comprises a recombination site, wherein the DNA fragments and vector arms alternate in the concatemer,

introducing the concatemer into a cell expressing a variant recombinase identified by the method of claim 1, wherein the recombinase mediates recombination of the recombination sites thereby generating circles each containing a DNA fragment and a vector arm.

51. A method for cloning large DNA fragments, the method comprising ligating a DNA fragment to be cloned to vector arms, wherein each vector arm comprises (i) a blunt end, (ii) another end which is compatible with an end of the DNA fragment to be cloned, and (iii) a recombination site, wherein concatemers are not formed, and

introducing the ligated DNA fragment and vector arms into a cell expressing a variant recombinase identified by the method of claim 1.

52. A method for cloning large DNA fragments, the method comprising ligating a plurality of DNA fragments to be cloned with a plurality of first and second vector arms, wherein each first vector arm comprises two ligatable ends, wherein each second vector arm comprises a recombination site and one non-ligatable end,

wherein, following ligation, the DNA fragments and first vector arms alternate in concatemers, wherein the concatemers are flanked by second vector arms,

introducing the concatemers into a cell expressing a variant recombinase identified by the method of claim 1, wherein the recombinase mediates recombination of the recombination sites thereby generating circles containing the DNA fragments.

53. A variant recombinase identified by the method of claim 1.

54. A nucleic acid molecule encoding a variant recombinase identified by the method of claim 1.

55. The nucleic acid molecule of claim 54 wherein the nucleic acid molecule is a plasmid.

56. A cell containing the nucleic acid molecule of claim 54.

57. The cell of claim 56 wherein the cell is a eukaryotic cell, a mammalian cell, a yeast cell, a fungal cell, a prokaryotic cell, a bacterial cell, an archae bacterial cell, or a cell in a multicellular organism.

58. The cell of claim 57 wherein the multicellular organism is a plant, an animal, or a mammal.

59. A nucleic acid molecule having at least one variant recombination site, wherein the variant recombination site is recognized by a variant recombinase identified by the method of claim 1 and is not recognized by wild type recombinase.

60. The nucleic acid molecule of claim 59 wherein the recombination site is not recognized by wild type recombinase.

61. The nucleic acid molecule of claim 59, wherein a first recombination site and a second recombination site are connected by a pre-selected DNA segment.

62. The nucleic acid molecule of claim 59 wherein the nucleic acid molecule is a plasmid.

63. A cell containing the nucleic acid molecule of claim 59.

**METHOD FOR SELECTING RECOMBINASE VARIANTS  
WITH ALTERED SPECIFICITY  
ABSTRACT OF THE DISCLOSURE**

Disclosed are variants of Cre recombinase that have broadened specificity for the site of recombination. Specifically, the disclosed variants mediate recombination between sequences other than the loxP sequence and other lox site sequences on which wild type Cre recombinase is active. In general, the disclosed Cre variants mediate efficient recombination between lox sites that wild type Cre can act on (referred to as wild type lox sites), between variant lox sites not efficiently utilized by wild type Cre (referred to as variant lox sites), and between a wild type lox site and a variant lox site. Also disclosed are methods of recombining nucleic acids using the disclosed Cre variants. For example, the disclosed Cre variants can be used in any method or technique where Cre recombinase (or other, similar recombinases such as FLP) can be used. In addition, the disclosed Cre variants allow different alternative recombinations to be performed since the Cre variants allow much more efficient recombination between wild type lox sites and variant lox sites. Control of such alternative recombination can be used to accomplish more sophisticated sequential recombinations to achieve results not possible with wild type Cre recombinase.


## Figures 1 and 2

### *loxP* vs. *loxK1* vs. *loxK2*

	17												17'											
	11						11'						17						17'					
<i>loxP</i>	5' ATA	ACT	TCG	TAT	AAT	GTA	TGC	TAT	ACG	AAG	TTA	T 3'	3' TAT	TGA	AGC	ATA	TGA	CAT	ACG	ATA	TGC	TTC	AAT	A 5'
<i>loxK1</i>	5' GAG	CCT	TTG	TAT	ATA	CCT	TTC	TAT	ACA	AAG	GCT	T 3'	3' CTC	GGA	AAC	ATA	TAT	GGA	AAG	ATA	TGT	TTC	CGA	A 5'
<i>loxK2</i>	5' GAT	ACA	ACG	TAT	ATA	CCT	TTC	TAT	ACG	TTG	TAT	T 3'	3' CTA	TGT	TGC	ATA	TAT	GGA	AAG	ATA	TGC	AAC	ATA	A 5'
	17'					11'			17				17'				11'				17			


**Fig. 1:** Comparison of the three different *lox* sites used in this study. *loxP* is the original substrate for wt Cre, catalyzing site-specific recombination. The characteristic two 13 bp inverted repeats and the two ATG start codons (located in the non-canonical spacer of 8 bp) are indicated by the horizontal arrows. The strand cleavage sites for Cre are indicated by the vertical arrows. This cleavage leads to a 6 bp 5' overhang and a 3' phosphotyrosine linkage with Y324, Cre's catalytic residue. The positions in the *lox* sites are assigned as proposed by Hoess, *et. al.* (1982).

*loxK1* and *loxK2*, the two altered *lox* sites used in this study, differ from *loxP* mainly in positions 10/14, and 11/12, respectively (as indicated by bold letters). These alterations are believed to inhibit wt Cre activity on the sites. The other differences, the complete 8 bp spacer and three outermost bp (indicated by bold letters) were shown not to influence wt Cre.



**Fig. 2:** Illustration of the influence of the direction of *loxP* sites on Cre recombination. If the sites are orientated in the same direction (defined by the two ATG's in the 8 bp non-canonical spacer region) recombination catalyzed by Cre will result in excision of the DNA flanked by the *lox* sites, whereas recombination events on sites orientated in the same direction will result in an inversion.


**Figure 3**




**Figure 3:** Illustration of the random mutagenesis procedure, called DNA shuffling. The procedure mimics what is believed to be evolution: mutagenic events and recombination between pools of different but highly related sequences:

*In vitro*, a PCR of the gene of interest (*cre*) is used as the basis for the mutagenic event, resulting in a pool of varying but related sequences. Random fragmentation leads to the indicated pool of random size fragments, breaking the linkage between the occurred point mutations. A reassembly process by PCR eventually allows to recover an enlarged variety of different mutants. The final step, a selection for the desired mutants, permits to recover the ones with combinations of beneficial mutations and eliminates deleterious combinations. The selected pool will then serve as starting material for the next round.

Figure 4



## Figures 5 and 6




**Fig. 5:** Represented are agarose gels used during the mutagenesis procedure (DNA shuffling). Gels were run after DNase I digest and after the reassembly process by self-priming and reassembly PCR.

(A) The random fragment pools obtained after the DNase I digest and separated on a 2% GTG Sea Kem Agarose gel (FMC, Rockland, ME) are shown.


(B) The same gel is presented: The random fragments of 25 bp to 300 bp size have migrated and stuck to the described DE81 paper resin (Whatman, Maidstone, UK).

(C) 5 $\mu$ l aliquots of the self-priming PCR mix and the reassembly PCR are analyzed by gel electrophoresis. During self-priming PCR (left lane) a smear of fragments of 300 bp to 2 kb has been generated out of the pool of small fragments. However, no distinct product is achieved. After the reassembly PCR (right lane), in which the original *cre* primers are added, one distinct product of approximately 1.1 kb size is obtained. This represents a pool of different *cre* mutants, to be used in the selection procedure.




**Fig. 6:** Shown is pBAD33, chosen for the expression of the mutant *cre* pools during the selection procedure (adapted from Guzman, *et. al.*, 1995). pBAD33 contains parts of the arabinose operon, including the pBAD promoter and the gene encoding for the regulatory protein AraC. Any gene inserted into the MCS will be under pBAD control. This permits to regulate its expression from low level to nearly complete repression by changing 0.2% L-(+)-arabinose in the medium to 0.2% D-glucose. In addition, Cm can be used for selection for pBAD33 containing cells and the pACYC184 derived origin of replication is compatible to ColE1 origins.

**Figure 7**




**Fig. 7:** Construction of the first generation of selection plasmids, pBS568 and pBS569: (i) pBS561 was assembled using three fragments: the RSVneo backbone, the 5'-modified *neo* gene from pBS398, and the MCS. The used restriction sites are highlighted. The complete sequence of the MCS, made of oligonucleotides, is indicated, too. Note the SD sequence, ATG start, and TGA stop codons, necessary for the described selection strategy. (ii) In the following steps, the *EGFP* gene as a spacer was inserted along with the two *lox* sites orientated in the same direction, by using the highlighted restriction sites. Unexpectedly, *lox* recombination in the final selection plasmids did not lead to *neo* expression as selectable marker for desired K1<sup>+</sup> or K2<sup>+</sup> Cre mutants. For further information, see text.

## Figures 8 and 9




**Fig. 8:** Construction of the second generation of selection plasmids, pBS583 and pBS584: (i) The original *neo* sequence was restored by inserting the *lox*<sup>2</sup> cassette of pBS568 and pBS569 into the RSVneo backbone by using the highlighted restriction sites. (ii) A transcriptional terminator, *rrnBT*<sub>1</sub>*T*<sub>2</sub>, obtained by PCR from pBAD33, was inserted 3' of the EGFP spacer as indicated. The derived plasmids were suitable for the desired selection for K1<sup>+</sup> or K2<sup>+</sup> Cre mutants: Excision of the EGFP spacer and the transcriptional terminator by K1<sup>+</sup> or K2<sup>+</sup> Cre-mediated *loxK1* or *loxK2* recombination rendered the *E. coli* host Kan<sup>R</sup> as anticipated. For more information, see text.



**Fig. 9:** Control plasmid pBS613: A *loxP* selection plasmid, constructed similarly to pBS583 and pBS584. It was used as control plasmid to determine the recombination frequency of Cre mutants on *loxP* (as described for *loxK1* and *loxK2* before).


**Figure 10**




**Fig. 10:** Construction of the screening plasmids pBS601 and pBS602: (i) Deletion of the *Pvu* II fragment of *neo* of plasmids pBS581/pBS582 (an intermediate of the pBS583/584 construction) restored the possibility to use it as selectable marker in a different selection, provided by the bacterial background (see text). (ii) The *EGFP* spacer gene was replaced by the *lac* promoter derived from pUC19 by PCR. (iii) the *abfA.st* marker gene from pBS481, encoding an α-L-arabinofuranosidase, was inserted between the two *lox* sites. Note, that the restriction sites used during this construction process are highlighted as before. *loxK1* or *loxK2* recombination will result in excision of *abfA.st*, allowing a blue/white screen with Z-ara as described in the text.

Figure 11


Interrupted  
(deletion)






Flanked  
(deletion)




Inverted  
(inversion)






Deletion

Figure 12A



Inversion


Figure 12B



Combination

Figure 12C

Figure 13



R3M1	P - A	- - -	N - S - I - - G - - -
R3M2	P - -	- - -	G - - - - G - G - S - S
R3M3	- I -	- - -	N S - - Q - - RG - S L -
R3M4	- - -	C - K	- - - - - - Q - - -
R3M5	- - A	- Q	- - - Q - - - G - - - S
R3M6	- - -	- - -	- - - - - G Q - - S

# In Vivo Recombination Assay

A

	% of Cre-mediated recombination			
	TT	GG	CC	AA
R3M3 Cre	97	82	67	90
E262G/D29A Cre	95	37	34	47
E262G/T316S Cre	98	21	14	32
E262G/D189N Cre	93	6	5	22
E262G Cre	90	20	10	28
wt Cre	95	0	0	0

*loxP* Halfsite      ATAACCTTCGTATA

B

	% of Cre-mediated recombination			
	<i>loxP</i> <sup>2</sup>	<i>loxK2</i> <sup>2</sup>	<i>loxP-loxK2</i>	<i>loxK1</i> <sup>2</sup>
R3M3 Cre	97	90	95	30
E262G/D29A Cre	95	47	80	2
E262G/T316S Cre	98	32	81	1
E262G/D189N Cre	93	22	71	1
E262G Cre	90	28	78	2
wt Cre	95	0	18	0

*loxP*<sup>2</sup>      *loxK2*<sup>2</sup>      *loxP-loxK2*      *loxK1*<sup>2</sup>      *loxP-loxK1*

Figure 14

*In vivo* tests of wt and mut Cre enzymes on different *lox* substrates

% Cre-mediated *lox*<sup>2</sup> recombination

	TT	TG	GT	GG	TC	CC	AA
R3M3 Cre	97	99	92	82	56	67	90
E262G/D29A Cre	95	95	82	37	35	34	47
E262G/T316S Cre	98	97	89	21	31	14	32
E262G/D189N Cre	93	98	68	6	9	5	22
E262G Cre	90	97	65	20	32	10	28
wt Cre	95	92	25	0	0	0	0

*loxP* Halfsite      ATAACTTCGTATA

Figure 15

Figure 16

Cre Gelshift Comparison




Figure 17

wt FRT: GAAGTTCCCTATTTC TCTAGAAA GTATAGGAACCTTC

Note - alternatively, a full site can also be used  
having 3 repeat elements:

GAAGTTCCCTATTCCGAAGTTCCCTATTTC TCTAGAAA GTATAGGAACCTTC

FRT-A1: GAAGTTCCCTATTTC TCTAGA t A GTATAGGAACCTTC

Spacer alteration

FRT-M: GAAGTTCCATATTTC TCTAGA t A GTATATGAACTTC

Symmetrical recognition

Figure 18




Figure 19

wt FRT: GAAGTTCCCTATTTC TCTAGAAA GTATAGGAACCTTC

Note - alternatively, a full site can also be used  
having 3 repeat elements:

GAAGTTCCCTATTCCGAAGTTCCCTATTTC TCTAGAAA GTATAGGAACCTTC

FRT-A2: GAAGTTCCCTATTTC TCTAGA

tA GTATAGGAACCTTC

Spacer alteration

FRT-M2: GAAGTTaCTATTTC TCTAGA

tA GTATAGtAACTTC

Symmetrical recognition

Please type a plus sign (+) inside this box → **[+]**

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR  
DESIGN  
PATENT APPLICATION  
(37 CFR 1.63)**

Declaration Submitted with Initial Filing      OR       Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	OMRF 178
First Named Inventor	Brian Lee Sauer
<b>COMPLETE IF KNOWN</b>	
Application Number	/
Filing Date	April 6, 2000
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**METHOD FOR SELECTING RECOMBINASE VARIANT WITH  
ALTERED SPECIFICITY**

the specification of which

*(Title of the Invention)*

is attached hereto

OR

was filed on (MM/DD/YYYY)  as United States Application Number or PCT International

Application Number  and was amended on (MM/DD/YYYY)  (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?
			<input type="checkbox"/>	<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/>

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
60/127,977	April 6, 1999	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OMRF 178

20487/247

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Customer Number   →   Place Customer Number Bar Code Label here  
 Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Patrea L. Pabst Robert A. Hodges Kevin W. King	31,284 41,074 42,737		

Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to:  Customer Number   OR  Correspondence address below

Name	Patrea L. Pabst				
Address	Arnall Golden & Gregory, LLP				
Address	2800 One Atlantic Center, 1201 West Peachtree Street				
City	Atlanta	State	GA	ZIP	30309-3450
Country	United States	Telephone	(404)873-8794	Fax	(404)873-8795

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:	<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle if any) Brian Lee			Family Name or Surname Sauer		

Inventor's Signature						Date	
Residence: City	Oklahoma City	State	OK	Country	USA	Citizenship	U.S.
Post Office Address	601 Robert S Kerr Avenue, Apt. 109						
Post Office Address							
City	Oklahoma City	State	OK	ZIP	73102	Country	USA

Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

April 6, 2000

Method for Selecting Recombinase Variants with Altered Specificity

Please type a plus sign (+) inside this box →

PTO/SB/02A (3-97)

Approved for use through 9/30/98. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION

### ADDITIONAL INVENTOR(S) Supplemental Sheet Page 1 of 1

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle [if any])		Family Name or Surname				
Andreas Walter		Rüfer				
Inventor's Signature						Date
Residence: City	Oklahoma City	State	OK	Country	USA	Citizenship
Post Office Address	125 N.W. 15th Street, Apt. #604					
Post Office Address						
City	Oklahoma City	State	OK	ZIP	73103	Country
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle [if any])		Family Name or Surname				
Inventor's Signature						Date
Residence: City		State		Country		Citizenship
Post Office Address						
Post Office Address						
City		State		ZIP		Country
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle [if any])		Family Name or Surname				
Inventor's Signature						Date
Residence: City		State		Country		Citizenship
Post Office Address						
Post Office Address						
City		State		ZIP		Country

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.